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ABSTRACT
Leveraging patient-provided data to improve understanding of disease risk
Fernanda Caroline da Graça Polubriaginof
Patient-provided data are crucial to achieving the goal of precision medicine. These
data, which include family medical history, race and ethnicity, and social and behavioral de-
terminants of health, are essential for disease risk assessment. Despite the well-established
importance of patient-provided data, there are many data quality challenges that affect how
this information can be used for biomedical research.
To determine how to best use patient-provided data to assess disease risk, the research
reflected in this dissertation was divided into three overarching aims. In Aim 1, I focused
on determining the quality of race and ethnicity, family history and smoking status in clin-
ical databases. In Aim 2, I assessed the impact of various interventions on the quality of
these data, including policy changes such as the implementation of the requirements im-
posed by the Meaningful Use program, and patient-facing tools for collecting and sharing
information with patients. In addition to these evaluations, I also developed and evaluated
a method “Relationship Inference from the Electronic Health Record” (RIFTEHR), that in-
fers familial relationships from clinical datasets. In Aim 3, I used patient-provided data to
assess disease risk both at a population level, by estimating disease heritability, and at an
individual level, by identifying high-risk individuals eligible for additional screening for a
common disease (diabetes mellitus) and a rare disease (celiac disease).
My research uncovered several data quality concerns for patient-provided data in clin-
ical databases. When assessing the impact of interventions on the quality of these data,
I found that policy interventions led to more data collection, but not necessarily to better
data quality. In contrast, patient-facing tools did increase the quality of the patient-provided
data. In the absence of high-quality patient-provided data for family medical history, I de-
veloped and evaluated a method for inferring this information from large clinical databases.
I demonstrated that electronic health record data can be used to infer familial relationships
accurately. Moreover, I showed how the use of clinical data in conjunction with the in-
ferred familial relationships could determine disease risk in two studies. In the first study, I
successfully computed disease heritability estimates for 500 conditions, some of which had
not been previously studied. In the second study, I identified that screening rates among
family members that are considered to be at high-risk for disease development were low
for both diabetes mellitus and celiac disease.
In summary, the work represented in this dissertation contributes to the understanding
of the quality of patient-provided data, how interventions affect the quality of these data,
and how novel methods can be applied to troves of existing clinical data to generate new
knowledge to support research and clinical care.
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Patient-provided information, such as family medical history, is crucial to achieving
the goal of precision medicine. Precision medicine focuses on disease prevention and treat-
ment while accounting for a patient’s variability (Collins and Varmus 2015). In precision
medicine, there is a need for understanding not only genetic causes of disease but also the
impact of environmental and behavioral factors on the disease (Aronson and Rehm 2015;
Cutting 2010; Maher 2008). Patient-provided information, such as family medical history,
self-reported race and ethnicity, social and behavioral determinants of health, and past med-
ical and surgical history, are important pieces of information that directly impact the risk
of disease. For example, women with a family history of breast cancer can be at higher
risk of developing the disease, and therefore, they are candidates for additional and/or early
screening (Ozanne et al. 2009). Similar approaches are well established for a variety of
conditions, including prevalent disorders, such as osteoporosis (U.S. Preventive Services
Task Force 2011) and lipid disorders in adults (Helfand and Carson 2008). With a better un-
derstanding of disease risk, clinicians can personalize the care they deliver by risk-adjusted
disease screening, prevention, and early diagnosis. While there has been increased interest
in precision medicine and the patient-provided information that drives it (Adams and Pe-
tersen 2016; Aronson and Rehm 2015; Collins and Varmus 2015), there is a lack of research
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on methods to most effectively capture patient-provided information in clinical databases.
Clinical databases, including those derived from electronic health records (EHRs), are
an important resource for biomedical research and have previously been utilized to shed
light on disease processes (Boland et al. 2015; Coopey et al. 2012; Hripcsak et al. 2016;
Li et al. 2015; Ritchie, Andrade, and Kuivaniemi 2015; Wei and Denny 2015), including
genetics (Kohane 2011; Polubriaginof et al. 2017; Wang et al. 2017), and on drug effec-
tiveness and interactions (Dudley, Deshpande, and Butte 2011; Lorberbaum et al. 2016b;
Tatonetti et al. 2012). Notwithstanding the utility of EHR data for research activities, there
are concerns regarding the quality of these data (Ahmad et al. 2017; Aronsky and Haug
2000; Arts et al. 2002; Brennan and Stead 2000; Brown, Kahn, and Toh 2013; Hasan and
Padman 2006; Hersh et al. 2013; Hogan and Wagner 1997; Hripcsak et al. 2011b; Kahn,
Eliason, and Bathurst 2010; Lei 1991; Rusanov et al. 2014; Thiru, Hassey, and Sullivan
2003). Limited research has been conducted to assess the quality of patient-provided infor-
mation in the EHR (Arsoniadis et al. 2015; Booth, Prevost, and Gulliford 2013; Chen et al.
2014; Lee, Grobe, and Tiro 2015; Melton et al. 2010), especially related to race and ethnic-
ity, family history, and smoking status. Because patient-provided information is frequently
stored in EHRs, it is critical to assess the quality of this information specifically.
Previous research has demonstrated that patients are an important and underutilized
source of information (Ball and Lillis 2001; Staroselsky et al. 2006), and that patient-
provided information can be used to overcome data quality issues (Arsoniadis et al. 2015;
Staroselsky et al. 2006, 2008; Wu et al. 2014). Some efforts have been made to enhance the
collection and use of patient-provided data. Those include broad policy initiatives such as
the Meaningful Use financial incentive program in the United States, which included, for
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example, standardization of the collection of family history (Centers for Medicare & Med-
icaid Services 2014a), smoking status (Centers for Medicare & Medicaid Services 2010),
and race and ethnicity (Centers for Medicare & Medicaid Services 2014b). In addition,
patient-facing tools, such as online patient portals, have been implemented in diverse clini-
cal settings. These portals allow patients to review their clinical information as available in
the EHR, and in some cases to record information that is fed back to the EHR (Cimino, Pa-
tel, and Kushniruk 2001; Collins et al. 2011; Delbanco et al. 2010; Greenhalgh et al. 2008;
Grossman et al. 2017; Halamka, Mandl, and Tang 2008; Hassol et al. 2004; Kaelber et al.
2008; Leveille et al. 2012; Nazi et al. 2010; Nazi et al. 2015; Pyper et al. 2004; Ralston et al.
2007; Reti et al. 2010; Tang and Lee 2009; Walker et al. 2011). These patient-facing tools
have been employed to help maintain up-to-date records (Staroselsky et al. 2006, 2008),
to promote disease screening and prevention through preventive health services (Murabito
et al. 2001; Reid et al. 2009; Staroselsky et al. 2006), to facilitate the assessment of dis-
ease risk and healthcare disparities (Chin 2015; Douglas et al. 2015; Kressin 2015; Woods,
Evans, and Frisbee 2016), to manage disease symptoms (Basch et al. 2009, 2017; Pakho-
mov et al. 2008; Weingart et al. 2005), and to improve the medication reconciliation process
(Dullabh et al. 2014; Finkelstein 2006; Kogut et al. 2014; Weingart et al. 2008).
While a substantial body of knowledge related to patient-provided data and patient-
facing tools exists, many questions remain. Three critical knowledge gaps are 1) a lack of
awareness of the quality of patient-provided information, particularly for race and ethnicity,
family history, and smoking status, 2) a limited understanding of the impact that various
interventions have on data quality, including policy decisions such as the Meaningful Use
program, and 3) the question of whether EHR data can be used in combination with patient-
3
provided information to assess disease risk.
The purpose of this thesis is to establish methods and tools 1) for assessing the qual-
ity of patient-provided data in clinical databases, 2) for studying the impact that distinct
interventions have on influencing the quality of patient-provided data, and 3) for using
patient-provided information to better understand disease risk and better inform clinical
decisions. I explored the quality of patient-provided information, specifically race and eth-
nicity, family history, and smoking status. I evaluated the impact of various interventions
designed to improve the quality of this information. Finally, I developed a novel method
that uses patient-provided information to extract familial relationships from existing clini-
cal databases, and I demonstrated how these relationships, in combination with EHR data,
may be used to better understand disease risk and support clinical research.
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1.1 Specific aims
Aim 1: Assess the quality of patient-provided data in clinical
databases.
Observational databases, including those containing EHR data, are a valuable resource
for biomedical research (Boland et al. 2015; Coopey et al. 2012; Dudley, Deshpande,
and Butte 2011; Hripcsak et al. 2016; Kohane 2011; Li et al. 2015; Ritchie, Andrade, and
Kuivaniemi 2015; Wang et al. 2017; Wei and Denny 2015). However, there are concerns
regarding the quality of EHR data, since these data are primarily collected as part of clinical
care, and not for research purposes (Weiner and Embi 2009; Weiskopf and Weng 2013).
Broadly, in this aim, I studied various data quality dimensions of patient-provided data such
as race and ethnicity, family history, and smoking status. The purpose of the analysis was
to assess the completeness, correctness, concordance, and plausibility of patient-provided
data stored in clinical databases and to identify opportunities for improvement.
To achieve this goal, I performed three studies. In the first, I investigated the quality
of race and ethnicity information in multiple clinical databases, both at a local level and
national level, based on completeness, correctness, and concordance using a combination of
data sources. In the second study, I focused on determining completeness of family history
information in the EHR by analyzing a sample of observations recorded using structured
and free-text note templates from a large academic medical center. And finally, in the third
study, I investigated the quality of smoking status information at the same medical center,
examining completeness, correctness, and plausibility of the data recorded. The results of
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the three studies included in this Aim provided generalizable knowledge about the quality
of patient-provided data in EHRs.
Aim 2: Evaluate methods for improving quality of patient-provided
data.
Results from the studies in Aim 1 demonstrated generally poor data quality in race
and ethnicity, family history, and smoking status based on the dimensions of quality an-
alyzed. These results showed a need to consider whether various types of interventions
could improve the quality of patient-provided data. Previous research on patient-provided
information sought to improve data collection and/or data quality using patient-facing tools
or by extracting important concepts from narrative text using natural language processing
techniques (Arsoniadis et al. 2015; Baumgart, Postula, and Knaus 2015; Bill et al. 2014;
Chen et al. 2012, 2014; Cohn et al. 2010; Feero 2013; Giovanni and Murray 2010; Hoyt
et al. 2013; Hulse et al. 2010; Masterson Creber et al. 2016; Melton et al. 2010; Murray
et al. 2013; Orlando et al. 2013; Ozanne et al. 2009; Peace, Valdez, and Lutz 2012; Pyper
et al. 2004; Staroselsky et al. 2006, 2008; Wang et al. 2016; Wilson et al. 2012a; Wu et al.
2014, 2015; Yoon, Scheuner, and Khoury 2003; Yoon et al. 2009). Some of the endeav-
ors to improve the quality of patient-provided information occurred at the national level
through policymaking efforts, such as the Meaningful Use program, while others occurred
in local institutions with the development of new applications, such as patient-facing tools.
While these interventions have been implemented to varying degrees, there has been little
research assessing whether data quality has improved. In this Aim, I studied the impact of
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policymaking efforts, patient-facing tools and informatics interventions on the quality of
patient-provided information.
To evaluate methods for improving quality of patient-provided data, I performed three
studies in Aim 2. In the first study, I analyzed the impact of the federal Meaningful Use
program and the Hospital Consumer Assessment of Healthcare Providers and Services (HC-
AHPS) survey in the quality of race and ethnicity information in the EHR. Additionally, I
analyzed the effect of a local informatics intervention that allowed patients to review and
update their race and ethnicity information obtained from the EHR. In the second study, I de-
veloped and evaluated a method that extracts familial relationships from clinical databases
using emergency contact information, a type of patient-provided data. Currently, clini-
cal databases do not record familial relationships, an important piece of information when
studying disease risk. In the third study, I analyzed the impact of the Meaningful Use pro-
gram on the completeness, correctness, and plausibility of smoking status in the EHR. The
results of these studies provided insight into the impact of various types of interventions on
the quality of patient-provided data.
Aim 3: Use patient-provided data to assess disease risk.
Accurately collecting patients’ family health history is important for the implementa-
tion of precision medicine in the clinical setting (Aronson and Rehm 2015; Guttmacher,
Collins, and Carmona 2004). The predictive value of family history for any given trait is
directly related to the fraction of phenotypic variance attributable to genetic factors, called
heritability (Tenesa and Haley 2013; Visscher, Hill, and Wray 2008), as well as to shared
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environmental factors. Knowledge of disease heritability combined with family history
information is clinically useful for identifying risk factors, estimating disease risk, cus-
tomizing treatment, and tailoring patient care (Chatterjee, Shi, and García-Closas 2016).
Unfortunately, heritability studies are typically time-consuming and costly. They are often
designed as prospective family-based studies and therefore have limited sample sizes, limit-
ing their power to detect associations. Further, identification of high-risk individuals in the
clinical setting can be complex. The proper identification of high-risk patients is a crucial
factor for the adherence to guidelines that target early screening and modified treatment for
patients considered at risk for disease development. However, the study of screening rates
is challenging due to the necessity of identifying patients that would have been deemed to
be high-risk but were not recognized as such during a clinical encounter.
Fortuitously, EHRs provide a valuable resource of clinical information that is currently
underutilized in genetic and clinical studies. EHRs are now widely adopted, capturing clin-
ical data for millions of individuals as part of clinical care. The use of EHR data in heritabil-
ity studies can overcome many of the challenges previously described, by increasing sample
sizes, thus enabling researchers to study diseases and relationships between diseases that
are currently poorly understood, and generate research hypothesis that can then be tested
using traditional genetic studies. EHR data, combined with health information technology,
can also support clinical research and clinical care. Identification of high-risk individuals
in existing clinical databases can facilitate better and easier measurement of adherence to
clinical guidelines.
In this Aim, I studied the use of EHR data to conduct genetic and clinical studies. Specif-
ically, I used the familial relationships identified as part of Aim 2 to perform two studies
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which estimated disease heritability and measured adherence to clinical guidelines. In the
first study, I assessed disease heritability using clinical traits, both dichotomous and quanti-
tative, recorded in the EHR. This study was conducted in three hospital systems from New
York. In the second study, I measure the adherence to guidelines rate for two distinct condi-
tions, diabetes mellitus and celiac disease. The results of these studies provided insight into
the heritability of multiple clinical traits, demonstrating that EHRs are a valuable resource
of clinical phenotypes. Further, it affirmed the ability to use EHR data to support clinical
care by identifying patients that are at high-risk for disease development.
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1.2 Significance and Contributions
This dissertation includes the following contributions: 1) an investigation of the perva-
siveness of data quality issues in patient-provided information, 2) measurement of the effec-
tiveness of different interventions to improve data quality of patient-provided information,
3) development and evaluation of a novel method to identify familial relationships from ex-
isting clinical databases using patient-provided data, and 4) generation of new knowledge
based on patient-provided information.
In the first Aim, I extensively explored the data quality of patient-provided information,
which is crucial to operationalizing precision medicine. Previous research has primarily fo-
cused on the quality of clinical data; whereas, in this Aim, I focused on studying the quality
of patient-provided data in clinical databases. The results of this Aim showed significant
data quality issues for race and ethnicity both at local institutions but also among national
databases. For family history, I identified data completeness issues among family history
information that was recorded in free-text format, which I found to be the strongly pre-
ferred method for recording and storing patient information. While assessing the quality of
smoking status, I found many implausible changes to patients’ smoking status. Together,
these data quality issues point to challenges in the way patient-information is collected and
stored. Furthermore, interventions to improve data quality certainly appear to have merit
in light of the findings of this Aim.
In the second Aim, I assessed the impact of different initiatives on the quality of patient-
provided data. I explored the effects of different types of interventions, such as policymak-
ing efforts, patient-facing tools, and informatics algorithms, on improving the quality of
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the information collected. In relation to race and ethnicity, I found that high-level policy
changes, such as moving to a two-question format to capture race and ethnicity, increased
collection of race and ethnicity information, but did not necessarily improve the quality of
that data. However, giving patients the opportunity to review and correct the information
was, in comparison, more successful. Similarly, assessing the impact of policy change on
smoking status showed more data collection, but also more data quality issues. Results
from Aim 1 showed that family history was poorly recorded in the EHR, and therefore, I
assessed the feasibility of inferring this information from other sources as a way to over-
come the completeness issues. In this Aim, I demonstrated for the first time the feasibility
of using patients’ emergency contact information, in combination with clinical data to accu-
rately infer family history. Overall, in this aim, I demonstrated various ways interventions
can be implemented to overcome data quality issues.
In the third Aim, I used patient-provided information along with the method to infer
familial relationships developed in Aim 2 to generate new understanding of disease charac-
teristics and disease management, demonstrating that the method developed opened up new
avenues for biomedical research. This Aim focused on two aspects, the measure of disease
heritability, and assessment of screening rates among high-risk individuals. Both of these
areas of research are traditionally resource-intensive and lie in two distinct fields: genetics,
and medicine. The results of this Aim showed that EHR data can be used to support genetic
studies by providing an opportunity to study conditions previously not investigated due to
the availability of larger sample sizes in EHRs. Further, this Aim also demonstrated the
potential of EHR data to be used to assess screening rates among high-risk patients. The
results of both of these studies demonstrate that EHR data has utility far beyond supporting
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clinical care.
The contributions of this thesis include 1) an overview of the quality of patient-provided
information in clinical databases, 2) an assessment of the impact of different interventions
types on the quality of patient-provided data, 3) the development and evaluation a novel
method that uses patient-provided information to generate an unique database that can sup-
port biomedical research, and 4) the use of readily available data to understand disease risk
and assess disease screening rates among high-risk individuals. The results of the presented
studies contributed to the understanding of data quality issues concerns regarding patient-
provided information in clinical databases. Further, the studies assessed how interventions
currently affect the quality of patient-provided data, ultimately building the foundational
work of how to better collect patient-provided information as part of healthcare encounters
and how EHRs could be designed to overcome these challenges. These studies also devel-
oped and validated a novel method that relies on data readily available in EHRs to extract
familial relationships from existing clinical databases. And lastly, these studies demon-
strated that the use of inferred family history information can support the execution of large
clinical and genetic studies, having a significant impact on biomedical research.
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1.3 Limitations
This thesis has several limitations. All studies presented in this thesis heavily relied on
data available in the EHR, and therefore, are subject to limitations of EHR data to conduct
research. Fragmentation of care, for example, is an important limitation when using EHR
data for research. Patients often receive treatment at multiple healthcare systems, and there-
fore, the information available in a single institution may be incomplete. Studies from Aim
1 (studies 2 and 3), Aim 2 (studies 1 and 3), and Aim 3 (study 2) were performed at a single,
large, urban academic medical center, and as such, the findings may not be generalizable to
other institutions. Aim 2 (study 1) had a small sample size due to patient recruitment con-
straints, limiting the generalizability of the findings. Additionally, recruitment was only
conducted with English-speaking participants, limiting the patient population in the study.
Studies conducted in Aim 3 extracted phenotypes from billing codes and did not necessarily
developed a careful EHR-phenotype for each analyzed trait. Biases in billing documenta-
tion may have affected the presented results.
13
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Chapter 2
Review of the Literature
Some consider that disease risk prediction began in 1948 with the Framingham Heart
Study. This study successfully developed a risk prediction model for cardiovascular dis-
ease using clinical data (Dawber, Meadors, and Moore 1951). Since this study, risk assess-
ment models have been developed for a variety of diseases, creating the basis of what is
now called “precision medicine.” Precision medicine focuses on disease prevention and
treatment while considering individuals variability in genes, environment, and lifestyle
(Collins and Varmus 2015; U S National Library of Medicine, Precision medicine). Despite
the growing importance of genomics and genetic sequencing, a crucial part of precision
medicine is patient-provided information. This information is a key element for individ-
ualizing disease screening, diagnosis, and treatment (Guttmacher, Collins, and Carmona
2004). Some patient-provided information, such as a patient’s medical history, family his-
tory, allergies, and medication use, can guide clinicians to determine the best course of
action based on the risk of disease development for the patient.
Patient-provided data are data collected directly from patients or caregivers (Basch
2010; Hirsch and Abernethy 2013), and include many important elements in clinical care.
Previous work demonstrated patient-provided data to be critical in multiple tasks pertain-
ing to clinical care, including disease risk assessment (Berry et al. 1997; Claus, Risch,
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and Thompson 1994; Ozanne et al. 2013; Tyrer, Duffy, and Cuzick 2004; Wu and Orlando
2015), and medication reconciliation (Dullabh et al. 2014; Staroselsky et al. 2008; Wein-
gart et al. 2008). Further, others have demonstrated that patient-provided information can
support activities related to symptom management (Basch et al. 2009; Pakhomov et al.
2008; Weingart et al. 2005) and to disease screening and prevention (Murabito et al. 2001;
Reid et al. 2009; Staroselsky et al. 2006). Patient-provided data have also been shown to be
valuable for broader tasks, such as assessment of healthcare disparities in healthcare sys-
tems (Chin 2015; Douglas et al. 2015; Kressin 2015; Woods, Evans, and Frisbee 2016).
Family history, allergies, adherence to treatment plans and preventive services are common
examples. Less common examples may not be perceived as patient-provided information,
such as chief complaint, history of present illness, and demographic information, such as
race and ethnicity and emergency contact information. Patient-provided data are stored in
patients’ records in EHRs, often recorded by physicians or other care providers during or
after a clinical encounter (Weiner and Embi 2009; Weiskopf and Weng 2013). Many pre-
vious studies have raised issues regarding the data quality of this information in the EHR.
Incompleteness and incorrectness are two data quality issues that have frequently been re-
ported in studies focusing on the quality of patient-provided data (Ball and Lillis 2001;
Douglas et al. 2015; Kaplan 2014; Klinger et al. 2015; Kressin 2015; Lee, Grobe, and Tiro
2015; Polubriaginof, Tatonetti, and Vawdrey 2015; Qureshi et al. 2009; Staroselsky et al.
2006; Welch, Dere, and Schiffman 2015).
Figure 2.1 shows the traditional process of collecting patient-provided data. Given
that this information is now commonly stored in the EHR, reuse of this data is increasingly
common, leading to discoveries and an improved understanding of the patient (Boland et
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Figure 2.1: The traditional process of collecting patient-provided information.
al. 2015; Coopey et al. 2012; Dudley, Deshpande, and Butte 2011; Hripcsak et al. 2016;
Kohane 2011; Li et al. 2015; Lorberbaum et al. 2016b; Polubriaginof et al. 2017; Ritchie,
Andrade, and Kuivaniemi 2015; Tatonetti et al. 2012; Wang et al. 2017; Wei and Denny
2015). Informatics interventions to improve quality and therefore data reuse can target
each one of these steps. Changes can be implemented to modify how data are collected and
structured, leading to improved data reuse and the generation of new knowledge.
Data collection
The first step in the process is the collection of patient-provided information. Tradi-
tionally, practitioners have used the patient’s appointment to collect a variety of patient-
provided information. As time for patient encounters has become compressed and filled
with other tasks, opportunities to collect and record patient-provided information have
decreased. Advancements in technology allow patients to provide this data directly to
providers through patient-facing tools (Bardes 2012; Warner 2010). Such tools include
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registration forms, which can be implemented in paper or electronic format, and patient
portals, which often also provide patients with access to some of their clinical informa-
tion in addition to collecting information from them (Cimino, Patel, and Kushniruk 2001;
Collins et al. 2011; Delbanco et al. 2010; Greenhalgh et al. 2008; Grossman et al. 2017;
Halamka, Mandl, and Tang 2008; Hassol et al. 2004; Kaelber et al. 2008; Leveille et al.
2012; Nazi et al. 2010; Nazi et al. 2015; Pyper et al. 2004; Ralston et al. 2007; Reti et al.
2010; Tang and Lee 2009; Walker et al. 2011).
Patient-facing tools can be used both in inpatient and outpatient care settings, or even at
home. These tools can be an avenue for patients to review and provide health information,
reducing practitioner burden and saving time during the patient visit, while simultaneously
engaging patients in their care (Arar et al. 2011; Epstein et al. 2010; Otte-Trojel et al.
2014). Previous research studies have used patient portals to improve data quality of past
medical, surgical and social history (Arsoniadis et al. 2015), quality of EHR medication
lists (Staroselsky et al. 2008), quality of medication information (Weingart et al. 2008),
collection of smoking status (Baumgart, Postula, and Knaus 2015), and quality of family
history data (Baumgart, Postula, and Knaus 2015; Volk et al. 2007). Others have used
other patient-facing tools such as tablet applications, websites, and surveys to collect and
improve quality of patient-provided information (Facio et al. 2010; Hamilton et al. 2009;
Klinger et al. 2015; Pakhomov et al. 2008; Staroselsky et al. 2006; Sweet et al. 2014; Wu
et al. 2015; Yoon et al. 2009). The use of these tools can also be beneficial for patients.
There is also considerable evidence showing that the use of patient portals have improved
patient engagement (Greenfield et al. 1988; Hack, Degner, and Dyck 1994; Kaplan et al.
1995) and patient outcomes (Arar et al. 2011; Davis Giardina et al. 2014; Dwamena and
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Rovner 2012; Epstein et al. 2010; Otte-Trojel et al. 2014).
Regardless of how the data is collected, patients play an important role in providing their
information, and they are often an underutilized resource (Ball and Lillis 2001; Staroselsky
et al. 2006). Others have emphasized the importance of patient participation by stating
that “patient and physician must meet as equals, bringing different knowledge, needs, and
concerns” (Bardes 2012). Previous research studies have shown that patients are not only
willing to provide their information, but they find it to be a useful experience (Arar et al.
2011; Wu et al. 2013). Furthermore, multiple studies have shown that the quality of the data
collected by patients is superior to data collected in the routine clinical practice (Cohn et al.
2010; Frezzo et al. 2003; Jones, McGhee, and McGhee 1992; Porter et al. 2000; Reid et al.
2009; Selvachandran et al. 2002; Sweet, Bradley, and Westman 2002; Wuerdeman et al.
2005), demonstrating the importance of giving patients the opportunity to directly provide
their information.
Data structure
It is important to understand how patient-provided data are stored in clinical documenta-
tion. Traditionally, patients’ medical information was kept on paper charts. The purpose of
these charts was to facilitate physicians’ clinical reasoning and management of the course
of treatment while communicating important decisions and relevant information to other
members of the clinical team (Cusack et al. 2013; Engle 1991; Siegler 2010). Over time,
documentation had to incorporate not only clinically meaningful information, but also a
variety of elements pertaining to billing and reimbursement, regulations and accreditations,
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and legal requirements (Cusack et al. 2013; Hagland 2011; Wasserman 2011). In the U.S.,
the Health Information Technology for Economic and Clinical Health (HITECH) Act, au-
thorized $27 billion in incentives for EHR adoption, resulting in the EHR adoption rates to
increase rapidly, resulting in 95% of hospitals reportedly using EHRs by 2016 (Conn 2016;
Health Information Technology 2017). The transition from manual clinical documentation
to EHR facilitated the reuse of clinical data for biomedical research, quality initiatives, and
other purposes (Hammond et al. 1980; Schriger et al. 1997, 2000).
Along with the implementation of EHR systems, there is a trend toward collecting infor-
mation using structured documentation, which facilitates reporting and data reuse but often
results in more cumbersome information entry processes, compared to narrative text. As
part of the HITECH Act, the federal government developed the Meaningful Use program,
a financial incentive program supporting the adoption of EHRs (CMS Electronic Health
Records Incentive Programs). The Meaningful Use program requires a set of data elements
to be collected in a structured format. Many of these elements are patient-provided infor-
mation, such as race and ethnicity (Centers for Medicare & Medicaid Services 2014b),
family history (Centers for Medicare & Medicaid Services 2014a), and smoking status
(Centers for Medicare & Medicaid Services 2010). The program also determined the use
of standards and terminologies to store this information in an effort to standardize the data
collected across organizations.
Rosenbloom and colleagues have described a tension between structure documenta-
tion and expressiveness (Rosenbloom et al. 2011). The use of free-text in clinical docu-
mentation versus structured data necessitates a trade-off between expressivity, flexibility,
efficiency, and ease of data reuse. Many practitioners prefer to use free-text documenta-
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tion to express subtleties and uncertainty; elements that structure documentation often does
not support. While policy change can require the documentation of patient-provided data
and storage in the EHR, concerns regarding the data quality of the information collected
remains, and the impact of implementation of new policy and tools is often poorly under-
stood.
Data reuse
With the broad availability of clinical data in electronic format, there has been a growing
interest in reusing clinical data collected during patient encounters in research. Traditional
clinical trials often rely on patient recruitment, a process that is labor-intensive and costly
(Drennan 2002; Institute of Medicine (US) Forum on Drug Discovery, Development, and
Translation 2010). EHRs store clinical data, including patient-provided data, that is col-
lected on a daily basis as part of clinical care. Use of EHR data can overcome many of
the challenges faced by traditional studies by enabling larger sample sizes with sharply
decreased costs. Data reuse can also support reproducibility of findings.
While EHR data are required to be kept in secure databases with limited access to safe-
guard protected health information, initiatives such as OHDSI (Hripcsak et al. 2015) and
i2b2 (Murphy et al. 2010) have developed strategies to support research reproducibility
while maintaining privacy (Yuan et al. 2017). These initiatives created open-source frame-
works that allow disparate teams of researchers to run the same analyses on separate private
databases, and combine the results with confidence in order to effectively achieve the bene-
fits of data aggregation on closed data. Using the OHDSI platform, Hripcsak and colleagues
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conducted the largest observational research study focusing on the characterization of treat-
ment pathways for disease, leveraging the medical records and administrative claims data
of 250 million patients (Hripcsak et al. 2016).
In addition to EHR data, other initiatives have taken place. In 2009, President Obama
created the Open Government Directive, an initiative created to make the government more
transparent. As part of this initiative, federal, state and local authorities began to release
de-identified health data. The data released was publicly accessible, available in multiple
formats, free of charge, and has unlimited use and distribution rights (Open Government
Directive). As a result of this initiative, there are currently more than 3,500 open datasets
available at HealthData.gov (HealthData.gov). In New York State, the use of open data
has already positively impacted emergency response during hurricanes, changes in policies
and medical education curriculum, patient safety, and accountability of healthcare costs
(Martin, Helbig, and Shah 2014).
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2.1 Patient-provided data
Even though clinical databases contain valuable information that is increasingly avail-
able, the use of this information in areas such as genetic research has been limited. In this
dissertation, I focus on the study of three types of patient-provided information: race and
ethnicity, family history, and smoking status.
Race and Ethnicity
Race and ethnicity are collected for many reasons, including for clinical, administra-
tive, and research purposes. Clinically, race and ethnicity are commonly used for estimat-
ing disease risk (Gail et al. 1989; Levey et al. 2009; Stevens et al. 2006) and for assessing
racial and ethnic health disparities (Dorsey et al. 2014; Douglas et al. 2015; Kressin 2015;
LaVeist, Gaskin, and Richard 2011). From an administrative standpoint, the Centers for
Medicare and Medicaid Services, through the Meaningful Use incentive program, requires
standardized collection of patients’ race and ethnicity (Centers for Medicare & Medicaid
Services 2014b). This is because race and ethnicity are a part of a patient’s socioeconomic
status, which has been discussed as a method for risk adjusting in payment reform (Buntin
and Ayanian 2017; Committee on Accounting for Socioeconomic Status in Medicare Pay-
ment Programs et al. 2016). From a research perspective, studies frequently report patients’
demographic information, including race and ethnicity.
Race and ethnicity can be collected from patients in a variety of formats and by a variety
of personnel. This information is often collected either verbally or through patient-facing
tools, such as intake forms completed during a clinical encounter. Race and ethnicity are ei-
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ther directly entered or transcribed from intake forms into the EHR (Adler and Stead 2015).
However, there are many challenges to the collection of race and ethnicity information that
may degrade the quality of this data in the EHR (Blustein 1994; Chakkalakal et al. 2015;
Gomez and Glaser 2006; Hamilton et al. 2009; Lee, Grobe, and Tiro 2015; Moscou et al.
2003). Cultural insensitivity and lack of understanding of the importance of race and eth-
nicity information are major challenges to collecting race and ethnicity information in the
hospital setting. Verbally asking patients their race and ethnicity can be an uncomfortable
situation for both healthcare workers and patients (Baker et al. 2007). A previous study
conducted in 2014 reported that registration personnel felt inadequately trained to ask pa-
tients’ race and ethnicity (Berry et al. 2014). Secondly, there is a lack of understanding
of why this information is collected and how it will be used. A study conducted in 2005
showed that information that is not known to be used by others is not accurately collected
(Nelson et al. 2005). Registration personnel are often unaware of the importance of race and
ethnicity and also do not know who uses the information. This lack of awareness presents
a barrier to registration personnel asking patients their race and ethnicity. From a patient’s
perspective, the question is often unexpected and may not come with an explanation of how
the information will be used and why it is important.
In the U.S., some effort has gone into standardizing the data structures for storing race
and ethnicity information. The Meaningful Use program specifies that race and ethnicity
data collection should follow the standard developed by the Office of Management and
Budget (OMB) (OMB 1997). According to this standard, race and ethnicity information
can be collected in either a single-question or in a two-question format. Despite this option,
there has been limited research on the impact of using a single-question or the two-question
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format on data quality. Furthermore, the OMB also established that patient-provided in-
formation be considered the gold standard for the collection of race and ethnicity data. In
this respect, there has been little effort to compare race and ethnicity information directly
provided by patients with the corresponding data stored in the EHR.
Family History
Family history has always been considered “a core element of clinical care” (Berg et al.
2009) and has been described as being a free genetic tool that almost every patient has access
to (Guttmacher, Collins, and Carmona 2004). Since the Human Genome Project, new
genomic tools have been described (Guttmacher and Collins 2003); however, family history
remains critical for identifying patients that may be at higher risk to develop disease. Family
history provides information that enables individualized disease diagnosis, treatment, and
prevention.
Several studies have shown that family history is an important element in deciding clin-
ical care. Knowing that a patient is at increased risk of developing a disease based on family
history enables disease prevention that can vary from intensive screening to prophylactic
surgery. It can also facilitate earlier diagnosis and more tailored treatment. For exam-
ple, current guidelines from the American Cancer Society define criteria for MRI eligibil-
ity in addition to mammography for breast cancer screening (Saslow et al. 2007; Smith,
Cokkinides, and Brawley 2012). The guidelines recommend that patients that have a life-
time risk of breast cancer greater than 20% by BRCAPRO (Berry et al. 1997), Tyrer-Cuzick
(Tyrer, Duffy, and Cuzick 2004), or Claus (Claus, Risch, and Thompson 1994) models
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should have screening MRI in addition to mammography. Each of these models was de-
veloped using different methods, different populations and different risk factors, and each
of them was developed to predict different outcomes, but all of them heavily rely on family
history and presence of risk factors (Ozanne et al. 2013). This is just one of many examples
of the importance of family history information for clinical care.
Given the variety of guidelines and models available, clinical decision support systems
have been developed to help clinicians deliver precision medicine. One of the earliest re-
search studies about the use of clinical decision support (CDS) systems to support precision
medicine was conducted by Emery and colleagues in 1999. The study identified that the
CDS systems available were not appropriate for use in a primary care setting (Emery 1999).
To address this problem, a system was developed to record and interpret family history data
in the primary care clinic. The system included family history relevant to breast, ovarian
and colorectal cancer (Emery et al. 1999). Over time, other clinical decision support sys-
tems were developed to manage other types of cancers, such as colorectal cancer and Lynch
syndrome, and all of these systems used family history information to provide disease risk
assessment (Welch and Kawamoto 2013).
Currently, the U.S. Preventive Services Task Force (USPSTF) recommends risk assess-
ment based on family history for some conditions such as screening for BRCA mutation
and BRCA-related cancers (Moyer and U.S. Preventive Services Task Force 2014), osteo-
porosis (U.S. Preventive Services Task Force 2011), and lipid disorders in adults (Helfand
and Carson 2008). A 2007 report commissioned by the Agency for Healthcare Research
and Quality (AHRQ) recommended that collection of family history information should in-
clude diseases in first-degree relatives and second-degree relatives from both the maternal
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and paternal side, the relatives’ age at the time of disease diagnosis, and each relatives’ race
and ethnicity (Qureshi et al. 2007).
Family history can be collected through several modalities; however, two common
methods for capturing family history information include directly from the patient using
either free-text or semi-structured patient-facing tools. Some examples of tools that have
been deployed to help collect family history include Family Healthware from the Centers
for Disease Control and Prevention (Yoon et al. 2009), Family HealthLink from The Ohio
State University Medical Center (Sweet et al. 2014), Health Heritage from University of
Virginia Health System (Baumgart, Postula, and Knaus 2015; Cohn et al. 2010), Hughes
RiskApps from the Massachusetts General Hospital (Ozanne et al. 2009), OurFamilyHealth
from Intermountain Healthcare (Hulse et al. 2011), andMeTree from Duke University (Or-
lando et al. 2011, 2013; Wu et al. 2015). Some of these tools not only capture family history
but also perform disease risk assessment based on the family history data. For example,
Family Healthware, a web-based tool developed by the Centers for Disease Control and
Prevention focused on the collection of family history to assess familial risk for six condi-
tions: heart disease, stroke, diabetes, colorectal cancer, breast cancer, and ovarian cancer
(Yoon et al. 2009). Previous studies describing tools for collecting family health history
highlighted data collection issues, such as time limitations. A study conducted in 2011 de-
scribed that the average time required for patient to input family history information using
a web-based tool was 15 minutes, in a range from 3 to 45 minutes (Owens et al. 2011).
Given the importance and utility of family history data, several initiatives have been
put implemented to increase the structured collection of family history. The goal of these
initiatives is to enable precision medicine, which requires accurate and detailed family his-
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tory data. For example, Stage 2 of the Meaningful Use program included a requirement of
clinicians to use structured data entry for family history. Under the program, eligible hos-
pitals must have recorded at least one structured family history data element for at least one
first-degree relative for 20% of their patients (Centers for Medicare & Medicaid Services
2014a).
In addition to the Meaningful Use program, other federal initiatives have focused on
collecting family history from the patient, such as the U.S. Surgeon General’s My Family
Health Portrait (My Family Health Portrait). This initiative promotes individuals to share
their information with family members and healthcare providers through a web-based ap-
plication. While most interventions have focused on collecting structured family history,
previous research has identified a tradeoff between strictly structured data, which promotes
reuse and standardization, and free-text documentation, which promotes expressiveness
(Rosenbloom et al. 2011). In fact, there has been little prior research comparing the impact
of data structures on the data quality of family history.
Smoking Status
Smoking is an important risk factor for multiple diseases, including cardiovascular
diseases and numerous types of cancer. It remains the number one cause of preventable
death in the United States, being responsible for more than 480,000 deaths annually (Na-
tional Center for Chronic Disease Prevention and Health Promotion Office on Smoking
and Health 2014). To provide patients with the resources to quit smoking, the collection of
patients’ smoking status during clinical encounters is critical (Boyle, Solberg, and Fiore
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2014). Smoking cessation can be difficult, and clinical visits are opportunities to intervene
and recommend smoking cessation programs and therapies. Obtaining a patient’s smok-
ing status is a crucial step in beginning smoking cessation interventions and monitoring
progress (Caplan, Stout, and Blumenthal 2011).
Similar to other types of patient-provided data, smoking status can be collected in a
variety of formats. Usually, this information is collected during a clinical encounter, by
clinicians verbally asking patients about their smoking status. This information is then en-
tered into the EHR, usually as part of clinical notes. It may seem that recording updates
to smoking status in a timely and accurate manner would be straightforward using modern
EHRs; however, previous research has shown that social and behavioral determinants of
health are often overlooked during clinical encounters (Adler and Stead 2015). The chal-
lenges related to the appropriate collection and documentation of smoking status include
lack of standard terminology and granularity for data collection, shifting cultural attitudes
regarding tobacco use, and potentially frequent changes in individuals’ smoking behavior
(Committee on the Recommended Social and Behavioral Domains and Measures for Elec-
tronic Health Records, Board on Population Health and Public Health Practice, and Institute
of, Medicine 2015; Winden et al. 2015).
Due to the positive impact of smoking cessation in health, tobacco control policies such
as smoke-free legislation, tobacco taxation, and smoking cessation services have been im-
plemented and have been shown to have substantial benefits in children’s health (Faber
et al. 2017).
Given the clinical importance of recording smoking status, the Meaningful Use finan-
cial incentive program for EHR adoption in the U.S. included a requirement for healthcare
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providers to capture patients’ smoking status electronically in a structured fashion (Centers
for Medicare & Medicaid Services 2010). Meaningful Use has helped to standardize data
collection of smoking status and other information. However, previous efforts to improve
patient-provided data types, such as race and ethnicity (Klinger et al. 2015; Lee, Grobe,
and Tiro 2015) and family history (Polubriaginof, Tatonetti, and Vawdrey 2015; Powell
et al. 2013) did not necessarily improve data quality through the adoption of standards for
representing information, but it often resulted in increased documentation of these data
types. There is little knowledge whether the data quality of smoking status improved after
Meaningful Use requirements were implemented.
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2.2 Knowledge gaps
This dissertation focused on several knowledge gaps related to patient-provided data.
First, there have been limited studies focusing on whether some patient-provided data types
are accurately captured in the EHR. Patient-provided data is traditionally collected by clin-
icians as part of clinical encounters and due to time constraints during clinical visits, the
appropriate collection and documentation of important information may be overlooked.
Second, due to the importance of patient-provided data, initiatives such as the Meaning-
ful Use program had the objective of ensuring that patient-provided data would be collected
and recorded in the EHR in a structured format. However, limited work has been performed
to measure the impact of the Meaningful Use program in the quality of patient-provided
data. Concerns regarding data quality of structured data in EHRs have been previously
raised. Previous studies have discussed the trade-off between the flexibility of free-text
documentation versus the easy reuse of structured data. The mandatory collection of these
data in a structured format may decrease data quality as clinicians have to rush more with
structured documentation, losing documentation flexibility which may lead to reduced ex-
pressiveness, and therefore poorer data quality.
Third, while patients are considered the reference standard for patient-provided data,
limited work has been done in assessing the impact of patients directly providing data as
compared to patient-provided data being recorded by clinical or administrative staff dur-
ing hospital encounters. Despite numerous patient-facing tools being developed, allowing
patients to contribute information to their care, there have been few attempts to assess the
quality of the information provided by patients in comparison to the data available in the
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EHR.
Fourth, there has been little work focusing on the use of informatics methods to infer
patient-provided data from clinical databases. Large amounts of clinical data are now avail-
able due to the broad adoption of EHRs, and these data could be used to infer additional
information and ultimately support research.
Fifth, there has been little work focusing on strategies to overcome the challenges of
data quality and biases in patient-provided information stored in the EHR for knowledge
generation. Clinical databases are a valuable resource of information, and the use of these
data should account for biases and data quality concerns when generating new knowledge
and supporting clinical research.
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Chapter 3
Aim 1 - Assess the quality of patient-provided data in clinical
databases
The purpose of this aim was to evaluate the quality of patient-provided data in clinical
databases. With the growing adoption of EHRs, research studies conducted on observa-
tional data can complement prospective studies. The use of EHR data not only provides
increased sample sizes and access to diverse populations but also allows for hypothesis
testing prior to the implementation of prospective studies (Benson and Hartz 2000; Berger
et al. 2009; Concato, Shah, and Horwitz 2000; Madigan et al. 2014; Ryan et al. 2012). EHR
data have been used to shed light on disease processes (Boland et al. 2015; Coopey et al.
2012; Hripcsak et al. 2016; Li et al. 2015; Ritchie, Andrade, and Kuivaniemi 2015; Wei
and Denny 2015), including genetics (Kohane 2011; Polubriaginof et al. 2017; Wang et al.
2017), and on drug effectiveness and interactions (Dudley, Deshpande, and Butte 2011;
Lorberbaum et al. 2016b; Tatonetti et al. 2012). However, there are concerns regarding the
quality of EHR data. Multiple research studies have demonstrated quality concerns with
EHR data (Ahmad et al. 2017; Aronsky and Haug 2000; Arts et al. 2002; Brennan and Stead
2000; Brown, Kahn, and Toh 2013; Hasan and Padman 2006; Hersh et al. 2013; Hogan and
Wagner 1997; Hripcsak et al. 2011b; Kahn, Eliason, and Bathurst 2010; Lei 1991; Rusanov
et al. 2014; Thiru, Hassey, and Sullivan 2003). For example, a study conducted in 2017
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Table 3.1: Description of the five dimensions of data quality.
analyzed the validity of cardiovascular data by comparing EHR data to data collected by
standardized research approaches in a cohort study. Overall, this study demonstrated that
some clinical features were better documented in the EHR than others, and therefore, data
quality concerns should be considered when using existing clinical databases for research
(Ahmad et al. 2017).
In this Aim, I analyzed dimensions of data quality for three distinct types of patient-
provided data: race and ethnicity, family history and smoking status. The purpose of the
analysis was to understand how reliable this information was in clinical databases, and
uncover opportunities for improvement. Data quality is defined along 5 dimensions: 1)
completeness, 2) correctness, 3) concordance, 4) plausibility and 5) currency (Weiskopf
and Weng 2013). Table 3.1 shows the definitions of each dimension of data quality. The
studies from this Aim describe data quality in terms of these dimensions.
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3.1 Aim 1.1 - Assessing the quality of race and ethnicity
data collected in clinical databases
Background
Race and ethnicity information has long been collected by U.S. hospitals (Adler and
Stead 2015; Hasnain-Wynia, Pierce, and Pittman 2004), and this information is frequently
reported in observational studies that use electronic health record (EHR) data. Race and
ethnicity are commonly used for estimating disease risk (Gail et al. 1989; Levey et al.
2009; Stevens et al. 2006) and for assessing racial and ethnic health disparities (Dorsey
et al. 2014; Douglas et al. 2015; Kressin 2015; LaVeist, Gaskin, and Richard 2011). The
use of race and ethnicity as a proxy for socioeconomic or as a marker for disparities in
health care is being increasingly discussed (Bach et al. 2004; Buntin and Ayanian 2017;
Committee on Accounting for Socioeconomic Status in Medicare Payment Programs et al.
2016).
The United States Centers for Medicare and Medicaid Services (CMS) “Meaningful
Use” financial incentive program for EHR adoption includes the collection of patients’ race
and ethnicity as one of its requirements (Centers for Medicare & Medicaid Services 2014b).
The Meaningful Use program adopted as a model for race and ethnicity data collection
the standard developed by the Office of Management and Budget (OMB) (OMB 1997).
According to this standard, race and ethnicity information can be collected in either a single
question or in a two-question format. It also established that patient-provided information
be considered the gold standard for the collection of race and ethnicity data.
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Race and ethnicity are typically collected in healthcare settings at the time of regis-
tration. Although EHRs now include structured fields for collection of patient-provided
data such as race and ethnicity information, previous studies report this information is of-
ten not accurate in the EHR (Blustein 1994; Chakkalakal et al. 2015; Gomez and Glaser
2006; Hamilton et al. 2009; Lee, Grobe, and Tiro 2015; Moscou et al. 2003; Polubriaginof,
Tatonetti, and Vawdrey 2015). A possible way to improve the quality of race and ethnicity
information in clinical databases is to have patients report this information themselves via
a paper or electronic form.
Objectives
The purpose of this study was to evaluate data quality of race and ethnicity data na-
tionally as well as in a large healthcare system in New York. Specifically, I evaluated the
completeness, correctness and concordance of race and ethnicity information in clinical
databases.
Research Questions
• What proportion of race and ethnicity data is clinically informative in observational
clinical databases?





United States National Databases
I analyzed data from two large observational health databases: HCUP and the Optum
Labs Data Warehouse. The HCUP (Healthcare Cost and Utilization Project) database is a
hospital transactional database created by AHRQ that includes over 90 million inpatient,
emergency visits, and ambulatory surgery encounters from multiple hospitals in the United
States (Healthcare Cost and Utilization Project (HCUP)). The Optum Labs Data Ware-
house is an administrative claims database of more than 70 million commercially insured
and Medicare Advantage enrollees, with greatest representation in the Midwest and South
US census regions (Optum Data Assets; Wallace et al. 2014).
I examined HCUP data from 2000 to 2011 and Optum data from 2000 to 2016. The two
databases stored race and ethnicity information using slightly different categories. Both
included “White,” “Black or African American,” “Hispanic or Latino” and “Unknown” as
categories, so I only included only these four options and reported the remaining groups
collectively as “Other.” A detailed description of these datasets, including the categories
used to collect race and ethnicity information, sample size and timeframes, is shown in
Table 3.2.
Academic Healthcare System in New York City
I conducted a retrospective analysis of race and ethnicity data recorded for patients that






























through December 2015 at an academic health system that serves a racially and ethnically
diverse population in 10 hospital campuses in and around New York City, including a qua-
ternary care hospital. The Ambulatory Care Network (ACN) consists of 14 primary care
practice sites and more than 50 specialty care clinics. The academic health system provides
millions of visits annually, including 2.2 million outpatient visits, 286,000 emergency de-
partment visits, and 126,000 inpatient discharges.
Race and ethnicity data were collected by the health system in one of two ways: 1) pa-
tients completed paper forms as part of the registration process, or 2) registration clerks ver-
bally asked patients about their race and ethnicity. To collect race and ethnicity, the health
system used a two-question format, the first field capturing the patient’s race (“American In-
dian or Alaska Native,” “Asian,” “Black or African American,” “Native Hawaiian or Other
Pacific Islander,” “White,” “Unknown,” “Other,” or “Declined to Answer”), and the sec-
ond field capturing the patient’s ethnicity (“Hispanic or Latino,” “Not Hispanic or Latino,”
“Declined to Answer,” or “Unknown”). Race and ethnicity information were collected at
every encounter and stored in a centralized location in the EHR.
From the same academic health system, I examined data from the Hospital Consumer
Assessment of Healthcare Providers and Systems (HCAHPS) Survey administered to pa-
tients who had a hospital stay from January 2014 through December 2015. The HCAHPS
Survey was sent via U.S. Mail after hospital discharge. To collect race and ethnicity, the sur-
vey used a two-question format, with one field capturing race (“White,” “Black or African
American,” “Asian,” “Native Hawaiian or other Pacific Islander,” “American Indian or




Since each data source collected race and ethnicity using different categories, I de-
scribed groups that were available in all data sources and reported the remaining groups
collectively as “Other.” I performed descriptive statistics for “White,” “Black or African
American,” “Hispanic or Latino,” and “Other racial and ethnic groups.” Patients classi-
fied as “Unknown,” “Other” or “Declined to Answer” were considered to have clinically
uninformative data; I combined these categories into a larger group designated as “Unin-
formative” for further analysis. Completeness was assessed based on the percentage of
“Uninformative” race and ethnicity in the database. Using EHR data, I also calculated de-
scriptive statistics on the frequency of race/ethnicity pairs, since these two fields are highly
correlated.
Changes in race and ethnicity information in the EHR
I analyzed changes to race and ethnicity recorded for the same patient over multiple
visits, using system logs from the EHR. Patients with two or more visits during the study
period were included in this analysis. I reported descriptive statistics on changes of race
and ethnicity pairs over time.
A race/ethnicity pair was recorded during each clinical encounter. To quantify the fre-
quency of changes recorded for a patient’s race and ethnicity, each race and ethnicity pair
was scored based on the amount of information it contained. Race and ethnicity pairs were
broken down into concept pairs, with one concept for race and another for ethnicity, and
each concept was scored individually. Each informative concept received a score of 1,
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and each uninformative concept received a score of 0. For example, “White”, “Hispanic”
would receive a score of 2 since both the race and ethnicity concepts are informative. Like-
wise, “White” with “Unknown” ethnicity would receive a score of 1, and “Unknown” race,
“Unknown” ethnicity received a score of 0. The scores were compared for each pair chrono-
logically.
The changes in the content of the race and ethnicity pairs were classified as: information
loss, neutral, or information gain. If the patient had the same score in the previous and
current visit (i.e., the difference between the previous and current race/ethnicity score was
0), it was considered to be neutral. If the score from the second visit was greater than the
previous visit, it was considered information gain. Finally, if the score from the second visit
was less than the previous visit, it was considered information loss. I reported descriptive
statistics of the aggregated scores.
Comparison to patient-provided data
I assumed patient-reported data to be the reference standard for race and ethnicity data
collection. To assess differences between patient-reported race and ethnicity information
and data from observational databases, I evaluated race and ethnicity reported in the HC-
AHPS survey. Because I had patient-level data from the New York academic healthcare
system from both the EHR and the HCAHPS survey I reported the concordance between the
patient’s race and ethnicity information in the EHR and the self-reported from HCAHPS.
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Comparison to Census data
To assess how well the data from the EHR and the HCAHPS survey represented the
population of the community in which the academic health system was located, I compared
the EHR and HCAHPS race and ethnicity distribution by ZIP Code of the patient’s home
address to the race and ethnicity distribution for that ZIP Code as reported by the U.S. Cen-
sus from the American Community Survey 5-Year Demographic and Housing Estimates.
For each ZIP Code, I calculated the percent difference between the Census data and the
EHR data for each race and ethnicity category. For this analysis, I included ZIP Codes that
had at least 50 patients in the EHR and HCAHPS data.
Results
United States National Databases
There were 165,975,722 combined patient records in the HCUP and Optum databases.
Of these, 25.3% and 26.0%, respectively, had uninformative race and ethnicity (Table 3.2).
Academic Healthcare System in New York City
In the New York academic health system, 2,338,421 patients had at least one visit during
the two-year study period. As shown in Table Table 3.2, 57.9% of patients did not have race
or ethnicity identified in the EHR. The distribution of all race-ethnicity pairs is described
in Table 3.3.
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Table 3.3: Frequency of race and ethnicity pairs in academic health system electronic health record.
*Patients designated as Hispanic in single question format surveys were assumed to be White-
Hispanic.
Changes in race and ethnicity information in the EHR
I identified 1,205,796 patients who had more than one visit to the academic health sys-
tem. There were 161,114 modifications made to race or ethnicity fields in the EHR for
147,061 distinct patients (12% of total population). There were 0.13 changes to race and
ethnicity fields made per patient, on average, over the two-year study period (max=18).
Modifications to race or ethnicity often improved completeness (i.e., a change was made
from an ‘uninformative’ concept to a specific race or ethnicity category), but this was not
always the case. Overall, I observed that 60% of the changes made in race and ethnicity
improved completeness (information gain), 31% of the changes resulted in information loss,
and 9% of the changes were information neutral.
The most frequent change resulting in information gain was an update of previously
documented race “Unknown” and ethnicity “Unknown” to race “White” and ethnicity “Not
Hispanic;” the most frequent change resulting in information loss was a modification from
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race “White” and ethnicity “Hispanic” to race “Unknown” and ethnicity “Unknown;” and
lastly the most frequent change that did not affect the amount of race and ethnicity infor-
mation collected was an update from race “Unknown” and ethnicity “Unknown” to race
“Declined to answer” and ethnicity “Declined to answer.”
Comparison to patient-provided data
During the study period, 25,664 unique patients responded to the HCAHPS survey. Of
those, 1,255 patients completed the survey more than once, and 356 had conflicting self-
reported race and ethnicity information.
After excluding cases with conflicting self-reported race and ethnicity information,
86.3% provided meaningful race or ethnicity data from a total of 25,308 patients. Among
these patients, race and ethnicity information from the EHR was available for 25,014 pa-
tients.
Among patients with both self-reported and EHR race and ethnicity information, 16,625
(66.5%) patients provided race or ethnicity information that was discordant with data
recorded in the EHR. Table 3.4 provides a list of the most common discrepancies between
EHR and self-reported race and ethnicity data. While 6,540 had both race and ethnicity as
“Uninformative,” self-reported data provided meaningful race or ethnicity information for
5,533 of these patients, 84.6% of patients that did not otherwise have meaningful informa-
tion recorded.
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Table 3.4: Ten most common discrepancies between EHR and self-reported data.
Comparison to Census data
There were 44 ZIP Codes with more than 100 patients in the EHR and HCAHPS
datasets. When comparing the distribution of race and ethnicity categories between the
EHR, HCAHPS and the Census datasets, I observed that, on average, the EHR data con-
tained a higher proportion of uninformative race than the Census (63% vs. 14%, Figure
3.1). However, when performing the same comparison using patient-reported information,
I observed that the rate of uninformative race in the HCAHPS dataset was similar to the
Census dataset (18.1% vs. 14%, Figure 3.1). Table 3.5 contains the distribution of race






































Figure 3.1: Comparison of the average Census, EHR and HCAHPS racial and ethnic distribution
among 44 ZIP Codes that contained at least 100 patients in the EHR and HCAHPS datasets.
Discussion
Accurate collection of race and ethnicity information is key to recognizing disparities
that affect racial and ethnic minority populations (Dorsey et al. 2014; Douglas et al. 2015;
Kressin 2015; LaVeist, Gaskin, and Richard 2011). Furthermore, this information can be
used to perform disease risk assessment both for individuals and populations (Gail et al.
1989; Levey et al. 2009; Stevens et al. 2006). Despite its importance, previous studies
have reported challenges in collecting race and ethnicity data (Blustein 1994; Chakkalakal
et al. 2015; Gomez and Glaser 2006; Hamilton et al. 2009; Lee, Grobe, and Tiro 2015;
Moscou et al. 2003). For example, a study conducted in 2015 reported data quality issues
by comparing patients’ race and ethnicity information from different data sources within
the same institution (Lee, Grobe, and Tiro 2015).
In this study, a large proportion of patients did not have informative documentation
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regarding their race and ethnicity, either in the national observational databases or in the
urban academic health system. These findings suggest that it is challenging to capture this
information despite the inclusion of race and ethnicity data collection as part of the U.S.
Meaningful Use program. When analyzing race and ethnicity data in the EHR from a single
institution, changes over time did not always improve the data quality of race and ethnicity.
Indeed, information loss occurred in 31% of updates.
Previous studies have illuminated some of the challenges of obtaining race and ethnicity
from patients in the healthcare delivery setting. First, verbally asking patients their race
and ethnicity may be perceived as a sensitive topic by both hospital personnel and patients
(Baker et al. 2007; Berry et al. 2014). Second, there is a general lack of understanding
of why this information is collected and how it will be used (Nelson et al. 2005). This
lack of understanding poses a barrier to registration personnel asking patients their race and
ethnicity. From the patients’ perspective, the question is often unexpected and may not be
framed with an explanation of how the information will be used and why it is important.
Some have argued that collecting race and ethnicity in the healthcare setting is increas-
ingly unnecessary in the context of inexpensive genetic testing (Ng et al. 2008). Race
and ethnicity have been used in medicine as a proxy to genetics. However, it is well estab-
lished that traits occur in gradients rather than in pre-determined race categories. Currently,
with the increased number of mixed populations, heritage can be more informative than the
racial category itself. Additionally, with the improvements in genetics and the decreased
cost of genetic testing, in the foreseeable future, we could rely on genetic testing instead
genetic proxies for determination of disease risk. However, genetic testing availability will
not facilitate the elimination of health disparities that have social determinants. Therefore,
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until health equity is achieved, collection of race and ethnicity data is necessary to measure
health disparities.
Until we transition to an era of ubiquitous genetic testing and health equity, one way to
improve the quality and completeness of patient demographics in electronic health records
is to allow patients to review and request updates to their information. In this study, the HC-
AHPS survey, a sources of patient-provided information had high rates of completeness for
race and ethnicity, with only 7.1% of the records documented as “Unknown.” This finding
suggests that patients are willing to provide their race and ethnicity information when they
have the opportunity to do so. A study conducted at one Veterans Affairs (VA) Medical
Center compared patient-reported race and ethnicity information to the data available in
the EHR. Investigators mailed 300 surveys to select patients that received care primarily at
the VA clinic. Of the completed surveys, 15.7% contained race and ethnicity information
discordant from the EHR (Hamilton et al. 2009). I compared race and ethnicity informa-
tion available in the EHR to data from HCAHPS survey. Among patients with survey data,
86.3% provided informative race and ethnicity information and 66.5% of the answers were
discordant with the EHR data. More than 84% of patients with uninformative race and
ethnicity in the EHR provided meaningful information in the survey.
Patient-facing tools give patients the opportunity to fill out or review their information
directly, removing some of the cultural sensitivity of having someone verbally asking for
this information. A previous study demonstrated improvement in race and ethnicity data
quality after using a custom patient portal application on a tablet computer to allow patients
to review their demographic information (Polubriaginof et al. 2016). Interestingly, when
self-reporting, many Hispanic patients did not seem to consider themselves to belong to
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any of the OMB-defined race categories, as the majority identified their race as ‘Other’ and
their ethnicity as “Hispanic or Latino” when self-reporting. Such phenomena have been
previously described (Berry et al. 2014; Bhalla, Yongue, and Currie 2012; Markus 2008;
Robbin 1999) and this behavior raises questions about the efficacy of the two-question
format (i.e., collecting race and ethnicity as separate fields) that is now widely used, as
well as the meaning of the constructs of “race” and “ethnicity” for patients. These findings
suggest that patient-facing tools that allow patients to provide race and ethnicity information
before, during, or after their healthcare encounters could markedly improve data quality.
This could be accomplished in many ways, but one useful method is to use patient portals.
In summary, race and ethnicity provide valuable information for precision medicine and
critical information for efforts to eliminate socially determined health disparities. However,
the quality of these data is concerning. While the use of genetics is not feasible at a popu-
lation level, the use of patient-facing tools have the potential of dramatically improving its
quality and ultimately facilitate disease risk assessment and identification and monitoring
of health disparities.
Conclusion
This study demonstrates that collection of race and ethnicity, particularly among diverse
populations, can be problematic. Poor data quality for race and ethnicity can negatively im-
pact clinical care decisions that are based on disease risk adjustment models incorporating
race and ethnicity. Moreover, incomplete or inaccurate race and ethnicity data prevents
public health professionals and policy-makers from measuring and reducing racial and eth-
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nic healthcare disparities. To address these challenges, we recommend patient-reported
data be used to improve quality and completeness of race and ethnicity.
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3.2 Aim 1.2 - Assessing the quality of family history data
collected in clinical databases
Background
Family history has always been considered critical component in care delivery (Berg
et al. 2009) and it is described as a free genetic tool that almost every patient has access
to (Guttmacher, Collins, and Carmona 2004). Since the Human Genome Project, new
genomic tools have been described (Guttmacher and Collins 2003); however, family history
remains critical for identifying patients that may be at higher risk to develop disease. Family
history provides information that enables individualized disease diagnosis, treatment, and
prevention.
Several studies have shown that family history is an important element in determin-
ing the appropriate clinical care. Knowing that a patient is at increased risk of developing
a disease based on family history enables disease prevention that can vary from intensive
screening to prophylactic surgery, early diagnosis and/or early and tailored treatment (Berry
et al. 1997; Claus, Risch, and Thompson 1994; Saslow et al. 2007; Smith, Cokkinides, and
Brawley 2012; Tyrer, Duffy, and Cuzick 2004). Currently, the U.S. Preventive Services
Task Force (USPSTF) recommends risk assessment based on family history for some con-
ditions such as screening for BRCA mutation and BRCA-related cancers (Moyer and U.S.
Preventive Services Task Force 2014), osteoporosis (U.S. Preventive Services Task Force
2011), and lipid disorders in adults. (Helfand and Carson 2008) A 2007 report commis-
sioned by the Agency for Healthcare Research and Quality (AHRQ) recommended that
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collection of family history information should include diseases in first-degree relatives
and second-degree relatives from both the maternal and paternal side, the relatives’ age at
the time of disease diagnosis, and each relatives’ race and ethnicity (Qureshi et al. 2007).
In addition to guidelines and recommendations encouraging the family history data be-
ing incorporated into clinical practice, several initiatives have been put in place to increase
the structured collection of family history. These goals of these initiatives are focused on
collecting data to enable precision medicine, where there is a need for accurate and detailed
family history data. For example, Stage 2 of the Meaningful Use program included a re-
quirement of clinicians to use structured data entry for family history. Eligible hospitals
had to have for 20% of their patients at least one structured family history data element, for
at least one first-degree relative in the electronic health record (Centers for Medicare &
Medicaid Services 2014a). A key hallmark in this initiative is the strict data structuring in-
volved, and yet, previous studies on data quality have shown that clinicians describe a need
for free-text documentation for expressiveness of documentation (Rosenbloom et al. 2011).
The contrast between clinician desires and goals of federal initiatives present challenges to
finding optimal ways to collect and store family history.
Objectives
The purpose of this study was to assess the quality of family history data captured in
an established commercial EHR system at a large academic medical center. This study
focused on the differences between family history data collected using structured fields vs.
free-text. Data quality was measured in terms of completeness.
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Research Questions
• Does the method (free-text vs structured template) of capturing family history infor-
mation impact the quality of family health history data in the EHR?
Methods
With Institutional Review Board approval, I conducted a retrospective analysis of data
from the Allscripts EHR (Allscripts Corp., Chicago IL) used at NewYork-Presbyterian Hos-
pital/Columbia University Medical Center from 2007 to 2014.
This study focused on the differences between family history data collected using struc-
tured fields vs. free-text. Each note template in the EHR contained one or more “obser-
vation” data elements. An observation could be a text box, a Boolean (e.g., a checkbox
or radio button), or numeric value. Text boxes could be fully free-text, or they could be
constrained to enumerated data types, allowing only options from a predefined list, such
as “low,” “medium,” or “high.” The EHR system contained 1,560 active templates for
documentation. Each of these templates contained one to several hundred discrete obser-
vations. Observations had an internal code and description specified using a configuration
tool in the EHR. While the EHR vendor provided some predefined observations, the vast
majority were locally defined and do not comport with any existing standard terminology.
There were 140,038 observations defined in the EHR; of those, 653 had an internal code
containing the words “fam hx” or “family hist.”
I identified the note templates that contained these observations and queried the EHR
database to identify the number of times each note template was used, as well as the number
54
Figure 3.2: Ambulatory OB/GYN Antepartum Record: the most-used template note that contained
structured family history observations.
of unique patients who had at least one of these observations recorded. The number of
times each note template was used varied from 1 to 79,505, and number of unique patients
varied from 1 to 67,276 for each note template. The note templates that contained the most
commonly used free-text and structured text observations were selected for further analysis.
The most-used note template that contained structured family history observations was
the Ambulatory OB/GYN Antepartum Record (Figure 3.2). This note template was used
in our institution for obstetric patients in the institution’s ambulatory care network. Overall,
this note template was used 79,505 times for 67,276 unique patients. The most-used free-
text family history observation was the Neurology Admission Note (Figure 3.3). This note
was used for every patient admitted to the neurology service. The Neurology Admission
Note was used 49,656 times for 22,642 unique patients.
For both the Ambulatory OB/GYN Antepartum Record and the Neurology Admission
Note templates, 10,000 family history observation entries were randomly selected from
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Figure 3.3: Neurology Admission Note: the most-used template note that contained free-text family
history observation.
notes between 2007 and 2014. Manual annotation by a clinical expert (FP) based on pre-
determined categories was performed in all 10,000 free-text observations, as well as in all
structured observations that occurred more than once (9,121 observations). The categories
were defined based on the content of information in the observations and the standards
endorsed by AHRQ. (Qureshi et al. 2007) The categories that were used are 1) presence of
disease in specified relative(s), 2) presence of disease in unspecified relative(s), 3) absence
of disease and 4) other (Table 3.6). The annotation results were compared between the
datasets. I performed descriptive statistics for each group, reporting the frequency of each
category per group. Data quality was assessed based on completeness, where the presence
of more detailed information was considered to be more complete. For example, records
that captured presence of disease in a specified relative were considered more complete







































The results of the manual annotation of family history observations is summarized in
Figure 3.4. Overall, the majority of observations (58.7%) captured by the Neurology Ad-
mission Note (free-text) included information regarding family history of disease along with
the family member affected. However, when analyzing data from the observations from the
Ambulatory OB/GYN Antepartum Record (structured), only 5.2% contained information
specifying the patient’s relative. In contrast, 7.3% of the observations from the Neurol-
ogy Admission Note (free-text) contained information categorized as “Presence of disease
in unspecified relative(s),” and 50.1% of the observations from the Ambulatory OB/GYN
Antepartum Record (structured) captured this type of information.
Furthermore, 27.5% of the observations from the Neurology Admission Note (free-text)
captured information about the absence of family history of a certain disease, while only
0.9% of the observations from the Ambulatory OB/GYN Antepartum Record (structured)
captured information with this level of detail.
A large proportion (39.2%) of the observations from the Ambulatory OB/GYN An-
tepartum Record (structured) were classified as “Other.” The vast majority of these cases
referred to family history described as “N/A.” Such description provides no information
of the patient’s family history. In contrast, 7.2% of the observations from the Neurology
Admission Note (free-text) were classified as “Other.” These observations often described
that patients were not verbal and therefore family health history could not be collected or
simply described as “None.”
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Figure 3.4: Comparison of categories from free-text (purple) and structured (blue) family history
observations.
Discussion
When analyzing family history data collected using structured vs. free-text data ele-
ments, the annotations revealed that there was a considerable difference between the content
of the family history information collected.
Overall, notes that used the free-text template were more comprehensive and often con-
tained more useful information compared with structured templates. The free-text note
template captured information regarding the family history of disease along with the family
member affected more frequently than the structured note template, 58.7% vs. 5.2%, re-
spectively. In the structured template shown in Figure 3.2, text could be optionally entered
in the free-text box on the right, which could be used to capture additional information such
as relatives, deny presence conditions, or even to record other types of information such as
age, type of cancer, etc. While both note templates provided the opportunity to collect addi-
tional information in free-text, the free-text note template captured affected relatives more
frequently; however, neither consistently captured other relevant details, such as the age of
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onset and vital status of the relatives.
Similarly, the free-text note template captured the absence of family history of disease
more consistently than the structured template. Even though the structured template in-
cluded the option “No” for the set of diseases of interest, information on the absence of
family history of disease was rarely reported.
Additionally, both note templates were used to record information not pertinent to fam-
ily history. Those observations classified as “Other” included indicators such as “intu-
bated,” and “no family at bedside and pt nonverbal.” These are important pieces of infor-
mation about the patient but should not be reported as part of the family history section.
The majority of the cases classified as “Other” in the structured template referred to family
history described as “N/A.” It was unclear what was meant by “N/A.” Possible interpre-
tations were that this could indicate that a patient would not or could not inform, had no
knowledge or even that such questions were not asked.
While notes that used the free-text note template captured more comprehensive family
history information, neither template captured complete family history as recommended
by AHRQ (Qureshi et al. 2007). Despite the well-known and well-described importance
of family history, several barriers exist in its collection and analysis, as well as in its use
for personalized management based on patients’ risk assessment. Barriers to collect family
history can be classified in two major categories: clinician-related and patient-related.
Clinician-related barriers include lack of time to obtain, organize and analyze family
history information; lack of resources and lack of reimbursement for such activity; under-
estimation of the value of family history data by the clinician; lack of expertise in obtaining
and analyzing family history information; lack of standards for family history collection;
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and lack of clear guidelines to assess patient risk based on family history. The first, and per-
haps the most critical barrier for family history collection is lack of time to obtain, organize
and analyze family history information (Green 2007; Guttmacher, Collins, and Carmona
2004; Rich et al. 2004; Scheuner et al. 2009; Sussner, Jandorf, and Valdimarsdottir 2011;
Wilson et al. 2012a). Obtaining complete and accurate family history information, orga-
nizing it in a pedigree and analyzing family history data is extremely time-consuming. Fur-
thermore, it is not sufficient to collect family history from patients only once. It is important
to regularly update family history information, analyze it, and reconcile conflicting infor-
mation. A 1989 study surveying four genetic clinics reported that the time patients spent
in the first consultation varied from 3–5.5 hours, with over half of this time spent before or
after the patient’s appointment (Bernhardt and Pyeritz 1989). A 2011 study demonstrated
that while the majority of clinicians (77.5%) reported collecting cancer family history on
their patients, only 26.0% included minimum adequate cancer family history. Furthermore,
57.4% of clinicians updated family history information just once a year, and 22.2% of clin-
icians never updated family history information for their patients at all. When questioned
about the barriers to collecting cancer family history, clinicians reported lack of time as
the primary issue (Sussner, Jandorf, and Valdimarsdottir 2011). The study focused on
cancer family history, but it demonstrated how challenging family history is to collect and
maintain, in general. Lack of resources and reimbursement for family history collection is
another important barrier (Green 2007; Rich et al. 2004; Scheuner et al. 2009; Wilson et al.
2012a). Clinicians are not reimbursed for the time spent on family history collection and
risk assessment. In fact, in 2009, lack of incentives from the government was being de-
scribed as one of the challenges prohibiting adequate collection of family history (Sussner,
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Jandorf, and Valdimarsdottir 2011). In addition to misaligned incentives, lack of standards
has also been reported as a challenge in this area (Ginsburg and Willard 2009; Green 2007;
Sussner, Jandorf, and Valdimarsdottir 2011). The lack of standards for data elements, ter-
minology, structure, interoperability, and clinical decision support rules for family history
data is a huge obstacle to implement it in the clinical workflow. This point is underscored
by the existence of multiple EHR templates available to assist physicians in capturing fam-
ily history data. Furthermore, limited knowledge and lack of expertise in obtaining and
analyzing family history by clinicians is another barrier that has been described in sev-
eral studies (Ginsburg and Willard 2009; Green 2007; Guttmacher, Collins, and Carmona
2004; Scheuner, Sieverding, and Shekelle 2008; Scheuner et al. 2009; Sussner, Jandorf,
and Valdimarsdottir 2011).
There are also barriers to collecting accurate family history data on the patient side.
These include uncertainty about biological family composition; uncertainty about the health
history of family members; inaccuracies in patient recall, language-related and cultural
factors. Clinicians often cite uncertainty about biological family composition as a chal-
lenge when collecting family histories, especially in cases where the patient is part of a
large biological family (Green 2007; Peace, Valdez, and Lutz 2012; Sussner, Jandorf, and
Valdimarsdottir 2011). Language-related and cultural factors can also be a factor that neg-
atively affects collection (Sussner, Jandorf, and Valdimarsdottir 2011).
There are several initiatives to facilitate and encourage the collection and use of family
history data. These initiatives are focused on the use of these data for precision medicine,
where the need for accurate and detailed family history data is great. Three such initiatives
are: Stage 2 of the federal “Meaningful Use” EHR financial incentive program, the U.S.
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Surgeon General’s “My Family Health Portrait,” and the HL7 Clinical Genomics Family
History/Pedigree Model.
Meaningful Use Stage 2
Stage 2 of the Meaningful Use program included a requirement of clinician’s to use
structured data entry for family history. Eligible hospitals had to have for 20% of their
patients at least one structured family history data element, for at least one first-degree
relative in the electronic health record (Centers for Medicare & Medicaid Services 2014a).
As discussed above, lack of incentives to collect family history is described as an important
barrier. The Meaningful Use program is a strong incentive for U.S. hospitals to collect
family history information. Although the determined measure of at least one structure data
entry for at least one first-degree relative is far from what is considered complete family
history, it is a start.
U.S. Surgeon General’s “My Family Health Portrait”
Since family history data collection is extremely time-consuming, innovative tools have
been created to facilitate this process. Some are leveraging patient-facing tools to collect
family history data (Cohn et al. 2010; Giovanni and Murray 2010; Hulse et al. 2011; Murray
et al. 2013; Orlando et al. 2013; Ozanne et al. 2009; Wu et al. 2015; Yoon et al. 2009). The
U.S. Surgeon General’s My Family Health Portrait, (My Family Health Portrait) a federal
initiative to collect family history, is a website that allows patients to collect family history
information and share their information with family members and healthcare providers.
A study conducted in 2011 described that the average time taken to input family history
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information was 15 minutes, in a range from 3 to 45 minutes (Owens et al. 2011). Instead
of having a healthcare provider questioning patients about their family history, patients
can enter their own data, saving clinician time–the major barrier for family history data
collection. This practice also engage patients in their care and gives them time to review
their family information and contact relatives and question them about information that
they may not know. Engaging patients in this fashion encourages more accurate family
history information. Of note, one advantage of using electronic questionnaires is that certain
questions can be made mandatory, and branching logic can be employed. In contrast, in a
clinical encounter, the doctor may forget to ask certain questions or may skip questions due
to lack of time.
HL7 Clinical Genomics Family History/Pedigree Model
It is important to emphasize that to fully represent family history information, data rep-
resentation must be multidimensional since it is necessary to not only capture the disease
but also the relative affected, age of onset, and cancer type if applicable. Moreover, devel-
opment of standards to support interoperability is essential for sharing data for clinical care
and clinical research purposes. In the domain of family history, HL7 has a workgroup that
specifically works on development of models for representing family history. The work-
group has developed the HL7 Clinical Genomics Family History (Pedigree) Model (HL7
Version 3 Implementation Guide: Family History/Pedigree Interoperability, Release 1 - US
Realm). It is a standard for capturing data within a system as well as to transmit family his-
tory data between systems. It includes patient’s family and familial relationships, diseases,
genetic data and risk analysis. This HL7 standard is already used by the U.S. Surgeon Gen-
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eral’s My Family Health Portrait application, and there is reason to believe that it will be
important for EHR vendors and other stakeholders to adopt this standard moving forward.
Limitations
The study analyzed only observations contained in two note templates (out of a total of
1,560 available) in our EHR. One note template was used in the ambulatory care setting and
the other template was used for hospital admissions. Although the templates were selected
based on the fact that they were the most frequently used templates at our institution, it is
unclear if analysis of other EHR templates would yield different conclusions. Additionally,
manual annotations were conducted by a single clinical expert, limiting the evaluation of
the annotations.
Conclusion
In summary, this study focused on the differences between family history data collected
using structured fields vs. free-text. While observations from the free-text note template
were more comprehensive than structured observations, neither was ideal for capturing pa-
tients’ complete family history. 58.7% of observations from the free-text note template
captured information regarding the family history of disease along with the family member
affected vs. only 5.2% from the structured note template. However, neither consistently
captured other relevant details, such as the age of onset and vital status of the relatives. Nu-
merous efforts have been made to collect family history data in the electronic format and to
facilitate its use in the clinical setting, but several barriers remain unsolved. Patient-facing
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tools for collecting family history data may improve data quality of family history in EHRs.
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3.3 Aim 1.3 - Assessing the quality of smoking status
collected in clinical databases
Background
Smoking is an important risk factor for multiple diseases, including cardiovascular dis-
eases and numerous types of cancer. It remains the number one cause of preventable death
in the United States (National Center for Chronic Disease Prevention and Health Promo-
tion Office on Smoking and Health 2014). The collection of patients’ smoking status during
clinical encounters is critical to providing patients with resources to quit smoking. Smok-
ing cessation can be difficult, and clinical visits are opportunities to intervene and recom-
mend smoking cessation programs and therapies. Obtaining a patient’s smoking status is
a crucial step in beginning smoking cessation interventions and monitoring progress (Ca-
plan, Stout, and Blumenthal 2011). It may seem that recording updates to smoking status
in a timely and accurate manner would be straightforward using modern electronic health
records. This may not be the case for several reasons, including lack of standard termi-
nology and granularity for data collection, shifting cultural attitudes regarding tobacco use,
and potentially frequent changes in individuals’ smoking behavior (Committee on the Rec-
ommended Social and Behavioral Domains and Measures for Electronic Health Records,
Board on Population Health and Public Health Practice, and Institute of, Medicine 2015;
Winden et al. 2015). As the American author, Mark Twain, famously quipped, “Giving up
smoking is the easiest thing in the world. I know because I’ve done it thousands of times.”
Given the clinical importance of smoking status, the “Meaningful Use” financial in-
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centive program for electronic health record (EHR) adoption in the U.S. included a require-
ment for healthcare providers to capture patients’ smoking status electronically in structured
fashion (Centers for Medicare & Medicaid Services 2010). Meaningful Use has helped to
standardize data collection of smoking status and other information. However, even with
improved standards for representing information, data quality issues have persisted in many
patient-provided data types, such as race and ethnicity (Klinger et al. 2015; Lee, Grobe,
and Tiro 2015) and family history (Polubriaginof, Tatonetti, and Vawdrey 2015; Powell
et al. 2013). Previous studies on data quality have shown that clinicians describe a need for
free-text documentation for expressiveness of documentation; however, these affordances
challenge data reuse (Rosenbloom et al. 2011).
Appreciating the challenges associated with data quality and the balance between the
expressiveness of free-text and the benefits of structured data, I set out to answer a very
simple question: how many of our hospital’s patients are known to be active smokers? I
undertook a study to analyze how smoking status is currently being collected in a large
academic medical center and to evaluate the quality of this data in EHRs.
Objectives
The purpose of this study was to assess how smoking status was collected in a large aca-
demic medical center, and to evaluate the quality of smoking status data in EHRs. Specifi-




• How is smoking status information captured in the EHR?
• What is the quality of smoking status information captured in the EHR?
Methods
I conducted a retrospective analysis of smoking status data from the Allscripts Sun-
rise EHR (Allscripts Corp., Chicago IL) used at NewYork-Presbyterian Hospital/Columbia
University Medical Center. All patients who had at least one hospital discharge during 2016
were included in the study.
The EHR system contained hundreds of active templates for documentation. Each of
these templates contained one-to-several hundred discrete observations. An observation
could be a text box, a Boolean (e.g., a checkbox or radio button), or numeric value. I iden-
tified observations in which the description contains the stemmed words “smok,” “cigar”
or “tobacco” and queried the EHR database to identify the number of times each one of
these observations was recorded during the study period. Smoking status information was
recorded either as free-text (i.e., when the parameter is “Cigarettes (packs per day)”) or
structured (i.e., selected from a picklist) observations. The picklist was often shown as a
set of radio buttons, such as with a parameter labeled “Tobacco Use / Smoking Status,” and
one possible choice in the picklist was “Never smoker.”
Prior exploratory analysis showed that 94% of patients had at least one structured smok-
ing status observation recorded in a structured field. Based on this finding, I only used
the structured data for the remainder of the analyses. Some of the structured observations
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Table 3.7: Description of the mapping from smoking status categories as recorded in the EHR to
the four clinically actionable categories. Smoking status categories documented in the EHR that
utilize the standard criteria defined by the Meaningful Use program are highlighted in bold.
captured smoking status following the standard criteria set by the Meaningful Use pro-
gram. The program specifies eight distinct categories for collecting smoking status: “Cur-
rent every day smoker,” “Current some day smoker,” “Former smoker,” “Never smoker,”
“Smoker, current status unknown,” “Unknown if ever smoked,” “Heavy tobacco smoker,”
and “Light tobacco smoker.” CentersforMedicareandMedicaidServicesCMS:2014wn I
classified smoking status from the EHR into one of four clinically actionable categories:
“Current smoker,” “Former smoker,” “Never smoker,” and “Unknown smoking status” as
described in Table 3.7.
Overall, data quality of smoking status was assessed based on the percentage of patients
with consistent and informative smoking status available (i.e., not classified as “Unknown”
in the database, or not conflicting if recorded multiple times). Patients with discrepancies
in recording smoking status, such as in the previous example, were classified as: plausible
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Table 3.8: Description of the mapping from smoking status categories as recorded in the EHR to
the four clinically actionable categories. Smoking status categories documented in the EHR that
utilize the standard criteria defined by the Meaningful Use program are highlighted in bold.
Figure 3.5: Changes of smoking status overtime. Dashed changes demonstrate implausible dis-
crepancies and continuous lines represent plausible changes in longitudinal data. The number of
changes recorded in our sample is reported in parentheses and the percentage it represents for each
category is included in the Figure.
and implausible. Plausible cases occurred when the change was feasible to happen such
as a change from “Never smoker” to “Current smoker”), and implausible occurred when
the conflict was not possible to happen or in cases where there was a loss of information.
For example, a change from “Former smoker” to “Never smoker”). More examples of this
classification are illustrated in Figure 3.5.
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Additionally, I analyzed the discrepancies in smoking status generated when inconsis-
tent information was recorded for a patient during the hospital visit in different clinical notes
in the EHR. I also investigated the discrepancies of smoking status recorded by different
provider types (e.g., nurses, medical doctors, care coordinators, social workers). To assess
whether provider type had an impact on the number of discrepancies observed, I calculated
the number of distinct providers’ roles recording smoking status for each admission. I then
compared the number of distinct provider roles for patients with and without discrepancies
in the recorded smoking status.
I also calculated the time interval (in days) between smoking status documentation
events to better understand the distribution of the data during the one-year study period.
For example, a time interval of zero means that two observations were recorded on the
same day, and a time difference of one indicates that a second observation was recorded
one day after the first observation.
Results
Overall, I reviewed 48,909 patients having 64,451 hospital encounters in the one-year
study period. I identified 203,048 observations of smoking status for 47,849 unique patients
across 62,988 distinct hospital encounters. No smoking status documentation was identified
for 1,463 visits from 1,060 distinct patients, representing 2% of the number of hospital
encounters and 2% of the overall number of patients. In other words, 98% of patients
and 98% of hospital visits had documentation regarding the patient’s smoking status. Of
those records with smoking status, 59,663 visits (93%) from 45,822 patients (94%) had this
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Figure 3.6: Smoking status of patients seen in 2016.
information recorded in structured format. After pre-processing, 45,771 patients (94%),
including 59,593 visits (92%) and 129,134 observations were classified into four distinct
smoking status categories. The number of observations and the mapping to the simplified
smoking categories are described in Table 3.7. The description of smoking status data
during the one-year study period is described in Table 3.8. Patients had an average of 1.3
visits/patient during the study period, with the maximum number of visits a single patient
being 23 visits.
How many patients are smokers?
Overall, 54.2% of the patients in our sample were classified as non-smokers, 6.5% as
former smokers, 2.9% as current smokers and 3.2% as having unknown smoking status.
The remaining 33.2% of patients had at least one discrepant assessment of smoking sta-
tus documented. I determined that only 63.6% of our study population had a consistent,
unchanging smoking status during the one-year study period (Figure 3.6).
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Longitudinal One-year Review
Overall, 15,048 patients (32.9%) had smoking status recorded in a single note, and
30,723 patients (67.1%) had more than one note with documentation regarding smoking
status. Among the patients with more than one note with smoking status documented, I
identified 83,363 changes in documented smoking status collected longitudinally during
the one-year study period.
Among the changes in smoking status documentation, 32,582 (39.1%) had a conflicting
smoking status. These discrepancies were observed in records from 15,207 distinct patients,
representing 33.2% of our study population. However, because the study used longitudinal
data and smoking status is not a static concept (i.e., it can change over time), some of these
discrepancies are feasible. For example, someone that never smoked can become a smoker.
Others, however, are implausible. For example, logically, a “never smoker” cannot become
a “former smoker”, nor can a “current smoker” become a “never smoker,” unless some of
the data were recorded incorrectly. Other changes are plausible but not good from a data
quality standpoint. Having a patient with documentation regarding smoking status and later
not having smoking status (smoking status as “unknown”) demonstrates loss of informa-
tion. Implausible changes as well as changes from a well-defined smoking status to an
uninformative category were considered discrepancies due to data quality issues. I iden-
tified 17,757 discrepancies (implausible changes and loss of information changes), which
constituted 54.5% of changes, in 10,836 distinct patients. These discrepancies are repre-
sented in Figure 3.5 as dashed lines, while the other changes are represented in continuous
lines.
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Figure 3.7: Number of smoking status changes by time interval documentation. Time interval is
measured in days. Number of status changes is represented in logarithmic scale. CDF = cumulative
distribution function.
On average, the time interval between different smoking status documentation was 11
days, with a minimum of 0 days (i.e, same-day documentation), and a maximum of 362
days. Most patients (80.6%) had a time interval between documentation events of less than
or equal to 10 days, with 61.1% of patients having a subsequent documentation event within
one day of the previous event. (Figure 3.7)
Duplicate Assessments During the Same Hospital Encounter
While it is plausible to observe changes in smoking status over the course of one year,
smoking status should not change during the same hospital encounter. Given this rationale,
I considered all changes during a hospital encounter to reflect a data quality issue, since
smoking status should be consistent throughout a single admission. During the study pe-
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Table 3.9: Description of smoking status data during the one-year study period.
riod, I identified 59,663 distinct encounters from 45,822 patients. Of those, 32.2% of the
hospital encounters (19,176 visits) had at least one conflicting smoking status recorded,
which includes 14,798 patients (32.3% of our cohort of patients).
Discrepancies Among Various Provider Roles
For patients with a smoking status recorded in a structured field, 70.8% were docu-
mented as part of nursing notes, 12.9% came from social work notes, 11.6% from physician
notes, and the remaining (4.7%) from notes entered by other health care professionals.
Among hospital encounters with more than one assessment of smoking status, encoun-
ters with documentation from a single role of provider (e.g., nurse) had fewer discrepancies
compared with encounters containing smoking status assessments from providers with dis-
parate roles (Table 3.9). For example, if multiple nurses documented smoking status dur-
ing an admission, the number of distinct provider roles would be equal to one. However, if
multiple nurses and multiple physicians documented this information, then the number of
distinct provider roles would be two.
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Discussion
The Centers for Medicare and Medicaid Services (CMS) Meaningful Use program re-
quires participating healthcare providers to record patients’ smoking status in a structured
fashion (Centers for Medicare & Medicaid Services 2010). The program specifies eight
distinct categories for collecting smoking status: “Current every day smoker,” “Current
some day smoker,” “Former smoker,” “Never smoker,” “Smoker, current status unknown,”
“Unknown if ever smoked,” “Heavy tobacco smoker,” and “Light tobacco smoker.”
I identified smoking status assessments (either represented in free-text or structured
fields) for 98% of patients and 98% of visits. When focusing on structured documentation,
I observed that 94% of patients and 92% of visits had at least one structured smoking status
observation recorded. When analyzing smoking status data in the EHR, I transformed the
Meaningful Use categories and other smoking status assessments into four clinically ac-
tionable categories: “Current smoker,” “Former smoker,” “Never smoker,” and “Unknown
smoking status.” I observed that a 33.2% of the patients had inconsistencies in the docu-
mented smoking status during the one-year study period and 32.3% of the patients had at
least one discrepancy during a single visit. These discrepancies suggest that reliable infor-
mation on smoking status may not be available for a large number of patients.
Going back to the initial question of “how many patients are current smokers?” – the
answer is, I do not know. Based on the analysis conducted in this study, more than half of
the patients during the one-year study period were recorded consistently as non-smokers
and just 2.9% were recorded consistently as current smokers. In contrast, other population-
based studies estimate that 15.1% of adult Americans smoke (Jamal et al. 2016). One-third
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of the studied population had inconsistencies in their smoking status, making the determi-
nation of tobacco use for these patients difficult. While smoking status was documented
in 98% of hospital encounters (and therefore the criteria of Meaningful Use were satis-
fied), our one-year sample of hospital encounters did not contain consistent smoking status
information for 36.4% of patients.
Despite the well-known and well-described importance of collecting smoking status,
our institution’s EHR did not have a centralized location to store smoking status informa-
tion. Smoking status was collected as part of clinical notes, in either structured or free-text
format. The fact that disparate healthcare providers recorded this information in several dif-
ferent notes resulted in many inconsistencies across notes. Further complicating the matter,
different note templates allowed for different granularities of smoking status data collec-
tion. Some templates included a free-text box that allowed clinicians to enter details such
as intensity of smoking, number of cigarettes per day, or when the patient stopped smoking.
Other templates had only the Meaningful Use-required structured fields embedded.
Since I used longitudinal data, and smoking status is not a static concept (i.e., it can
change over time), I classified smoking status changes into two distinct categories: plausi-
ble and implausible. In this study, implausible changes constituted 21.3% of all changes.
Previous research has also identified consistency issues regarding tobacco use recorded
in different notes in EHR systems. For example, in 2016 a research study used natural
language processing to parse clinical notes and extract smoking status from various clini-
cal notes. The authors identified several inconsistencies when comparing smoking status
recorded in clinical notes (Wang et al. 2016).
Inconsistencies can be attributed to challenges in the data collection process, includ-
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ing clinician-related and patient-related factors. Clinicians may not inquire at all about a
patient’s smoking status, or they might ask the question in a manner that leads to bias in
the patient’s answer. Depending on how clinicians phrase the question, patients may not
feel comfortable answering. On the other hand, patients may have their own motivations to
be less than truthful when providing smoking status information to clinicians, or they may
inexplicably provide different smoking status responses depending on the person asking.
I conducted an analysis to identify whether hospital encounters with more than one
clinical note without discrepancies were more likely to have documentation from a single
provider role than encounters with discrepancies. Interestingly, I identified that encounters
with multiple notes documented by the same type of provider had less discrepancies than
patients with documentation from multiple types of providers. The difference I observed
in discrepancies may be explained by the fact that clinicians usually do not read notes from
other clinicians’ roles. Previous studies have shown that most clinical notes are not read by
the entire clinical team (Hripcsak et al. 2011a). Instead, clinicians may be more inclined
to read clinical notes from their peers (i.e., within the same provider role). While it is
important for multiple providers to assess patients’ smoking status, barriers to accessing
previously documented information regarding tobacco use by healthcare providers may
increase vulnerabilities that allow discrepancies to propagate.
One limitation of our analysis was the use of data from only a single year and from
only a single healthcare system. During a one-year period within our EHR system, I found
that 33.2% of patients had discrepancies in documentation of smoking status. Furthermore,
54.5% of those inconsistencies were deemed implausible (Figure 3.5). Most patients had
changes recorded within 10 days of the previous smoking status assessment. Given the
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short time difference between documentation events, even plausible changes (e.g., convert-
ing from “current smoker” to “former smoker”) seem unlikely. These data quality issues
demonstrate just some of the considerable challenges healthcare providers and secondary
users of EHR data. If I have difficulty in identifying a single meaningful and consistent
smoking status using only one-year worth of data, the use and sharing of multiple years of
data present even bigger challenges. For example, for encounters with conflicting smoking
statuses, which one should be used in a clinical decision support system related to smoking
cessation? Or which one should be reported to external organizations? Efforts using smok-
ing status information from EHRs, including future smoking cessation initiatives, should
further investigate patients identified as “Unknown smoking status” as well as patients with
discrepancies in smoking status.
Recommendations
In this study, I observed that smoking status is currently being collected as part of clinical
notes by multiple healthcare providers, and for almost all patients. The categories used are
not consistent across clinical notes, recording smoking status in different granularities. I
propose the use of four distinct clinically actionable categories: “Never smoker,” “Current
smoker,” “Former smoker,” and “Unknown smoking status.” More detailed information
for each one of these could also be collected in a standardized fashion, such as “packs/day”
and start and quit date. Currently, this additional information is being captured in free-
text format and inconsistent across notes (e.g. some use packs/day while other record this
information as cigarettes/day).
In our institution, smoking status is not stored in a centralized location, but is rather
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being collected as part of disparate clinical notes. The current system of data collection
of smoking status presents challenges consistently collecting this information. While it is
important for multiple providers to collect patients’ tobacco use information, the fact that
this information is collected and stored in various notes without standardization makes it
challenging for clinicians to know if the patient already provided their smoking status to
other clinicians, and whether this information is longitudinally consistent. In an attempt to
solve these challenges, I propose to store patients’ smoking status in a centralized fashion
and having clinicians verifying this information in every encounter by asking patients about
tobacco use.
One way to improve the consistency and correctness of patient-reported information,
such as smoking status, is to allow patients to review and update their own information.
Previous studies have shown that self-reported smoking status is accurate (Patrick et al.
1994; Wagenknecht et al. 2011). This task can be facilitated by health information tech-
nology in many ways, including the use of patient portals and tablet computers for this
task. Patient-facing tools have been used for collection of multiple patient-provided data
types such as race and ethnicity, family history, symptoms, medication reconciliation and
adherence. These studies have shown that patients are willing to provide and review their
information (Dullabh et al. 2014; Pyper et al. 2004; Weingart et al. 2008), that EHR data
is often incomplete or inaccurate (Ball and Lillis 2001; Douglas et al. 2015; Kaplan 2014;
Klinger et al. 2015; Kressin 2015; Lee, Grobe, and Tiro 2015; Polubriaginof, Tatonetti, and
Vawdrey 2015; Qureshi et al. 2009; Staroselsky et al. 2006; Welch, Dere, and Schiffman
2015), and that patients can identify discrepancies, provide useful information and help
keeping records up-to-date (Arsoniadis et al. 2015; Staroselsky et al. 2006, 2008; Wu et
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al. 2014). Studies have also shown that there are many benefits of involving patients in
their care, including improving patient engagement, patient satisfaction, health behaviors
and health status as well as helping to attract and retain patients (Arar et al. 2011; Davis
Giardina et al. 2014; Dwamena and Rovner 2012; Epstein et al. 2010; Otte-Trojel et al.
2014). With patient-facing tools, patients could provide their smoking status based of the
four clinically actionable categories, as described above. Patients providing this informa-
tion to a computer could also mitigate the potential biases introduced by clinicians asking
the question.
Conclusion
In summary, while 98% of hospital encounters at our institution during 2016 contained
information regarding the patients’ smoking status, 32% of the encounters had discrepan-
cies in smoking status information. For encounters with more than one clinical note doc-
umenting smoking status information, 54% of the subsequent documentation events had
implausible changes. While other sources suggest that approximately 15% of adult Amer-
icans smoke, only 2.9% of our patients were consistently documented as current smokers.
This finding demonstrates that while Meaningful Use has improved data collection of smok-
ing status in terms of completeness, we may not be appropriately identifying patients that
smoke. Centralized documentation with clinically actionable smoking status categories
available for data collection, and implementation of patient-facing tools that allow patients




Aim 2 - Evaluate methods for improving quality of
patient-provided data
Health information technology (HIT) is often touted as a means to improve the quality
and efficiency of healthcare (Chaudhry et al. 2006). A number of HIT-related interven-
tions have focused on collecting patient-provided information, which can be categorized
in three different groups: 1) broad policy initiatives, 2) patient-facing tools, and 3) algo-
rithms and informatics methods for collecting and using patient-provided data. While these
interventions have generally been successful in improving the quantity of patient-provided
information, there is a limited understanding of the impact these interventions have on data
quality.
Policy initiatives
HIT-related policy changes can significantly impact healthcare. A major component
of the 2009 Health Information Technology for Economic and Clinical Health (HITECH)
Act focused on increasing adoption of EHRs (Blumenthal and Tavenner 2010; Blumen-
thal 2009). In order to achieve this goal, financial incentives through the Meaningful Use
program were made available to institutions in the United States, resulting in over 95%
of hospitals reportedly using EHRs by 2016 (Conn 2016; Health Information Technology
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2017). The Meaningful Use program required providers to collect patient-provided data
such as race and ethnicity (Centers for Medicare & Medicaid Services 2014b), family his-
tory (Centers for Medicare & Medicaid Services 2014a), and smoking status (Centers for
Medicare & Medicaid Services 2010) in a structured fashion in the EHR. To date, there
has been little research on the impact of Meaningful Use for improving the data quality of
race and ethnicity, family history, and smoking status in EHRs (Chakkalakal et al. 2015;
Douglas et al. 2015; Klinger et al. 2015).
Another example of a federal policy initiative that has impacted healthcare delivery in
the United States is the Hospital Consumer Assessment of Healthcare Providers and Sys-
tems (HCAHPS) survey. Currently, the Centers for Medicare & Medicaid Services (CMS)
require hospitals to administer HCAHPS surveys after patient discharge to measure patient
satisfaction and experience. These measures are tied to reimbursement, which can lead to
gain or loss of a percentage of the Medicare payments, transforming patient experience into
a financial priority for hospitals. (Hospital Consumer Assessment of Healthcare Providers
and System) As part of the HCAHPS survey, patients are requested to provide demographic
information, along with feedback regarding their medical care and hospital stay.
While broad policy initiatives may have increased the prevalence of certain patient-
provided information in EHRs, such policies have not been evaluated for their impact on
the data quality of the information collected.
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Patient-facing tools
HIT interventions have also been developed to supply patients with access to some
of their clinical information through patient portals, and also to collect information using
similar types of interventions. Online patient portals are now available in many healthcare
systems, allowing patients to view laboratory test results, medications, problem lists, and
health summaries, refill prescriptions, and schedule appointments (Caligtan et al. 2012;
Cimino, Patel, and Kushniruk 2001; Collins et al. 2011; Greenhalgh et al. 2008; Halamka,
Mandl, and Tang 2008; Hassol et al. 2004; Kaelber et al. 2008; Maher et al. 2015, 2016;
Masterson Creber et al. 2016; Nazi et al. 2010; O’Leary et al. 2015; Prey, Restaino, and
Vawdrey 2014; Pyper et al. 2004; Ralston et al. 2007; Reti et al. 2010; Tang and Lee 2009;
Wilcox et al. 2016). More recently, with the OpenNotes initiative, some healthcare provider
organizations are also enabling patients to review their own medical notes via online portals
(Delbanco et al. 2010; Grossman et al. 2017; Leveille et al. 2012; Nazi et al. 2015; Walker
et al. 2011). Computer applications have also been deployed by some hospitals to collect
patient-provided information. Patient-facing tools exist for collecting information such as
medical history, family history, preventive services information such as screening tests and
vaccines, and medication reconciliation (Arsoniadis et al. 2015; Feero 2013; Giovanni and
Murray 2010; Hoyt et al. 2013; Hulse et al. 2010; Murray et al. 2013; Peace, Bisanar, and
Licht 2012; Pyper et al. 2004; Staroselsky et al. 2006, 2008; Wilson et al. 2012a; Wu et al.
2014; Yoon, Scheuner, and Khoury 2003).
While numerous patient-facing tools exist, questions regarding the quality of the data
collected remain. Efforts have focused on providing information to patients and collecting
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information from them. However, there have been limited attempts to demonstrate whether
patient-provided information collected through patient-facing tools have equal or higher
quality than data collected by providers.
Algorithms and informatics methods focusing on using
patient-provided data
Algorithms and informatics methods have been developed to use the data already avail-
able in clinical databases to support biomedical research. Natural language processing
(Friedman, Hripcsak, and Shagina 1999) and EHR phenotyping (Hripcsak and Albers
2013) are important methods that support EHR data reuse for research studies. More re-
cently, initiatives such as Informatics for Integrating Biology & the Bedside (i2b2) (Mur-
phy et al. 2010) and Observational Health Data Science and Informatics (OHDSI) (Hripc-
sak et al. 2015) sought to produce open-source frameworks that allow different teams of
researchers to run the same analyses on separate clinical databases, and combine the re-
sults with confidence, an important step towards reproducibility in biomedical research.
Through the OHDSI platform, Hripcsak and colleagues conducted a 250-million patient
observational research study focusing on the characterization of treatment pathways for
disease, leveraging the medical records and administrative claims data from multiple coun-
tries (Hripcsak et al. 2016).
While many methods and frameworks have been developed to make discoveries from
EHR data, efforts assessing the quality of data available and improving these data sets using
informatics methods have been scarce. The use of patient-provided information in general
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has been limited, likely due to the missingness and incompleteness of these data in these
datasets. There has been little research on the potential impact of informatics methods to
improve availability and quality of patient-provided data in clinical databases. For instance,
on one hand, family history is difficult and time-consuming to collect directly (Green 2007;
Guttmacher, Collins, and Carmona 2004; Rich et al. 2004; Scheuner et al. 2009; Sussner,
Jandorf, and Valdimarsdottir 2011; Wilson et al. 2012b). On the other hand, emergency
contact information, a patient-provided data element that often contains family relationship
information, is requested from patients at nearly all hospitals. There have been few efforts
to deduce family relationship from emergency contact information to discover family his-
tory, even in research. Methods that glean useful information from data that are already
commonly collected can enhance the utility of large databases, further supporting discov-
eries and clinical research.
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4.1 Aim 2.1 - Analyze the impact of various interventions
on the quality of race and ethnicity information
Background
Race and ethnicity are commonly used for estimating disease risk (Gail et al. 1989;
Levey et al. 2009; Stevens et al. 2006) and for assessing health disparities (Dorsey et al.
2014; Douglas et al. 2015; Kressin 2015; LaVeist, Gaskin, and Richard 2011), and these
characteristics are frequently reported in observational studies that rely on EHR data. The
goal of health information technology (HIT) is to improve the quality and efficiency of
healthcare. In the United States, the Meaningful Use financial incentive program required
that EHRs collect patients’ race and ethnicity in a structured fashion (Centers for Medicare
& Medicaid Services 2014b; Rao et al. 2011). The Meaningful Use program adopted the
model for race and ethnicity data collection developed by the Office of Management and
Budget (OMB) (OMB 1997). According to this standard, race and ethnicity information
can be collected either in a single question or in a two-question format. It also established
that patient-provided information should be considered the gold standard for the collection
of race and ethnicity data.
Previous research on the quality of race and ethnicity data recorded in EHRs was con-
ducted with small groups of selected patients, and did not include analysis on the impact
of the Meaningful Use program on the quality of these data (Hamilton et al. 2009; Klinger
et al. 2015). Because of the critical importance of race and ethnicity information for ad-
dressing health disparities and for assessing disease risk, I undertook a study to assess how
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different interventions impacted the data quality of race and ethnicity. Specifically in this
study, I focused on whether data quality improved over time as a result of implementing
Meaningful Use requirements, and the impact of allowing patients to directly provide or
curate their race and ethnicity information.
Objectives
The purpose of this study was to analyze the impact, separately, of a policy and an
informatics intervention on the quality of race and ethnicity information. Specifically, this
study analyzed the impact of the Meaningful Use program and patient-facing tools, such as
patient surveys and a pacing-facing tablet application, on the quality of race and ethnicity
data.
Research Questions
• What is the impact of Meaningful Use on the data quality of race and ethnicity infor-
mation?
• Does allowing patients to provide their race and ethnicity information change the
data quality of this data?
Methods
To analyze the impact of policy change, I conducted a pre-/post- comparison of the
percentage of race and ethnicity data that was informative as recorded in the EHR to analyze
the impact of the Meaningful Use program. Additionally, for the patients that had both
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EHR data and a completed HCAHPS survey, I compared the usefulness of the information
provided by patients to what was stored in the EHR. Lastly, I analyzed the impact of a local
informatics intervention in the quality of race and ethnicity information using data from a
block-randomized controlled trial.
Policy change - Meaningful Use program
I conducted a retrospective analysis of race and ethnicity data recorded for unique pa-
tients who visited NewYork-Presbyterian Hospital/Columbia University Medical Center
(NYPH/CUMC) from 2004 to 2014. Before Meaningful Use Stage 1, race and ethnic-
ity data were collected using a single field. The following categories could be entered in
that field: “American Indian or Alaska Native,” “Asian,” “Black or African American,”
“Hispanic or Latino,” “Native Hawaiian or Other Pacific Islander,” “White,” “Unknown,”
“Other,” or “Declined to Answer.” In response to Meaningful Use requirements, our in-
stitution implemented a two-question format for race and ethnicity data collection, where
one field captured a patient’s race (“American Indian or Alaska Native,” “Asian,” “Black
or African American,” “Native Hawaiian or Other Pacific Islander,” “White,” “Unknown,”
“Other,” or “Declined to Answer”), and a second field captured the patient’s ethnicity (“His-
panic or Latino,” “Not Hispanic or Latino,” “Declined to Answer,” “Unknown”). I obtained
race and ethnicity data collected during the study years and from before and after Meaning-
ful Use changes were implemented. I performed descriptive statistics on the frequency and
quality of data captured using the EHR. Our institution attested compliance to Meaningful
Use Stage 1 requirements at the end of 2012; therefore my analysis segmented records from
2004–2012 as pre-Meaningful Use and from 2013–2014 as post-Meaningful Use. When pa-
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tients had multiple visits to the institution, I only used data from the most recent visit. Pa-
tients classified as “Unknown,” “Other” or “Declined to Answer” were considered to have
clinically uninformative data. I combined these categories into a larger category designated
as “Uninformative.” Quality was assessed based on the percentage of “Uninformative” race
and/or ethnicity in the database.
Patient-facing tools – United States National Databases
As previously described in Aim 1.1, I conducted a retrospective study to assess the
quality of race and ethnicity information using data from HCUP and Optum Labs Data
Warehouse, two large observational databases. To assess the difference in race and ethnic-
ity data quality between national databases and patient-provided datasets, in addition to the
HCUP and Optum databases, I examined the dataset generated from the National Health
and Nutrition Examination Survey (NHANES). NHANES collects data from 5,000 U.S.
adults and children per year (Disease Control and Prevention 2007). Among other infor-
mation, it collects race and ethnicity in a single-question format, with the response coded
as “White,” “Black or African American,” “Hispanic or Latino,” “Not Hispanic or Latino,”
or “Unknown.” I used NHANES data from 1999 to 2011 as a source of patient-provided
race and ethnicity data, and reported the percentage of patients with uninformative race and
ethnicity data.
Patient-facing tools - Academic Healthcare System in New York City
As reported in Aim 1.1, I previously assessed the quality of race and ethnicity data from
the EHR at an academic health system that serves a racially and ethnically diverse popula-
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tion in 10 hospital campuses in and around New York City. To assess differences between
patient-reported race and ethnicity information and data from the EHR, I conducted a ret-
rospective analysis using data from the EHR of the academic medical center and from the
Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey.
I identified patients who had at least one hospital encounter from January 2014 through De-
cember 2015. Among these patients, I identified patients who had answered the HCAHPS
survey. The HCAHPS survey collected demographic information from hospital patients in
the form of a document sent via U.S. Mail after discharge. To collect race and ethnicity
data, the survey used a two-question format to collect race (“White,” “Black or African
American,” “Asian,” “Native Hawaiian or other Pacific Islander,” “American Indian or
Alaska Native”), and ethnicity (“Not Spanish/Hispanic/Latino,” “Puerto Rican,” “Mexican,
Mexican American, Chicano,” “Cuban,” and “Other Spanish/Hispanic/Latino”). I assumed
patient-reported data to be the reference standard for race and ethnicity data collection. I
reported the concordance rate between the patient’s race and ethnicity information in the
EHR and the self-reported information from the HCAHPS survey.
To assess the impact of allowing patients to review their race and ethnicity information
directly, I utilized a custom patient portal application on a tablet computer where patients
reviewed and corrected their race and ethnicity information obtained from the institution’s
EHR. As part of a randomized controlled trial, I recruited 65 patients who were admitted
through the emergency department and provided them with the tablet computer to review
their demographics information. I analyzed and reported descriptive statistics on the num-
ber of patients that make modifications to their records as well as the most common changes
made.
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Figure 4.1: Frequency of race and ethnicity categories before and after Meaningful Use attesta-
tion. *Patients designated as Hispanic in single question format surveys were assumed to be White-
Hispanic.
Results
Policy change - Meaningful Use program
As shown in Figure 4.1, before Meaningful Use was implemented (from 2004–2012),
37.3% of patients did not have race or ethnicity identified in the EHR. After Meaningful
Use was implemented, 49.4% of patients did not have an identified race, and 36.5% did not
have an identified ethnicity. However, we observed a significant increase in the percentage
of patients classified as Hispanic or Latino after Meaningful Use implementation (19.1%
to 31.9%, p=2.62e-97).
Patient-facing tools – United States National Databases
There were 165,975,722 combined patient records in the HCUP and Optum databases.
Of these, 25.3% and 26.0%, respectively, had uninformative race and ethnicity. There were
71,916 records in the NHANES survey, and only 6.4% contained uninformative race and
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ethnicity. Table 4.1 includes a description of the data sources along with the race and
ethnicity categories.
Patient-facing tools - Academic Healthcare System in New York City
As reported in Aim 1.1, 2,338,421 patients had at least one visit during the two-year
study period and 57.9% of patients did not have race or ethnicity identified in the EHR.
During the study period, 25,664 unique patients responded to the HCAHPS survey. Of
those, 1,255 patients completed the survey more than once, and 356 (28.4%) had conflicting
self-reported race and ethnicity information. After excluding cases with conflicting self-
reported race and ethnicity information, 86.3% provided meaningful race or ethnicity data
from a total of 25,308 patients. Among these patients, race and ethnicity information from
the EHR was available for 25,014 patients.
Among patients with both self-reported and EHR race and ethnicity information, 16,625
(66.5%) patients provided race or ethnicity information that was discordant with data
recorded in the EHR. While 6,540 had both race and ethnicity as “Uninformative” in the
EHR, the self-reported data provided meaningful race or ethnicity information for 5,533
(84.6%) of these patients, that did not otherwise have meaningful information recorded.
In the randomized trial that assessed patient-reported demographic data entered at the
time of hospital admission, 65 patients were recruited. Of those, 35 (53.85%) made changes
to their race and/or ethnicity (30 patients edited both, four patients edited ethnicity only, and
one patient edited race only). Analysis of all of the “Uninformative” categories for race and
ethnicity demonstrated that the majority of patients were willing to provide their informa-
















































and 42 had “Uninformative” ethnicity documented in the EHR. After patients reviewed and
optionally edited their information, the race of only six (18.75%) patients, and the ethnic-
ity of 13 (30.95%) patients remained “Uninformative.” Of the 20 patients who verified
or modified their ethnicity to be “Hispanic,” the majority did not consider their race to be
available in the list of options; 10 patients recorded or retained their race as “Other,” and
two as “Unknown.”
Discussion
Categories defined by the Meaningful Use program for collecting race and ethnicity
are based on current standards published by the Office of Management and Budget (OMB)
in 1997 (Rao et al. 2011). Based on these standards, self-reporting using two separate
questions is the preferred method for collecting data on race and ethnicity (OMB 1997).
When comparing ethnicity data before and after Meaningful Use implementation, we
observed a significant increase in the percentage of patients identified as Hispanic. Im-
plementing the two-question format allowed us to better identify our Hispanic population;
however, the ethnicity of 36.5% of our patients was still unidentified after Meaningful Use
compared to 37.3% before Meaningful Use. In terms of race, 37.3% of patients were labeled
“Unidentified” before Meaningful Use versus 49.4% after Meaningful Use. This increase
in unidentified patients may be due to the difference in how data was collected in the two
time periods. Based on the previous single-question format, collecting only ethnicity data
would have identified a patient’s race/ethnicity, whereas in the two-question format, both
race and ethnicity had to be collected separately.
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The appropriate collection of race and ethnicity information is key to recognizing dis-
parities that affect minority populations (Kressin 2015). Furthermore, this information can
be used to perform risk assessment both for individuals and populations. Our findings sug-
gest that EHR changes implemented because of Meaningful Use improved the collection
of race/ethnicity data for our Hispanic population; however, we still have a considerable
number of patients without meaningful information for both race and ethnicity.
The comparison between survey data and data from large observational databases
demonstrated that patients are willing to provide their racial information leading to higher
data quality of race and ethnicity data in these databases. However, 28.4% of patients that
completed the HCAHPS survey more than once reported conflicting data. Most of these
cases were patients recording more than one race in one survey and reporting a single race
in another survey response or patients that chose to report their ethnicity in one survey but
not in another.
When comparing ethnicity data before and after patient review through an inpatient
portal, we observed that patients were willing to review their information and make changes
when needed. The majority of the patients with uninformative race and ethnicity in the EHR
changed these values to more meaningful concepts. Interestingly, our Hispanic patients did
not seem to consider themselves to belong to any of the OMB-defined race categories as
the majority identified their race as “Other” and often entered “Hispanic,” “Latino” or their
country of origin in a free-text field.
Taking the findings from HCAHPS survey responses to demographic questions as well
as the patient review of race and ethnicity data in their health record, these findings raise
questions about the efficacy of the two-question format (i.e., collecting race and ethnicity
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data collection as separate fields) that is now widely used, as well as the clarity of the
difference between “race” and “ethnicity” for patients. While patient-facing tools do appear
to capture race and ethnicity data more effectively than other methods, the current categories
might be confusing or insufficient for patients to self-report.
Conclusion
This study found many challenges in the collection of race and ethnicity. Policy change
efforts such as the Meaningful Use program resulted in better collection of ethnicity. How-
ever, a large proportion of patients remain without race and ethnicity information in the
EHR. The use of patient-facing tools can dramatically improve the data quality of this in-
formation, potentially improving identification of health care disparities and supporting
disease risk assessment. Future work could explore how to determine better race and eth-
nicity categories that would allow patients to consistently report their racial and ethnic back-
ground.
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4.2 Aim 2.2 - Development and evaluation of a novel
method to extract familial relationships from existing
clinical databases using patient-provided emergency
contact information
Background
Family history is one of the most important disease risk factors necessary for the
implementation of precision medicine in the clinical setting (Aronson and Rehm 2015;
Guttmacher, Collins, and Carmona 2004). It is critical for disease risk assessment (Berry
et al. 1997; Claus, Risch, and Thompson 1994; Ozanne et al. 2013; Tyrer, Duffy, and Cuzick
2004; Wu and Orlando 2015), and appropriate disease screening and prevention (Murabito
et al. 2001; Reid et al. 2009; Staroselsky et al. 2006). While several studies have shown that
family history is an important element in deciding clinical care (Berry et al. 1997; Claus,
Risch, and Thompson 1994; Ozanne et al. 2013; Saslow et al. 2007; Smith, Cokkinides, and
Brawley 2012; Tyrer, Duffy, and Cuzick 2004), several barriers exist in its collection and
analysis, as well as in its use for personalized management based on patients’ risk assess-
ment. Lack of time to obtain, organize and analyze family history information is perhaps
the most critical barrier for the use of family history in clinical encounters (Green 2007;
Guttmacher, Collins, and Carmona 2004; Rich et al. 2004; Scheuner et al. 2009; Sussner,
Jandorf, and Valdimarsdottir 2011; Wilson et al. 2012a). These challenges ultimately re-
sult in data quality issues, particularly incompleteness and incorrectness of family history
99
data in the EHR. In an attempt to recover this valuable information from existing clinical
databases, in this study I used emergency contact information—a type of patient-provided
data collected at nearly every hospital as part of the routine admission process—to infer
familial relationships. I present a novel algorithm for extracting relationships called Re-
lationship Inference From The Electronic Health Record (RIFTEHR) and use it to infer
familial relationships among patients.
Objectives
This study developed and evaluated a method that uses patient-provided data to infer
familial relationships. The method used emergency contact information, a type of patient-
provided data collected at nearly every hospital as part of hospital registration, to infer
familial relationships. The familial relationships were evaluated using both clinical and
genetic data.
Research Questions
• Can routinely collected patient-provided administrative data from the EHR be used
to identify familial relationships?
Methods
The data for this study were obtained from the inpatient EHR used at the hospitals
affiliated with three large academic medical centers in New York City: Columbia University
Medical Center, Weill Cornell Medical Center, and Mount Sinai Health System. Columbia
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University Medical Center and Weill Cornell Medical Center operate together as NewYork-
Presbyterian Hospital and herein, I will refer to the hospitals and the data associated with
them as Columbia and Weill Cornell, respectively. Similarly, I will refer to Mount Sinai
Health System and its data as Mount Sinai. The study was approved by Institutional Review
Boards independently at each site.
The standard operating procedures require patients who receive care at one of the three
academic medical centers to provide information about an emergency contact. This infor-
mation included the person’s name, address, phone number, and their relationship to the
patient (e.g., parent, sibling, friend). Using a method I call “Relationship Inference From
The Electronic Health Record” (RIFTEHR), I used the emergency contact information to
identify familial relationships in the EHR in cases where the emergency contact person had
his or her record generated by an encounter with the healthcare system. Algorithmically,
I then inferred additional relationships from the connectedness of the identified individu-
als. This information was validated against genetic data and a separate module of the EHR
which documented the linkage between mothers’ and their newborns’ medical records.
Deriving familial relationships from emergency contact data
To match the emergency contact to the medical records, the algorithm created for each
patient a list of all reported emergency contacts. Then, for each emergency contact, it
attempted to identify a medical record by matching first name, last name, primary phone
number, and ZIP code. First, I considered all cases with first name and filtered the table that
contains all patients’ information to identify records that contain the same first name. I then
returned the identified records and performed the same comparison with last name, primary
101
phone number, and ZIP code. Subsequently, I compared the combination of two variables
at a time (i.e., first name and last name, first name and primary phone number, first name
and ZIP code, etc.). I then performed combinations of three variables and then of all four
variables. I only considered it successful when I identified a single patient that matches to
the emergency contact information given. I also captured which variables were used in the
matching process for each one of the emergency contacts (i.e., first name and last name;
first name, last name and phone number, etc.). The output of this algorithm contained a
patient’s identifier, the relationship between the patient and the matched emergency contact,
the emergency contact’s identifier, and a list of the variables used to perform the matching
process. I used as patient identifiers the Enterprise Master Patient Index (EMPI), when
available or the medical record number (MRN). EMPIs are a unique identifier created to
refer to multiple MRNs across the healthcare organization. Using EMPIs allowed us to
perform better in the matching process since duplicates from patients having more than one
MRN were excluded.
Once the matches were identified, as a quality control step, I excluded patients with
non-biological relationships (i.e., spouse, friend). Specific relationships were mapped to re-
lationship groups (e.g., the relationship “mother” is mapped to “parent”). I then calculated
the age difference between two related patients and excluded parents that were less than 10
years older than their children, children that were less than 10 years younger than their par-
ents, grandparents that were less than 20 years older than their grandchildren, grandchildren
that were less than 20 years younger than their grandparent. Since parents and grandpar-
ents must be older than their children and grandchildren, I also flipped relationships when
the age difference between parent or grandparent and its child or grandchild was negative.
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Specifically, the relationship “parent” became “child,” and the relationship “grandparent”
became “grandchild.” The same process was done when the age difference between chil-
dren and grandchildren was positive. I also excluded every patient that matches to 20 or
more distinct emergency contacts since it is unlikely that patients have such a high number
of family members as a direct emergency contact. Finally, I generated the opposite rela-
tionship for every relationship pair. For example, if I determined that A is a parent of B,
the opposite relationship is that B is a child of A.
Using the matches identified, I also inferred additional relationships. The inference
process was made based on familial relationship rules. For example, if patient A is the
mother of patient B and patient B is the mother of patient C, then by inference I know that
A is the grandmother of C and C is the grandchild of A. The rules used to perform these
inferences are described in Table 4.2.
Once additional relationships are inferred, I removed ambiguous relationships
such as “Parent/Aunt/Uncle” if the same pair contained a unique specific rela-
tionship, in this case, either “Parent” or “Aunt/Uncle.” The same was done for






To identify families in the datasets, I excluded all non-biological relationships such as
spouses and in-laws, as well as ambiguous relationships such as “Parent/Parent-in-law.”
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 1Table 4.2: Relationship inference rules.
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Using both provided and inferred relationships, I created a network where each node corre-
sponds to a patient and edges represent familial relationships. To identify different families,
I decomposed the network into individual connected components.
To identify twins, I matched siblings that shared the same last name and the same date of
birth. I did not have enough information to distinguish between monozygotic and dizygotic
twins.
Evaluation of automatically inferred relationships
I used the EHR’s mother-baby linkage as the reference standard to evaluate identified
maternal relationships. Cases were considered true-positives when maternal relationships
identified by RIFTEHR were also present in the EHR’s mother-baby linkage table. Cases
were considered false-positives cases when maternal relationships identified by our algo-
rithm were discordant with the EHR’s mother-baby linkage table. And lastly, false-negative
cases occurred when a maternal relationship was captured by the EHR’s mother-baby link-
age but not by our method. Overall performance was evaluated by calculating sensitivity
and positive predictive value (PPV). To assess if matches identified by different variables
performed differently, I also computed sensitivity and PPV. I stratified the identified rela-
tionships by the number of variables used to match the emergency contact to a patient in a
healthcare system (Table 4.3), as well as by the combination of variables (e.g., last name
only, first name and last name, etc.) used to perform the match (Table 4.4). Additionally, I
used the EHR mother-baby linkage information to infer siblings. I then used these relation-
ships to evaluate siblings identified by RIFTEHR. Similarly to the maternal relationships
evaluation, overall sibling performance was evaluated by calculating sensitivity and PPV.
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Columbia Weill Cornell
N of Paths True Positive False Positive PPV True Positive False Positive PPV
1 4340 1021 0.8096 2979 391 0.884
2 3911 355 0.9168 4114 95 0.9774
3 2438 55 0.9779 4753 53 0.989
4 2696 89 0.968 2089 63 0.9707
5 3075 16 0.9948 4219 29 0.9932
6 5840 30 0.9949 10170 19 0.9981
7 3892 10 0.9974 4100 12 0.9971
8 3105 13 0.9958 1739 19 0.9892
9 2575 6 0.9977 1451 3 0.9979
10 2460 8 0.9968 1217 5 0.9959
11 857 1 0.9988 532 3 0.9944
12 308 0 1 156 0 1
13 34 0 1 29 0 1
14 12 0 1 6 0 1
 1
Table 4.3: Performance by number of paths.
To further evaluate the familial relationships, I used genetic data to perform analy-
sis for kinship. Genotype data were collected from existing sources for 1,524 individu-
als. At Columbia, genetic data were available for 302 individuals. Data were collected
from three separate sources: the Institute for Genomic Medicine, The Columbia Univer-
sity Medical Center Pathology Department, and the Washington Heights/Inwood Informat-
ics Infrastructure for Comparative Effectiveness Research (WICER) project, using whole
exome sequencing, Affymetrix CytoScan HD array, and the Illumina Multi-Ethnic Geno-
typing Array, respectively. To select single-nucleotide polymorphisms (SNPs) for kinship,
minor allele frequency was filtered to greater than 5%, and genotyping rate to 99% using
PLINK Purcell:2007dg. Independent SNPs were selected using the sliding window (100

























































































































































































































































































































































































































































































































































Institute for Genomic Medicine data, 8,544 SNPS from the WICER data, and 32,938 SNPs
from the Pathology Department data. PLINK was then used to calculate identity by descent
(IBD) by determining π̂ results (P (IBD = 2)+0.5∗P (IBD = 1)(proportionIBD)) for
each pair of individuals. I considered that the predicted relationship was correct if the blood
relationship fraction between the two people was the same as the one expected for the pre-
dicted relationship with a margin of error of 20% of the expected blood relationships. For
example, for inferred mother-child pairs, two individuals in a pair share 50% (±10%) of
their genetic information, then that provides evidence that the predicted relationship is cor-
rect. Likewise, for inferred aunt-niece pairs, the two individuals are expected to share 25%
(±5%). The performance was evaluated by calculating PPV.
Using the Mount Sinai data, I leveraged genome array data for 24,441 participants re-
cruited to the BioMe Biobank Program of The Charles Bronfman Institute for Personalized
Medicine. Genotyped participants had a mean age 55.8 years, and approximately 61% are
female. Participants self-identified as: Hispanic/Latino (45%), African American (31%),
White/Caucasian (8%), Asian (6%), Mixed ancestry (6%), or Other (11%). To calculate
genetic relatedness, I first merged BioMe participants (N) genotyped either on the Illumina
OmniExpress HumanCore (N=11,212) or Multi-Ethnic Genotype Array v1.0 (N=10,467)
platforms, retaining only the intersection of sites (n) between the two arrays (n=385,531). I
subsequently removed palindromic sites (n=7,215 SNPs) and sites with a missingness rate
> 1% (n=517) and a MAF < 5% (n=112,537) leaving a total of 112,537 SNPs. Of 21,679
BioMe participants with genotype data, emergency contact information was available for
16,341, and in 1,222 cases both family members with relationship inferred by RIFTEHR
were in BioMe. Pairwise genetic relationships were estimated by Identity-by-State anal-
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ysis with PLINK1.9 using the –genome flag. Inferred relationships from RIFTEHR were
compared to pairwise genetic relationships to assess performance metrics using the “caret”
package with R version 3.0.3. Pairs of patients with conflicting familial relationships were
analyzed based on the closest relationship available. For example, if the same pair has two
distinct relationships inferred based on their emergency contact information (e.g., parent
and aunt/uncle), I consider the first-degree relationship to be correct (in this case, parent)
for evaluation of the relationship against genetic data. Parent-offspring and sibling rela-
tionships groups were both expected to share 50% genetic relatedness IBS (π̂ mean 0.5,
s.d. ± 0.1). I could distinguish between these two groups by examining the IBS measures
at heterozygous (IBS1) and homozygous (IBS2) sites. Parent-offspring were defined as
IBS1 > 0.75 and IBS2 < 0.25 (n=1087 pairs), full-siblings were defined as pairs that shared
between 0.35 and 0.65 IBS1, and IBS2 > 0.15 and < 0.5 (n=502), monozygotic twins were
defined as individuals sharing > 0.8 IBS2 (n=2). In each RIFTEHR group, I calculated pos-
itive predictive values (PPV) based on how many predicted parent-offspring and siblings
met these genetic criteria. Grandparental, avuncular and half-siblings are all expected to
share 25% genetic relatedness IBS (π̂ mean 0.25, s.d. ± 0.05). Avuncular relationships 
involved one sibling and the offspring of the other sibling regardless of sex; therefore, the
term avuncular refers to both aunts and uncles.
I could not distinguish these groups any further, so I calculated positive predictive
values for each group based on how many total pairwise relationships met these criteria
(n=976). I did not calculate PPV for cousins, grand-avuncular, great-grandparental, great-
grand-avuncular, first cousin-once-removed relationships as the numbers of predicted re-
lationships per group were low (n≤10). Finally, as negative control, I compared predicted
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spousal relationships with low or no evidence of IBS sharing (π̂ < 0.05, < 0.1 IBS1 and <
0.1 IBS2). The BioMe Biobank Program (Institutional Review Board 07–0529) operates
under a Mount Sinai Institutional Review Board-approved research protocol. All study
participants provided written informed consent.
As a subjective validation of all relationship types, including distant relationships such
as great-grandparent, I calculated age difference between all pairs of family relatives and
stratified it by relationship type. I compared the identified age differences to what would be
expected in a real family structure. For example, great-grandparents should be much older
than their great-grandchildren.
Results
In total, 3,550,598 patients provided 6,587,594 emergency contacts at the three medical
centers. Of these, I identified the emergency contact as a patient in 2,191,695 cases (825,880
at Columbia, 573,804 at Weill Cornell and 792,011 at Mount Sinai). Of those, 1,902,827
provided 1,588,134 family members as emergency contact (488,932 at Columbia, 297,011
at Weill Cornell, and 802,191, at Mount Sinai; Table 4.5). Using these next-of-kin data,
I inferred an additional 2,755,448 relationships at Columbia, 1,237,749 at Weill Cornell
and 1,819,581 at Mount Sinai (Figure 4.2). Including inferences, I identified a total of
3,244,380 unique relationships at Columbia, 1,534,760 at Weill Cornell, and 2,621,772
at Mount Sinai. Inferred relationships included first to fourth-degree relatives as well as
spouses and in-laws (Tables 4.5 and 4.6). I grouped individuals into families by identifying
disconnected subgraphs. I found 223,307 families at Columbia containing 2 to 134 mem-
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Variable Columbia Weill Cornell Mount Sinai
N 682,267 437,375 783,185
Relationships 3,244,380 1,534,760 2,621,772
     N provided relationships 488,932 297,011 802,191
     N inferred relationships 2,755,448 1,237,749 1,819,581
Families 223,307 155,811 187,473
Gender, Female 418,657 (61.36%) 261,482 (59.78%) 449,878 (57.45%)
Age 40.15 (24.81) 39.85 (25.02) 51.44 (23.20)
Race/Ethnicity
     Black or African American   69,506 (10.19%)   30,975 ( 7.08%)  79,854 (10.20%)
     White 123,800 (18.15%) 110,485 (25.26%) 285,559 (36.46%)
     Hispanic or Latino 373,552 (54.75%)   52,087 (11.91%) 151,785 (19.38%)
     Other   11,438 ( 1.68%)   26,687 ( 6.10%)  25,864 ( 3.30%)
     Unknown/Declined to answer 103,971 (15.24%) 217,141 (49.65%) 240,123 (30.66%)
Degree of relationship
     First (i.e. child, parent) 1,388,858 814,650 798,440
     Second (e.g. grandchild) 605,922 225,796 243,434
     Third (e.g. great-grandparent) 432,262 137,712 136,936
     Fourth (e.g. great-great-grandchild) 215,300 61,986 58,500
     Other
          None (e.g. spouse, in-laws) 172,158 127,748 571,250
          Unknown (e.g. parent/parent-in-law) 429,880 166,868 813,212
 1
Table 4.5: Demographic data of the electronic health records at Columbia University Medical
Center, Weill Cornell Medical Center, and Mount Sinai Health System.
bers per family. Similarly, I found 155,883 families at Weill Cornell, with up to 129 mem-
bers per family and 187,473 families at Mount Sinai, with up to 57 family members. These
include 4,271 families with fourth-degree relatives (i.e., families that contain first cousin
once removed, great-grandaunt/great-granduncle or great-grandnephew/great-grandniece)
at Columbia, 1,045 families at Weill Cornell, and 992 families at Mount Sinai.
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Degree of relationship Relationship N Columbia N Weill Cornell N Mount Sinai
First
Child 482,308 298,136 252,584
Parent 482,308 298,136 252,584
Sibling 424,242 218,378 293,272
Second
Aunt/Uncle 185,822 65,410 75,404
Nephew/Niece 185,822 65,410 75,404
Grandparent 117,139 47,488 46,313
Grandchild 117,139 47,488 46,313
Third
Cousin 148,806 37,370 27,994
Grandaunt/Granduncle 96,675 31,764 36,069
Grandnephew/Grandniece 96,675 31,764 36,069
Great-grandchild 45,053 18,407 18,402
Great-grandparent 45,053 18,407 18,402
Fourth
First cousin once removed 94,404 19,596 19,914
Great-grandaunt/Great-granduncle 42,594 13,664 12,945
Great-grandnephew/Great-grandniece 42,594 13,664 12,945
Great-great-grandchild 17,854 7,531 6,348
Great-great-grandparent 17,854 7,531 6,348
Other
Child-in-law 0 278 0
     None
Parent-in-law 0 278 0
Spouse 172,158 127,192 571,250
Aunt/Uncle/Aunt-in-law/Uncle-in-law 13,220 5,234 45,950
     Unknown
Child/Child-in-law 52,186 24,733 62,804
Child/Nephew/Niece 31,818 8,078 96,925
Grandaunt/Granduncle/Grandaunt-in-law/Granduncle-in-law 12,035 4,278 36,242
Grandchild/Grandchild-in-law 12,876 4,578 32,781
Grandnephew/Grandniece/Grandnephew-in-law/Grandniece-in-law 12,035 4,278 36,242
Grandparent/Grandparent-in-law 12,876 4,578 32,781
Great-grandchild/Great-grandchild-in-law 5,799 2,346 18,343
Great-grandparent/Great-grandparent-in-law 5,799 2,346 18,343
Nephew/Niece/Nephew-in-law/Niece-in-law 13,220 5,234 45,950
Parent/Aunt/Uncle 31,818 8,078 96,925
Parent/Parent-in-law 52,186 24,733 62,804
Sibling/Cousin 41,270 9,142 88,956
Sibling/Sibling-in-law 132,742 59,232 138,166
 1
Table 4.6: Relationships by degree.
112
Figure 4.2: 680,000 at Columbia, 430,000 at Weill Cornell, and 780,000 at Mount Sinai reported
next-of-kin data that could be identified in the institutional EHR. From these initial relationships, I
was able to infer additional relationships resulting in 3.2 million patient relationships at Columbia,
1.5 million relationships at Weill Cornell, and 2.6 million relationships at Mount Sinai. A family
was identified as a group of patients with no relationships outside of the group. In total, we identified
223,000 families at Columbia, 155,000 families at Weill Cornell, and 187,000 at Mount Sinai. The
largest 400 families from Columbia were visualized as a graph using a force layout (Methods). Each
disconnected subgraph is a family. Each node is an individual. Solid nodes represent patients in our
respective EHRs. Colored nodes indicate the presence of a disease diagnosis in one of four classes:
cardiovascular disease (red), musculoskeletal disease (purple), metabolic disease (blue), and skin
disease (green). The top left shows 93 of the top families at Columbia. The largest family shown
contains 23 individuals and the smallest, 12. I constructed detailed pedigrees for one family from
Columbia (bottom left). The pedigree shown was modified for de-identification purposes. Each
node is an individual. Individuals indicated by dashed lines are inferred to exist but did not exist
in the EHR. The top right shows a map of the number of individuals from Columbia for whom
relationships were identified. The colors represent the number of individuals that live in each ZIP
code. The bottom right bar graph shows the number of individuals by relationship type for each
institution. We used all disease diagnosis data and clinical pathology report data (laboratory tests)
available for patients in our cohort to study genetic heritability. At Columbia, 6.6 million disease
diagnoses were used to estimate heritability of dichotomous traits and 42 million laboratory tests
were used to estimate heritability of quantitative traits. At Weill Cornell, 3 million disease diagnoses
were used and 16 million laboratory tests and at Mount Sinai, 4 million disease diagnosis.
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The relationship between mother and child was explicitly documented in the EHR for
newborns delivered at Columbia and Cornell. This ‘EHR mother-baby linkage’ provided a
reference standard for maternal relationships, allowing us to compute sensitivity and pos-
itive predictive value (PPV) of the relationship inference method. For maternal relation-
ships, I obtained 92.9% sensitivity with 95.7% PPV at Columbia and 96.8% sensitivity
with 98.3% PPV at Weill Cornell. Similarly, for siblings, I obtained 92.2% sensitivity with
98.3% PPV at Columbia and 96.5% sensitivity with 99.6% PPV at Weill Cornell (Figure
4.3A). Tables 4.3 and 4.4 present the stratified performance of the identified relationships
by the number of variables used to match the emergency contact to a patient in a healthcare
system, and by the combination of variables (e.g., last name only, first name and last name,
etc.) used to perform the match, respectively.
I validated the identified relationships by comparison to genetically-derived related-
ness (Figure 4.3). I collected data for 1,222 patients from Mount Sinai and 302 patients
from Columbia for whom EHR-inferred relationships and available genetic data were con-
sented for reuse. I included spousal relationships as a negative control using a heuristic
definition of being genetically unrelated (IBS < 0.1). I estimated relatedness using PLINK
(Purcell et al. 2007). At Columbia, almost all 134-predicted parent-offspring relationships
had the expected genetic relatedness of 50%, and the three grandparental relationships had
the expected relatedness of 25%. All 26 sibling relationships were genetically related, but
four were identical twins, and three were half-siblings (Figure 4.3B). At Mount Sinai, the
positive predictive value (PPV) to predict spousal relationships was 91%, 80% for parent-
offspring, 66% for sibling, and 47% for grandparental and 32% for avuncular relationships
(Figure 4.3D). Overall, relationships extracted from the EHR significantly correlate with
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Figure 4.3: Validation of familial relationships inferred from the EHR. (A) The medical centers at
both Columbia and Weill Cornell have implemented a link between the electronic health records of
mother and baby at the time of birth. I used these links as a gold standard to evaluate RIFTEHR,
my algorithm for automatically inferring relationships from the EHR. I also inferred siblings using
the mother-baby link data. (B) Through biobanks at Columbia, 302 of the patients with identified
relationships from RIFTEHR also had genetic data available and appropriately consented for use
in our study. For these, RIFTEHR predicted a total of 172 relationships. Genetic relatedness was
determined for each pair of individuals. Almost all 134 parent/child relationships had the expected
genetic relatedness of 50% (51%±3%). Of the siblings predicted by RIFTEHR 19 were full siblings,
3 were half siblings (genetic relatedness of 25%), and 4 were identical twins. The high rate of
twins in our small sample is a result of the secondary use of existing data – which was originally
collected for genetic studies. Excluding these twins yields a more accurate estimate of RIFTEHR’s
performance (PPV=86.4%). Overall the RIFTEHR relationship and the genetic relationship were
significantly correlated (r=0.60, p=1.81e-18). (C) Average age differences for each relationship
type. I computed the age differences for each pair of individuals at Columbia (blue), Weill Cornell
(red) and Mount Sinai (purple). The age differences are consistent across sites. (D) At Mount
Sinai, I identified 1,222 patients that had familial relationships from RIFTEHR and also had genetic
data available with appropriate consent for use in our study. Among these, RIFTEHR inferred 937
relationships. Genetic relatedness was determined for each individual pair and compared to the
relationships inferred by RIFTEHR. RIFTEHR’s performance varied from 32% to 91% PPV, being
more accurate in identifying members of the nuclear family. Overall the RIFTEHR relationship and
the genetic relationship were significantly correlated (r=0.67, p<1.2e-162).
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the expected genetic relatedness (r=0.60, p=1.81e-18 at Columbia and r=0.67, p<1.2e-162at
Mount Sinai).
Discussion
Analysis of EHR data has yielded insight into drug effectiveness and allowed precise
definition of phenotypes to investigate disease processes (Birkhead, Klompas, and Shah
2015; Boland et al. 2015; Lorberbaum et al. 2016a; Ritchie, Andrade, and Kuivaniemi
2015; Tatonetti et al. 2012; Wei and Denny 2015). For the first time on a large scale, I used
EHR data to infer pedigrees from patient-provided emergency contact information. I pre-
sented a novel algorithm for performing this relationship extraction, RIFTEHR, validated
its performance, and applied it to the medical records of three independent institutions.
Previous research studies have used existing databases to identify twins. In 1987, a
Vietnam Era (1964-1975) Twin Registry of American male-male veterans born between
1939 and 1955 was developed to provide a study sample for research evaluating the impact
of Vietnam service on the medical and psychosocial aspects of health. Twins were identified
using an algorithm which involved matching entries on the database for same last name,
different first name, same date of birth, and similar social security number (Eisen, True, and
Goldberg 1987). In 2014, researchers used a similar method to identify twins from an EHR
database (Mayer et al. 2014). Unlike the methods employed in these studies, RIFTEHR
identified familial relationships including distant relatives up to four generations apart, in
addition to twins.
The availability of family structures in addition to clinical data has significant implica-
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tions for the use of EHR data in clinical and genetic studies. EHRs are in broad use and
offer an alternative to traditional phenotyping. Every day, the EHR records information for
thousands of patients from drug prescriptions and disease diagnosis to clinical pathology
results and physician notes. Use of EHR data presents a novel opportunity to conduct rapid
and expansive genetic studies such as of disease and phenotype heritability. In particular,
EHR data enables access to traits that otherwise might not be explored. Similarly, the use
of EHR data with familial structures allows for large-scale clinical studies, including dis-
ease risk assessment and screening. In addition, data captured by these systems represent
the diversity of the patient populations they serve, and, in ethnically diverse regions like
New York City, make previously unattainable cohorts available for study (Hripcsak et al.
2016). The caveat is that EHR data are known to contain issues regarding missingness and
accuracy which limits their use (Hripcsak and Albers 2013; Weiskopf and Weng 2013).
Future studies should use robust methods that account for these data quality concerns.
Conclusion
We have described and validated a novel method for identifying familial relationships
in medical records and used 7.4 million relationships inferred from the EHRs at three aca-
demic medical centers. The availability of family structures in addition to clinical data has
significant implications for the use of EHR data in clinical and genetic studies, enables ac-
cess to clinical information that otherwise might not be explored, and ultimately advancing
clinical and genetics research.
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4.3 Aim 2.3 - Impact of a federal initiative (Meaningful
Use) on collecting patients’ smoking status
Background
Smoking remains the number one cause of preventable death in the United States, re-
sponsible for more than 480,000 deaths annually (National Center for Chronic Disease
Prevention and Health Promotion Office on Smoking and Health 2014). Policy change,
such as tobacco control policies, smoke-free legislation, tobacco taxation, and smoking
cessation services have been shown to have substantial benefits in children’s health (Faber
et al. 2017). In addition to these policies, obtaining a patient’s smoking status during clini-
cal encounters is a crucial step in beginning smoking cessation interventions and monitor-
ing progress (Caplan, Stout, and Blumenthal 2011). Accurately recording smoking status
during a clinical encounter may appear to be a straightforward task; however, this impor-
tant behavioral determinant of health is often overlooked (Adler and Stead 2015). Given
the clinical importance of recording smoking status, the Meaningful Use (MU) financial
incentive program for electronic health record (EHR) adoption in the U.S. included a re-
quirement for healthcare providers to capture patients’ smoking status electronically in a
structured format (Centers for Medicare & Medicaid Services 2010).
Objectives
The purpose of this study was to assess the impact of the Meaning Use program in
the data quality of smoking status in a pre-/post- design with data collected over a 10-year
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period in an established commercial EHR system at a large academic medical center.
Research Questions
• How did Meaningful Use impact the quality of smoking status collected in the EHR?
Methods
I conducted a retrospective study to analyze smoking status data before and after Mean-
ingful Use criteria were implemented at NewYork-Presbyterian Hospital/Columbia Univer-
sity Medical Center. In our institution, smoking status was collected in clinical notes by
several types of providers (e.g., physicians, nurses, social workers). The EHR contained
thousands of note templates containing a variable number of observations. An observa-
tion could be a free-text box, a Boolean, or a numeric value. As described previously in
Aim 1.3, I extracted data from observations, including structured and free-text, whose de-
scription contained the stemmed words “smok,” “cigar” or “tobacco,” and identified the
number of times each observation was used. This analysis showed that approximately 94%
of patients had at least one smoking status recorded in a structured observation. Given this
finding, in this study, I limited this analysis to structured observations.
While our institution was accredited as being compliant with Meaningful Use Stage
One criteria in the end of 2012, changes to the note templates were implemented through-
out the preceding years. Therefore, patients that had at least one hospital admission be-
tween November 2007 and August 2017 were included in the study. I analyzed changes
in the documentation pattern of smoking status during the 10-year study period. Prior to
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the Meaningful Use program, smoking status was collected as part of clinical notes using
locally defined templates, without standardized categories. Categories for smoking status
were defined by each group responsible for developing note templates. With the imple-
mentation of the Meaningful Use program, eight distinct categories for collecting smoking
status were specified: “Current every day smoker,” “Current some day smoker,” “Former
smoker,” “Never smoker,” “Smoker, current status unknown,” “Unknown if ever smoked,”
“Heavy tobacco smoker,” and “Light tobacco smoker” (Centers for Medicare & Medicaid
Services 2010). All observations were stored independently from each other, and not trans-
ferred to other sections of the EHR.
All smoking status observations, pre- and post-Meaningful Use, were mapped to one
of four clinically meaningful categories: 1) “Current smoker,” 2) “Former smoker,” 3)
“Never smoker,” and 4) “Unknown smoking status,” as described in Table 4.7. Once the
categories were mapped, I examined smoking status collected over time for each patient
and analyzed whether subsequent updates to smoking status were plausible or implausible.
Plausible cases occurred when the change was feasible to happen such as a change from
“Never smoker” to “Current smoker”), and implausible occurred when the conflict was not
logically possible or in cases where there was a loss of information; for example, a change
from “Former smoker” to “Never smoker.” Figure 4.4 demonstrates all possible changes
in smoking status along with the plausibility of each change.
Additionally, I analyzed the number of discrepancies in smoking status between clini-
cal notes recorded during the same hospital admission for each patient. It is unlikely that
patients will have changes to their smoking status during a single hospitalization; therefore,
discrepancies in patients’ smoking status recorded during a single hospitalization were con-
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Clinically Actionable Smoking 






Current every day smoker
Current some day smoker
Light smoker
Heavy Smoker













Table 4.7: Description of the mapping from smoking status categories as recorded in the EHR to
the four clinically actionable categories. Smoking status categories documented in the EHR that
utilize the standard criteria defined by the Meaningful Use program are highlighted in bold.
Figure 4.4: Changes of smoking status overtime. Dashed changes demonstrate implausible dis-
crepancies and continuous lines represent plausible changes in longitudinal data..
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sidered plausibility issues. I assessed quality of smoking status based on the percentage of
patients with consistent and informative smoking status recorded in the EHR (i.e., not classi-
fied as “Unknown” in the database, or not conflicting if recorded multiple times). I reported
the number of patients with and without smoking status, the number of times smoking status
was recorded per visit, the number of different provider types (e.g., nurses, medical doctors,
care coordinators, social workers) recording smoking status, the percentage of visits with
discrepancies, and the number of plausible and implausible changes per year. To assess the
impact of Meaningful Use on the data quality of smoking status, I compared the descriptive
statistics described above during the years before and after Meaningful Use criteria were
adopted.
Results
I reviewed data from 304,926 patients, who together had 529,236 hospital admissions
during the 10-year study period, wherein 858,512 observations of smoking status were
recorded. The accompanying Table 4.8 presents the number of patients and visits with
more than a single smoking status collected, as well as the average number of times smok-
ing status was collected, the number of provider types that collected smoking status, and the
rate of discrepancies and implausible changes. As shown in Figure 4.5, over the 10-year
study period, smoking status was documented increasingly frequently and by more provider
types (e.g., nurses, medical doctors, care coordinators, social workers). However, the rate
of discrepancies increased both at the patient and visit levels from 5% to 40% and 5% to
41%, respectively. Similarly, the rate of implausible changes increased from nearly 2% to
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Figure 4.5: Number of times of provider types that collecting smoking status per patient.




The Meaningful Use program specifies eight distinct categories for collecting smoking
status: “Current every day smoker,” “Current some day smoker,” “Former smoker,” “Never






























































































































































































































smoker,” and “Light tobacco smoker” (Centers for Medicare & Medicaid Services 2010).
While the Meaningful Use program helped to standardize data collection of smoking status,
it did not necessarily improve data quality. We observed that the number of times smoking
status was collected increased over the years both at the patient level and the visit level.
Because the EHR did not provide a central location to store smoking status information,
different healthcare providers recorded this information in several different notes, resulting
in many inconsistencies across notes.
To improve the data quality of smoking status in EHRs, I recommend that patients’
smoking status be stored in a centralized fashion using clinically actionable categories. At
our institution, data regarding smoking status was only available as part of clinical notes and
therefore, not available in other sections of the EHR, making it challenging to identify this
information in the patients’ records. If smoking status were available in a centralized loca-
tion, clinicians could then more easily verify this information in every encounter by asking
patients about tobacco use. Future work should focus on identifying ways to overcome
discrepant smoking status. To maintain and improve data quality, implausible changes and
updates resulting in information loss should require explanation by the user.
Another method to improve data quality of smoking status is to involve patients directly
to provide this information. Previous studies on improving patient-reported data demon-
strated efficacy in improving data quality by utilizing patients to directly review and update
their information using kiosks, portals, or printed forms (Caligtan et al. 2012; Cimino, Pa-
tel, and Kushniruk 2001; Collins et al. 2011; Greenhalgh et al. 2008; Halamka, Mandl, and
Tang 2008; Hassol et al. 2004; Kaelber et al. 2008; Maher et al. 2015, 2016; Masterson Cre-
ber et al. 2016; Nazi et al. 2010; O’Leary et al. 2015; Prey, Restaino, and Vawdrey 2014;
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Pyper et al. 2004; Ralston et al. 2007; Reti et al. 2010; Tang and Lee 2009; Wilcox et al.
2016). Eliciting this information via a computer may also mitigate the potential biases in-
troduced by clinicians asking questions regarding smoking behavior. Given that smoking
status may have negative connotations for certain patients (Gorber et al. 2009), electroni-
cally collected smoking status without direct elicitation from care providers may alleviate
some hesitation from patients to provide the truth.
Conclusion
The Meaningful Use program increased data collection of smoking status; however, the
quality of the information collected did not improve over time. The rate of inconsistencies
and implausible changes in smoking status has risen over the years, challenging the ap-
propriate identification of smokers. Centralized documentation with clinically actionable
categories and patient-facing tools might improve the quality of smoking status in EHRs.
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Chapter 5
Aim 3 - Use patient-provided data to assess disease risk
Family history is one of the most important disease risk factors necessary to implement
precision medicine in the clinical setting (Aronson and Rehm 2015; Guttmacher, Collins,
and Carmona 2004). It is frequently collected as part of clinical encounters, and provides
information regarding the heritability of disease, along with environmental factors (Tenesa
and Haley 2013; Visscher, Hill, and Wray 2008). Yet despite its importance and ubiquity in
free-text form, structured family history has rarely been utilized to better understand disease
risk or improve care delivery (Chatterjee, Shi, and García-Closas 2016).
Disease heritability has traditionally been determined through in-depth family studies
for many reasons. For one, EHR data generally only capture positive disease cases, whereas
traditional in-depth studies capture both verified disease positive cases and verified disease
negative instances. Furthermore, EHR data may not be considered sufficiently accurate for
research studies, and previous studies in this dissertation demonstrated data quality issues
in EHR data related to family history. At the same time, EHR data holds many promises
that can greatly improve upon in-depth family studies to estimate heritability. By their
nature, these studies require substantial resources to carry out, and they are often limited in
sample size and, subsequently, their power. A notable exception, and perhaps the largest
single study of it’s type, used 80,309 monozygotic and 123,382 same-sex dizygotic twins
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to conclude that there is significant familial risk for prostate, melanoma, breast, ovary, and
uterine cancers (Mucci et al. 2016). Another study conducted a meta-analysis of 2,748
twin studies conducted since 1955 covering 14.5 million subjects (Polderman et al. 2015).
Outside of these two studies, family-based studies on disease heritability have involved
much smaller sample sizes, often in the tens or hundreds.
Thus the use of EHR data for disease heritability studies presents great potential given
the frequently large quantities of data available in the EHR for each patient. EHRs already
in broad use offer an alternative to traditional disease phenotyping. Every day, EHRs doc-
ument information for thousands of patients, from drug prescriptions and disease diagnosis
to clinical pathology results and physician notes. Use of EHR data presents a novel op-
portunity to conduct rapid and expansive studies of disease and phenotype heritability. In
particular, it enables access to traits that otherwise might not be explored. In addition, data
captured by these systems represent the diversity of the patient populations they serve, and,
in ethnically diverse geographies like New York City, make previously unattainable cohorts
available for study (Hripcsak et al. 2016). The caveat is that these data are known to con-
tain issues regarding missingness and accuracy which limits their use (Hripcsak and Albers
2013; Weiskopf and Weng 2013). The most critical limitation for genetic studies may be the
uncontrolled ascertainment bias (Kaplan, Chambers, and Glasgow 2014). The probability
that a particular trait is recorded in the EHR is not uniform across disease conditions or
patients. For example, a patient that lives far from a hospital and only visits that hospital to
see a specialist will most likely have incomplete records. However, a patient that lives near
to a hospital may receive much of her care at that hospital, and thus, the EHR will contain
relatively more complete records. Another factor that determines the presence of a trait in
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patients’ records is the presentation of symptoms. For example, a patient seen for a routine
checkup with no symptoms is unlikely to undergo an MRI, regardless of whether he has an
unruptured brain aneurysm (Bederson et al. 2000). A recent study used the first release of
the UK Biobank data to estimate hundreds of heritabilities from 130,000 patients’ genotype
and EHR data; however, they did not account for the issues of ascertainment biases (Ge
et al. 2017).
In the era of precision medicine, there has been increased focus not just genomics and
gene-disease relationships but also on disease prevention and early diagnosis at cohort lev-
els. Early diagnosis and disease prevention are often accomplished by assessing the in-
dividual risk for development of certain diseases. Family history is one of the key risk
factors that enables disease risk assessment. Current clinical guidelines suggest additional
or early disease screening for patients considered at high risk for the development of a vari-
ety of conditions, including cancer, cardiovascular, and gastrointestinal conditions. Given
the importance of such efforts, the U.S. Preventive Services Task Force (USPSTF) recom-
mends early or additional screening for numerous diseases. However, given the rarity of
high-quality structured family history information, there has been limited effort in assessing
adherence to clinical guidelines and demonstrating the potential of using EHR data to im-
prove adherence to guidelines. To date, there has been little research on clinician adherence
to the recommendation of early screening among high-risk patients (An et al. 2018; Jemal
and Fedewa 2017; Solbak et al. 2018). Given that EHRs hold troves of information about
diagnostic tests ordered, there is an opportunity to measure clinical guideline adherence in
an automated and large-scale way.
In this Aim, I demonstrated the utility of the EHR as a resource for genetics research,
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even in the absence of genetic patient data, by using extracted familial data as described in
Aim 2 to estimate the heritability of clinical phenotypes, both quantitative and dichotomous.
Additionally, I used these familial relationships to assess screening rates among patients
considered at high risk due to family history of disease.
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5.1 Aim 3.1 - Estimating disease heritability of 500 traits
using electronic health records data
Background
While heritability studies have been conducted for numerous diseases (Almgren et
al. 2011; Hemani et al. 2013; Lichtenstein et al. 2009; Locatelli et al. 2007; Mucci et al.
2016; Ronald and Hoekstra 2011; Sandin et al. 2014; Sullivan, Daly, and O’Donovan 2012;
Sullivan, Kendler, and Neale 2003; Visscher et al. 2007), traditional genetic studies have a
number of limitations, including focusing on a single racial and ethnic group. Further, these
are prospective studies that take decades to recruit and observe large cohorts, at the cost of
hundreds of millions of dollars. I hypothesized that EHR data could be used to overcome
some of these limitations. EHRs provide a unique opportunity to increase sample sizes and
conduct heritability studies for a much larger array of clinical traits. In the EHR, clinical
traits such as diagnosis, procedures, and laboratory tests are collected on a daily basis as
part of clinical care. Genetic research based on EHR data can be used to study multiple
conditions in a short period, generate new research hypothesis that can later be tested by
traditional genetic studies.
Objectives
The purpose of this study was to estimate disease heritability using data available from
EHRs. To do so, I used EHR data and familial relationships extracted from EHRs, as de-
scribed in Aim 2.2, to estimate disease heritability. This study was conducted at three
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academic medical centers. Heritability estimates were compared across study sites. I eval-
uated the findings of this study by comparing heritability estimates computed using EHR
data to those published by traditional genetic studies.
Research Questions
• Can EHR data be used to identify highly heritable diseases in a highly diverse pop-
ulation?
• How can we overcome the biases and challenges of EHR data to estimate highly
heritable diseases for a diverse population?
Methods
Based on the familial relationships I identified in Aim 2.2, I computed disease heri-
tability for all traits available in the EHR. The data for this study were obtained from the
inpatient EHR used at the hospitals affiliated with three large academic medical centers in
New York City: Columbia University Medical Center, Weill Cornell Medical Center, and
Mount Sinai Health System. Columbia University Medical Center and Weill Cornell Medi-
cal Center operate together as NewYork-Presbyterian Hospital and herein, I will refer to the
hospitals and the data associated with them as Columbia and Weill Cornell, respectively.
Similarly, I will refer to Mount Sinai Health System and its data as Mount Sinai.
Phenotyping in the EHR
I used diagnostic test results, such as hemoglobin A1c (which is primarily used to mea-
sure the three-month average glucose concentration in plasma), as quantitative traits and
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diagnosis billing codes (ICD codes) as dichotomous traits. I extracted the most commonly
performed laboratory tests and mapped them to LOINC codes so that they could be easily
matched between institutions. Each patient may have multiple laboratory reports over time.
To extract a single value for each test, I collapsed all reports for each patient into a single
value using the mean. This mean reflected the average value for the laboratory result for
the patient. For example, I used a patient’s mean blood glucose value over their lifetime
instead of individual values of blood glucose.
For dichotomous traits, I used any diagnosis billing code that was used for at least 1,000
distinct patients. Any patient with evidence of that billing code in their medical record
history was considered a “case.” For ICD-9 codes, controls were chosen as any patient
that did not have that diagnosis nor any diagnosis that shared an ancestor according to the
Clinical Classifications Software (CCS).
CCS was developed by the Agency for Healthcare Research and Quality (AHRQ) and
is composed of diagnoses and procedures organized in two related classification systems.
In this study, I used the diagnoses classifications. The single-level system consists of 285
mutually-exclusive diagnosis categories. It enables researchers to map any of the 3,824
ICD-9-CM diagnosis codes into one of the 285 CCS categories.
CCS also has a multi-level system composed of 4 levels representing a hierarchy of the
285 categories. The first level is broken into 18 categories. To define a control group, I
linked the ICD-9 codes associated with a phenotype of interest to their corresponding CCS
categories using the top-level hierarchical categories. I also generated a table associating
each patient to CCS categories from their diagnosis. Once this mapping was done, each
phenotype was associated with one or more distinct CCS categories. I matched the CCS
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categories in the multi-level system to identify the first-level parent category. I considered
these top-level categories as our exclusion criteria since the control cohort for this phe-
notype should have no mention of any CCS under these categories in its medical records.
For example, the controls for atrial fibrillation would exclude patients with cardiovascular
diseases.
For conditions recorded using ICD-10 codes, I used the hierarchy from ICD-10 to iden-
tify patients for the control group. Patients that did not have the same ICD-10 code as
diagnosis nor any diagnosis that shared an ancestor code were considered controls.
I curated a set of 85 phenotypes to use for training and testing the heritability algorithm.
For these 85 phenotypes, I grouped closely related diagnoses codes together to increase the
total number of patients (Table 5.1).
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Estimation of heritability from the Electronic Health Records
The most significant challenge when using traits defined from an observational
resource, like the EHR, is the lack of ascertainment. In a heritability study, the phenotype
of each study participant is, ideally, carefully evaluated and quantified. This is infeasible,
however, when the cohort contains millions of patients with thousands of phenotypes.
The differential probability that a given individual will be phenotyped for a study trait is
the ascertainment bias. The bias may depend on many latent factors, including the trait
being studied, the trait status of relatives, the degree to which an individual’s healthcare
data is contained in the EHR (which is influenced, among other factors, by geographic
proximity to the hospital), and an individual’s ethnicity and cultural identification. The
consequence of this uncontrolled ascertainment bias is that heritability estimates will
be highly dependent on the particular individuals in the study cohort. I hypothesized
that repeated subsampling would be robust to biases introduced by extremely different
ascertainment between families. I define the observational heritability, or h2o, as the
average of the statistically significant sample estimates (using median). For a given
trait, the procedure, which I call SOLARStrap, involves sampling families, running
SOLAR (Almasy and Blangero 1998) to estimate sample heritability, and rejecting or
accepting the estimate based on a set of quality control criteria. Each step is detailed below.
SOLARStrap Protocol
To compute disease heritability using EHR data, I built pedigree files using the data
from each one of the study sites. When building pedigree files, of the 223,307 families at
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Columbia, there were 6,894 that contained conflicting relationships – where two individuals
were inferred to have two different relationships. At Weill Cornell, 3,258 families out of
155,811 contained conflicts, and at Mount Sinai 25,438 families out of 187,473. These
families were excluded from the heritability studies. In some cases, more than one mother
or father is annotated for an individual. This could be because of duplicate patient records
or errors in the EHR relationship extraction. I resolved these issues by choosing the mother
or father that has more relationships in the family. The other relationship is discarded. I then
constructed a master pedigree file for each site. To construct this pedigree file, I iterated
through each member of each family. For each individual, I either know the mother and
father from the EHR-derived relationships or not. If not known, then a new identifier was
created to represent the parent. At this point, I iterated through all other family members and
recorded the relationships between the new individual and each family member. I repeated
this process until the entire pedigree file was filled, thus creating a master file. The master
pedigree files contained 1,404,671 individuals at Columbia, 949,440 at Weill Cornell, and
863,340 at Mount Sinai.
To computer heritability estimates for each trait, I sampled an empirically-defined pro-
portion of the available families. The number of families that are sampled combined with
the prevalence of the trait defines the power of the heritability analysis. A smaller heritabil-
ity can be detected with larger sample sizes. As the sample size increases towards the total
number of available families, the variance in heritability will decrease, but the estimate
will be less robust to bias (Figure 5.1). This is because I sampled without replacement.
Based on my simulation studies, I used sample sizes of 15% and 20% of the total number
of families with at least one case. I then assessed the quality of the computed estimates.
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SOLAR does not converge on a solution for heritability for all samples. Errors in the
pedigree or in the ascertainment of phenotypes are the most likely causes for these failures.
As part of the quality control measures, I rejected any runs of SOLAR that result in no
solution for the heritability. I then considered two additional criteria that must be met for
a solution to be considered legitimate: edge epsilon and noise epsilon. Edge epsilon (ϵe)
is a threshold that determines if the estimate is sufficiently close to 1 or 0. Any estimate
within ϵe of 1 or 0 was rejected. Noise epsilon (ϵn) is a threshold that determines if an
estimate has implausibly low error. Any estimate with implausibly low error was rejected
(h2 error is less than ϵn of the h2 estimate). These hyperparameters were set using simu-
lated heritability data. After filtering the SOLAR solutions for these criteria, I defined an
additional quality control metric called the Proportion Of Significant Attempts, or POSA.
POSA is defined as the number of solutions with a p value less than (αPOSA) divided by
the total number of converged solutions (or attempts). The POSA is important because it is
closely related to the power of the analysis. A fully powered analysis will have a POSA of
1, meaning that all converged estimates are statistically significant. A POSA of 0.5 means
that only half of the converged estimates are statistically significant. When the families
were sampled, the observed heritability was large enough to be detected with p < αPOSA
half of the time. Or, in other words, the study was powered to detect a heritability in 50%
of samplings. I demonstrated that the higher the POSA, the more accurate the heritability
estimates are (Figure 5.1I). I chose a minimum POSA score, POSAlower and the αPOSA
using simulations.
For those estimates that did not pass the defined quality control criteria when sampling
15% and 20% of the total number of families, I increased the number of families sampled
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to 45%. The maximum sample size was defined by the limitations of SOLAR, which could
only handle a maximum of 32,000 individuals per pedigree file. For each sample size, I
performed 200 samplings. For each of these, I built a custom pedigree and phenotype files
and ran SOLAR to estimate the heritability. I then aggregated the results and reported the
median heritability with the 95% confidence interval.
For each sampling, a set of N families was selected. To construct the sample pedigree
file, I identified all rows from the master pedigree files that corresponded to these families
and created a new file from this subset.
Once the pedigree file was created, I iterated over every individual in the pedigree and
used the reference trait data and demographic data to enter the phenotype status and age of
the patient. If no phenotype data were available for the individual, I enter it as missing. For
dichotomous traits, the trait values were either 0 (absence), 1 (presence), or missing and a
“proband” was randomly assigned by selecting a single individual from each family that
has the trait. For quantitative traits, I entered the quantitative value or missing.
I used SOLAR to estimate both quantitative and dichotomous trait heritability using a
pre-defined mixed linear model. In both cases, sex and age were modeled as covariates.
After the pedigree and phenotype files were loaded, the heritability of each trait was esti-
mated with the ‘polygenic –screen’ command. I used the ‘tdist’ command in SOLAR to
adjust quantitative traits that were not normally distributed. For dichotomous traits, one
“proband” was chosen at random for each family. SOLAR automatically detected the pres-
ence of a dichotomous trait and converted the estimate from the observed scale to the liabil-
ity scale. The heritability estimate, error on the heritability estimate, and the p-value were
saved from each run for later analysis and aggregation. To investigate the relative contri-
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bution of the environment to the studied phenotype, I used SOLAR to compute household
effects. For this analysis, I assigned the mother ID as the household ID.
For each sampling that passed the quality control criteria previously described and met
the minimum POSA score, I computed the h2o as the median. The median h2o corresponds to
a single run of SOLAR that has passed all quality control filters. I used the 95% confidence
interval as the error of the h2o. I found that this error is closely related to the standard error
reported by SOLAR (Figure 5.1).
Preparation of data for analysis on external computing clusters
Due to the high number of heritability estimates that need to be computed, external com-
puting resources from The Open Science Grid (OSG) and Amazon Web Services (AWS)
were used. The Open Science Grid (OSG) is a massive computing resource funded by
the Department of Energy and the National Science Foundation. The OSG is comprised
of over 100 individual sites throughout the United States, primarily located at universities
and national laboratories. The sites contain anywhere from hundreds to tens of thousands
of CPU cores available for scientific research Pordes:2007ho, Sfiligoi:2009gp. AWS is
used to supplement this resource, which makes available on-demand compute instances
with high-performance capacity. Per institutional requirements, no protected health infor-
mation or personally identifying information can be transferred to systems outside of our
institutional networks. To leverage these resources for our computing task, I prepared a
data subset according to the Safe Harbor guidance provided by the U.S. Department of
Health and Human Services (https://www.hhs.gov/hipaa/for-professionals/privacy/special-
topics/de-identification/index.html).
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The following is a description of how I processed the data for Safe Harbor for each
of the 18 identifiers here enumerated from (A) through (R): (A) I removed first, middle,
and last names for all patients, (B) all patient address information was removed, (C) all
dates were removed and all ages over 89 were coded as “90”, (D) telephone numbers
and (E) fax numbers were removed, (F) there were no email addresses in the subset of
the clinical data, (G) there were no social security numbers in the subset of the clinical
data, (H) medical record numbers were mapped to a 10 digit random number and the
mapping was stored on a limited access PHI-certified server within the institutional
firewall and will never be made available, (I) there were no health plan beneficiary
numbers in the data subset, (J) there were no account numbers in the data subset, (K)
there were no certificate or license numbers, (L) there were no vehicle numbers or serial
numbers in the data subset, (M) there were no device identifiers or serial numbers,
(N) there were no URLs in the data subset, (O) there were no IP addresses in the data
subset, (P) there were no biometric identifiers in the data subset, (Q) there were no
full-face or comparable images in our data subset, (R) there were no other uniquely
identifying characteristics or numbers. All data were transferred using secure file trans-
fer protocols using encryption and were destroyed immediately after retrieval of the results.
Validation of accuracy and robustness of SOLARStrap using Simulated Traits
To validate the accuracy and robustness of SOLARStrap, I constructed a set of 4,195
families containing 14,690 individuals chosen from the families extracted from the EHR
using RIFTEHR. Relationships and pedigree structures are heterogeneous across these fam-
ilies. I used the ‘simqtl’ command from SOLAR to simulate quantitative traits with heri-
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tability values of 5% to 95% at 5% intervals for this pedigree. Traits were simulated for 19
different heritability values in total. To generate binary traits, a threshold for the quantitative
value was chosen for each of the 19 simulations so that the prevalence of the dichotomous,
or binary trait, was 15%. I used the prevalence of 15% for dichotomous traits because over-
all, the average prevalence of disease among patients with familial relationships was 15.9%
(min-max: 8% – 37%). The result of each simulation was a phenotype file containing the
family id, the individual id, and the quantitative or binary trait value.
I evaluated the quantitative and dichotomous simulated traits by running SOLAR using
the simulated phenotype files for each of the 19 different values for heritability. I summa-
rized performance using the r2 and ran a test of significance.
I then created trait files for SOLARStrap. SOLARStrap is designed to use trait files
that are similar to the phenotype files used by SOLAR but can contain more than one type
of trait per file and more than 32,000 individuals (SOLAR’s limit). I used a python script
to combine the 19 heritability estimates into a single trait file.
To evaluate the accuracy of SOLARStrap on quantitative traits, I ran SOLARStrap on
each of the 19 simulated datasets. I repeated these runs using a different sampling size
(argument nfam in SOLARStrap) between 100 and 700 increasing by 100. I selected the
largest sample size (nfam=700) and evaluated the accuracy of SOLARStrap using r-squared
and tested significance using regression analysis.
When working with dichotomous traits, there are two scenarios that had to be consid-
ered to evaluate the accuracy of SOLARStrap. Either 1) the cases and controls are equally
known, meaning that each individual in the pedigree can be assigned to either being a case
or control, or 2) the cases are higher confidence than the controls. This latter case more
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closely resembles the scenario present in the electronic health records. Documentation of a
disease in the EHR can be very indicative of the patient having the disease, but the absence
of this documentation does not mean the patient does not have the disease. I evaluated the
accuracy of SOLARStrap in both cases. For the former, I included all individuals in the
pedigree, and for the latter, I excluded any families where there were no cases. In the pedi-
grees where the cases are higher confidence than controls, I assigned a proband so that the
estimate of heritability is not biased. This was accomplished by randomly selected a single
individual in each family as the “proband.”
To evaluate the robustness of SOLAR and SOLARStrap to missing data, I chose a single
simulated trait (h2 = 50%) and randomly changed individual phenotypes to unknown. I
evaluated removing 5% to 60% of the phenotype data at 5% intervals.
To evaluate the robustness of SOLAR and SOLARStrap to biases, specifically non-
random missingness, pedigrees were removed from the heritability estimation with a prob-
ability determined by a beta distribution. The beta distribution is a continuous probability
distribution bounded by 0 and 1 and parameterized alpha and beta. Each family can be as-
signed a probability by sampling this distribution. Most families will have the same prob-
ability of missing data with a small number of families have a much lower probability. By
varying the beta and alpha parameters I can change the proportion of families with a much
lower probability of missing data. I varied the value of the beta parameter from 0.001, 0.01,
0.1, 1.0, 10.0, to 100.0 and I set the alpha parameter such that the average probability of
missingness across all families was constant at 50%.
Using the simulation results, I evaluated the effect of increasing the sample size (or
the number of families being sampled in each iteration when running SOLARStrap). I
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hypothesized that as the number of families approaches the number of available families
the heritability estimate of SOLARStrap would converge to the heritability estimate of
SOLAR. I expected that the number of families sampled would not have an effect on the
heritability estimate produced by SOLAR or SOLARStrap. I evaluated this relationship
using linear regression of the simulation results. One of the primary quality control metrics
for SOLARStrap is the Proportion of Significant Attempts (or POSA). I evaluated the
relationship between the POSA score (which ranges from 0 to 1) and the accuracy of the
heritability estimates produced.
Computational and statistical software
Statistical analysis, data preparation, and figure creation were performed using Python
2.7. Relationship inferences were implemented in Julia 0.4.3. All correlations were
reported as Pearson correlation coefficients unless otherwise noted.
Literature review
For validation purposes, I compared the heritability estimates from this to the ones re-
ported in the most recent meta-analysis of twin correlations and heritability (MaTCH) (Pol-
derman et al. 2015). Using the ICD-10 hierarchy, I grouped our ICD codes to match the
main chapters and subchapters reported in the MaTCH database. Since the meta-analysis
grouped all traits into higher-level traits, losing a lot of granularity, I also performed a liter-
ature review on heritability estimates on 128 traits. I started by analyzing studies that were
included in the table available at http://www.snpedia.com/index.php/Heritability (accessed
on March 2016). In total, I reviewed heritability estimates with confidence intervals from
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UK Biobank MaTCH dataset Observational heritability
Code Trait h2 SE h2 SE site model ho2 ho2 SE
VI Diseases of the nervous system 0.0246 0.0216 0.5221 0.0302 Weill Cornell AE 0.1505 0.0431
X Diseases of the respiratory system 0.0506 0.0191 0.6215 0.0385 Mount 
Sinai
AE 0.1556 0.0422
X Diseases of the respiratory system 0.0506 0.0191 0.6215 0.0385 Weill 
Cornell
AE 0.3111 0.0592
XI Diseases of the digestive system 0.0354 0.0092 0.4390 0.0193 Weill 
Cornell
AE 0.3098 0.0345
XII Diseases of the skin and 
subcutaneous tissue




Table 5.2: Comparison of heritability estimates from the UK Biobank, the MaTCH database and
observational heritability.
61 published reports.
Additionally, I compared our heritability estimates to those reported using the UK
Biobank dataset (Ge et al. 2017). I used the estimates reported with ICD 10 codes to
match the heritability estimates reported by Ge et al. to our estimates. Overall, I observed
that the estimates from the UK Biobank were significantly lower than those computed using
EHR data (Figure 5.2). I also compared the heritability estimates from this set of traits to
the MaTCH database. Table 5.2 contained the traits along with heritability estimates from
the UK Biobank, the MaTCH database, and our estimates using EHR data.
Results
To validate the accuracy and robustness of SOLARStrap, I used simulations of quanti-
tative and dichotomous traits with heritability ranging from 5-95%. SOLAR was precise in
estimating the heritability of both quantitative (r2 = 0.999) and dichotomous (r2 = 0.994)
traits (Figure 5.1A). I ran SOLARStrap in the simulated quantitative traits, and it accu-
rately estimated the heritabilities regardless of the sampling size (Figure 5.1B, r2 = 0.986,
p = 3.22e-15). For dichotomous traits, I ran SOLARStrap in two scenarios: 1) including all
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families regardless of the number of cases in the family and 2) including only families with
at least one case. In the latter scenario, I randomly chose one of the cases in each family to
be the proband. SOLARStrap accurately recapitulated the heritability estimates regardless
of the number of families sampled in both cases, with lower accuracy when a proband was
assigned than the complete ascertainment (r2 = 0.988, p = 7.57e-15 without proband and r2
= 0.930, p = 2.85e-11 with proband; Figure 5.1C and 5.1D). I found that both SOLAR and
SOLARStrap produced accurate estimates given complete data and in the presence of ran-
dom missingness (Figure 5.1E). However, SOLARStrap produced more accurate estimates
in the presence of ascertainment biases that vary from family to family (Figure 5.1F).
As expected, SOLARStrap produced estimates with larger confidence intervals than
SOLAR. SOLARStrap becomes more sensitive to bias as the number of families sampled
increased towards the total number of families available (Figure 5.1G); however, the es-
timate of heritability is not dependent on the number of families sampled (Figure 5.1H,
r=0.02, p=4.1e-8). I used the Proportion of Significant Attempts (POSA) as a quality score
for the heritability estimates generated by SOLARStrap. A higher POSA score represents
a more accurate heritability estimate from SOLARStrap (Figure 5.1I). I injected noise into
the data by randomly shuffling a subset of the patient diagnoses, simulating misclassifi-
cation (misdiagnosis or missed diagnosis) in the medical records. Injection of 5% noise
reduced the estimate 13% (from h2o =0.77 to h2o =0.67) and 10% noise reduced the estimate
30% (from h2o =0.77 to h2o =0.53, Figure 5.1J). Misclassification was one explanation of












Figure 5.1: Validation of SOLARStrap accuracy and robustness using simulated data. (A) Traits
with heritability ranging from 5% to 95% were generated using the SOLAR. We used actual family
structures extracted from the EHR by RIFTEHR to generate the simulated traits. We then created
dichotomous (binary) versions of the trait by choosing a threshold that would yield a trait with 15%
prevalence. SOLAR was very accurate at recapitulating the correct heritability for both quantita-
tive (r2 = 0.999) and binary (r2 = 0.994) traits. In (B), (C) and (D), the number of families varied
from 100 to 1000, being represented by different colors. (B) SOLARStrap was run on each of the
simulated quantitative traits and was accurate at estimating the true heritability (r2 = 0.986). SO-
LARStrapwas accurate regardless of the number of families that was used in the sampling procedure
(left). (C) SOLARStrap was run on each of the binary traits in the setting of complete ascertainment.
SOLARStrap achieved equal accuracy as in the quantitative case (r2 = 0.988). (D) SOLARStrap
was run on each of the binary traits in the setting of incomplete ascertainment. In this case, families
without any cases were dropped and a proband was randomly assigned in each family. The accuracy
is lower than the case of complete ascertainment (r2 = 0.930). (E) In the presence of randomly miss-
ing information, both SOLAR and SOLARStrap produce accurate estimates of the true heritability
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even when up to 60% of the data are removed. However, in four cases where the proportion removed
was 35%, 45%, and above 50% SOLARStrap estimates did not pass our internal quality control cri-
teria. (F) SOLAR is sensitive to this bias and produces inaccurate results as the strength of the bias
increases. SOLARStrap is robust to these biases and produces accurate estimates of heritability
even in the most extreme case of bias. (G) As the number of families sampled increases toward
the total number of available families SOLARStrap becomes more sensitive to bias – in the most
extreme case where the number of sampled families is equal to the total number of available families
SOLARStrap reduces to simply running SOLAR. (H) The estimate of heritability is not dependent
on the number of families sampled (r=0.02, p=4.1e-8). (I) The Proportion of Significant Attempts
(POSA) is a primary estimate of quality for heritability estimates produced by SOLARStrap. The
accuracy of SOLARStrap increases as the POSA increases (shown as error here). (J) The effect
of noise injection on the estimate of observational heritability of rhinitis. We injected noise into
the data by randomly shuffling a subset of the patient diagnoses. This simulates misclassification
(misdiagnosis or missed diagnosis) in the medical records. When no noise is injected the estimate is
0.77 (0.60-0.92). As noise is introduced the estimate of the heritability decreases to 0.36 (0.23-0.49)
once one quarter of the data are randomized.
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Figure 5.2: Estimating heritability of disease using electronic health records. We designed a
method, called SOLARStrap, for estimating the heritability of traits where the phenotype is de-
rived under unknown ascertainment biases, the h2o. (A) We found that performance was consistent
across sites and (B) that h2o is significantly correlated with literature estimates of h2. (C) Heritability
estimates stratified by race and ethnicity using the AE model are correlated with estimates of h2o.
(D) These models are also correlated when computing heritability estimates for ICD10 codes alone.
(E) Heritability of traits that have been studied before, such as height, have been recapitulated by
our study. We also stratified heritability of height by self-reported race and ethnicity as available
in EHR. (F) Observational heritability of HDL cholesterol (blue) is significantly higher than heri-
tability of LDL cholesterol (red). This difference is still observed after stratifying patients by the
presence or absence of HMG-CoA reductase inhibitors as treatment for hypercholesterolemia.
I found that heritability estimates are significantly correlated across sites (Figure 5.2A).
I identified traits with heritability estimates and then computed the correlation between the
estimates found in each one of the study sites to the other two sites. Columbia had 147 traits
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that overlapped with traits from the other two sites, with correlation r=0.35, p=1.32e-05.
Similarly, Weill Cornell had 147 traits, with correlation r=0.48, p=8.20e-10, and Mount
Sinai had 58 traits, r=0.36, p=5.48e-03. I mined the literature for heritability estimates and
found 91 phenotypes that mapped to phenotypes I curated from the EHR. I also included
all traits reported in the latest meta-analysis (Polderman et al. 2015). I used simulations to
set the quality control parameters of the SOLARStrap procedure. Thirty-three traits passed
these quality control criteria. I found that they were significantly correlated with literature
estimates for these traits (r=0.45, p=9.11e-03, Figure 5.2B), and 16 (48%) had overlapping
confidence intervals (Table 5.3). On average, observational heritability estimates were
27% lower than those reported in the literature. I also stratified the heritability estimates by
race and ethnicity. The estimates stratified by race and ethnicity are significantly correlated
with the overall heritability estimates (Figures 5.2C and 5.3).
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Name Site ho2	(95%	CI) h2	(95%	CI)
Acne Columbia 0.35	(0.22-0.55) 0.81	(0.73-0.89)
Allergy,	Unspecified Columbia 0.30	(0.18-0.42) 0.67	(0.61-0.72)
Asthma* Weill	Cornell 0.37	(0.21-0.58) 0.30	(0.22-0.37)
Asthma* Columbia 0.51	(0.30-0.63) 0.30	(0.22-0.37)
Asthma	with	status	asthmaJcus Columbia 0.45	(0.27-0.56) 0.67	(0.61-0.72)
Atopic	dermaJJs Columbia 0.42	(0.25-0.62) 0.78	(0.73-0.83)
Atopic	dermaJJs	and	related	condiJons* Columbia 0.50	(0.34-0.78) 0.78	(0.73-0.83)
AKenJon	deficit	hyperacJvity	disorder Columbia 0.36	(0.22-0.50) 0.72	(0.56-0.85)
Celiac	disease* Columbia 0.77	(0.41-0.98) 0.75	(0.55-0.96)
Depression Columbia 0.25	(0.17-0.30) 0.37	(0.31-0.42)
Depressive	disorder* Weill	Cornell 0.25	(0.15-0.41) 0.39	(0.36-0.42)
Depressive	disorder Columbia 0.27	(0.13-0.35) 0.39	(0.36-0.42)
Disease	of	skin	and	subcutaneous	Jssue Columbia 0.30	(0.17-0.46) 0.79	(0.75-0.83)
Diseases	of	the	digesJve	system* Weill	Cornell 0.31	(0.22-0.40) 0.44	(0.40-0.48)
Diseases	of	the	nervous	system Weill	Cornell 0.15	(0.08-0.23) 0.52	(0.46-0.58)
Diseases	of	the	respiratory	system Weill	Cornell 0.31	(0.22-0.40) 0.62	(0.55-0.70)
Diseases	of	the	respiratory	system Mount	Sinai 0.16	(0.10-0.25) 0.62	(0.55-0.70)
Diseases	of	the	skin	and	subcutaneous	Jssue Weill	Cornell 0.23	(0.13-0.32) 0.79	(0.75-0.83)
Eczema	(adults)* Columbia 0.44	(0.30-0.57) 0.34	(0.02-0.66)
ExacerbaJon	of	asthma* Columbia 0.46	(0.26-0.63) 0.67	(0.61-0.72)
Glaucoma* Columbia 0.39	(0.24-0.65) 0.36	(0.18-0.54)
Height* Columbia 0.79	(0.67-0.94) 0.77	(0.74-0.80)
Major	depressive	disorder,	recurrent* Columbia 0.36	(0.21-0.51) 0.39	(0.36-0.42)
Major	depressive	disorder,	single	episode Columbia 0.25	(0.17-0.31) 0.39	(0.36-0.42)
Migraine* Columbia 0.31	(0.17-0.48) 0.45	(0.41-0.49)
Obesity* Weill	Cornell 0.57	(0.40-0.82) 0.76	(0.67-0.85)
Obesity Columbia 0.41	(0.31-0.49) 0.76	(0.67-0.85)
OsteoarthriJs Columbia 0.26	(0.15-0.38) 0.53	(0.44-0.62)
RhiniJs	(children)* Weill	Cornell 0.63	(0.39-0.95) 0.95	(0.78-0.97)
RhiniJs	(children) Columbia 0.64	(0.47-0.77) 0.95	(0.78-0.97)
Type	1	diabetes	mellitus* Weill	Cornell 0.35	(0.23-0.53) 0.66	(0.49-0.84)
Type	1	diabetes	mellitus Columbia 0.37	(0.20-0.70) 0.88	(0.78-0.94)
Type-2	diabetes* Columbia 0.25	(0.15-0.32) 0.25	(0.15-0.35)
 1
Table 5.3: Comparison between observational heritability (h2o) and heritability estimates (h2) pre-
viously reported in the literature. Among the 33 traits, 16 (48%) have overlapping confidence inter-
vals, highlighted with a star (*).
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Figure 5.3: Correlation between the estimates stratified by race and ethnicity and the overall heri-
tability estimates using the ACE model.
In addition to the additive genetic model (AE), I also modeled heritability with a term
for common environment (ACE) using the mother ID as the household ID. ACE and AE
models are overall significantly correlated (r=0.66, p=1.25e-34, Figure S2) and are also
correlated when computing heritability estimates for ICD10 codes alone (r=0.49, p=4.21e-
13, Figure 5.2D).
I found that phenotypes from the EHR could increase sample size and recapitulate heri-
tability estimates that are well known. For example, the most heritable trait I found was for
sickle cell disease, h2o=0.97 (0.75-1.00), N=857 (Table 5.1). I also computed heritability
of height and stratified the estimates based on self-reported race and ethnicity as captured
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in the EHR. The latest meta-analysis reported heritability of height to be 0.77 (CI=0.74-
0.80) (Polderman et al. 2015). Using EHR data, I obtained observational heritability of
0.80 (CI=0.74-0.86). The heritability of height among whites had a lower quality control
score and is higher than the other groups. (Figure 5.2E).
Using phenotypes from the EHR for heritability can provide clarity for poorly studied
traits, revealing subtle differences between closely related conditions, and open up new
avenues of heritability research. For example, two previous studies had shown conflicting
evidence for the relative heritability of HDL cholesterol and LDL cholesterol (Pietiläinen
et al. 2009; Souren et al. 2007). The larger of these two studies (N=378) found no difference
in the heritability of these two traits when adjusting for age and sex, while the other found
a slightly higher heritability for HDL, but was underpowered to detect significance. In this
study, I presented evidence that HDL is more heritable than LDL (h2o =0.48 95% CI: 0.42 -
0.56 vs 0.36 95% CI: 0.27 - 0.45 at Columbia; h2o =0.51 95% CI: 0.35 - 0.67 vs 0.26 95%
CI: 0.15 - 0.38 at Weill Cornell). This finding held when accounting for the use of HMG-
CoA reductase inhibitors as treatment for hypercholesterolemia (Figure 5.2F). At 96,241
patients in the Columbia cohort and 33,239 patients in the Weill Cornell cohort, this study

































































































































































































































































































Table 5.4: Heritability Ranges for Dichotomous and Quantitative Trait Categories. The median
observational heritability and ranges are shown for dichotomous trait categories, both ICD9 and
ICD10 codes, and for quantitative trait categories, LOINC codes. Within each category, the trait with
the highest heritability and the trait with the lowest heritability are shown. Mendelian conditions
are annotated with (*) and traits with literature heritability estimates are marked with.
Heritability is used to estimate genetic contribution to complex, polygenic, or quanti-
tative traits rather than classic Mendelian disorders in which the presence or absence of a
single genetic mutation determines the development of the disease. Interestingly, our al-
gorithm was able to provide estimates of heritability for Mendelian traits without genetic
information based only on EHR data. For example, I observed high heritability estimates
for common highly penetrant Mendelian diseases with autosomal transmission, such as
sickle cell disease (h2o = 0.97, 95% CI 0.75-1.00, N=857 families), but low heritability es-
timates for other rare recessive Mendelian traits, such as cystic fibrosis (h2o = 0.01 95%
CI: 0.01-0.02 N=7,682 families). Recovering a heritability estimate of almost 1 for sickle
cell is reassuring since that is exactly what would be expected in the presence of a highly
penetrant mutation and when carriers are also frequently correctly identified in the EHR.
However, the heritability of cystic fibrosis was very low. This is likely because the additive
model used for heritability estimation is clearly misspecified for a rare disease with a known















Aunt/Uncle 189 0.0608 2526 0.0699 3.08e-01 0.0092 1.1506
Child 316 0.1016 6312 0.1748 2.18e-14*** 0.0731 1.7196
Cousin 166 0.0534 1997 0.0553 8.35e-01 0.0019 1.0357
First cousin once removed 78 0.0251 1330 0.0368 1.57e-03** 0.0117 1.4679
Grandaunt/Granduncle 65 0.0209 1239 0.0343 1.10e-04*** 0.0134 1.6410
Grandchild 60 0.0193 2024 0.0560 1.63e-20*** 0.0367 2.9041
Grandnephew/Grandniece 141 0.0454 1673 0.0463 8.21e-01 0.0010 1.0215
Grandparent 123 0.0396 1486 0.0411 1.00e+00 0.0016 1.0401
Great-grandaunt/Great-granduncle 30 0.0096 570 0.0158 8.9e-03** 0.0061 1.6357
Great-grandchild 34 0.0109 860 0.0238 1.35e-06*** 0.0129 2.1775
Great-grandnephew/Great-grandniece 89 0.0286 786 0.0218 1.06e-02* -0.0069 0.7603
Great-grandparent 22 0.0071 598 0.0166 1.52e-05*** 0.0095 2.3400
Great-great-grandchild 24 0.0077 388 0.0107 1.40e-01 0.0030 1.3918
Great-great-grandparent 13 0.0042 272 0.0075 3.55e-02* 0.0034 1.8012
Nephew/Niece 213 0.0685 2866 0.0794 2.84e-01 0.0108 1.1584
Parent 920 0.2959 4324 0.1197 2.00e-159*** -0.1762 0.4046
Sibling 532 0.1711 4925 0.1364 1.34e-14*** -0.0347 0.7970
Spouse 94 0.0302 1938 0.0537 5.37e-08*** 0.0234 1.7749
Cystic Fibrosis (CF) Sickle Cell Disorder (SCD)
Table 5.5: Distribution of relationship types among families with cystic fibrosis and sickle cell
disease.
availability of carrier screening and prenatal diagnosis, cystic fibrosis families are nowa-
days typically small (Castellani et al. 2009; Dupuis et al. 2005; Scotet et al. 2012; Slieker
et al. 2005); affected cases also frequently suffer from infertility limiting the number of
observed disease transmissions per family. Indeed, in our dataset families with cystic fi-
brosis were smaller (average family size 3.0 for cystic fibrosis vs 4.6 for sickle cell disease,
p=8.8e-14), had more advanced average age (average 40 years old vs 36 years old for sickle
cell disease, p=4.1e-17), had fewer “child” and “grandchild” relationships (p=2.18e-14 and
p=1.63e-20, respectively), and included more parental relationships (p=2.00e-159) when
compared to the sickle cell disease cohort (Table 5.5).
In addition, subtle phenotypical variations that are routinely collected clinically can be
studied. For example, analysis of the highest and lowest heritability estimates by category
provides us with interesting findings. Among neurological diseases, I observed that sleep
disorders are highly heritable (h2o=0.31 95% CI: 0.19-0.48); whereas headache syndromes
are not (h2o=0.02 95% CI: 0.01-0.03). A comprehensive list of heritability estimates for
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multiple diseases’ categories is available in Table 5.1. Finally, this study demonstrated that
the EHR can identify novel traits for future genetic studies. Of the 500 traits I computed
heritability estimates for, only 33 of which had been previously studied as part of the latest
meta-analysis or identified by our literature review.
Discussion
Heritability is a key component in precision medicine and is typically estimated based
on family history. Collection of comprehensive and accurate family history is time-
consuming and does not occur during the vast majority of clinical encounters (Polubriagi-
nof, Tatonetti, and Vawdrey 2015). The construction of pedigrees by inference of relat-
edness from administrative records, as described in Aim 2.2, allows for rapidly assessing
family history and heritability at scales that were previously impossible to achieve. I used
EHR-inferred relationships to calculate heritability estimates among individuals with de-
fined relationships.
Previous research in this area has focused on family studies of known relatives, primar-
ily twins. Mayer and colleagues used EHR data to create a cohort of 2,000 twins/multiple
births and measured concordance among identified twins for two highly heritable diseases,
muscular dystrophy and fragile-X syndrome (Mayer et al. 2014). This study looked not
only at twins, but entire families across several generations.
Importantly, most previous studies have predominantly involved White Europeans and
may not be representative of other populations. However, the results presented reflect the
diverse, multiethnic population of New York City – the majority of our patient population
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is not self-reported as “white.” For example, I stratified patients that had height available in
the EHR by self-reported race and ethnicity and used these cohorts of patients to compute
heritability of height. I observed that the heritability estimate was higher among whites in
comparison to other race and ethnicity groups. Bias might explain this difference since this
group had a lower quality control score than the others. I also investigated income as a
possible confounder using patient ZIP codes and Census data. Overall, the population self-
identified as white has twice the average income than other populations – one possible ex-
planation for this difference given that heritability estimates increase in more homogenous
environments. This could create a difference in heritability of height both across ethnicities
and across income levels. In other cases, traits have been shown to be more heritable in
high socioeconomic strata than in lower strata (Bronfenbrenner and Ceci 1994; Harden,
Turkheimer, and Loehlin 2007; Turkheimer et al. 2003).
However, the stratification by race and ethnicity was not feasible for all traits. Over 68%
of the families have a single race and ethnicity reported and over 29% of the families have
two distinct race and ethnicity groups reported. Estimates of traits that had a large enough
sample size to stratify by race and ethnicity are available at http://riftehr.tatonettilab.org.
For traits that were stratified by race and ethnicity, heritability estimates were significantly
correlated with the overall heritability estimate.
The primary challenge when using traits defined from an observational resource, like
the EHR, is incomplete phenotype information resulting in ascertainment bias. In a heri-
tability study, the phenotype of each study participant is, ideally, carefully evaluated and
quantified. This is not feasible, however, when the cohort contains millions of patients with
thousands of phenotypes. The bias may depend on many latent factors, including the trait
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being studied, the trait status of relatives, the proximity to the hospital, and an individual’s
ethnicity and cultural identification, among others. The consequence of this uncontrolled
ascertainment bias is that heritability estimates will be highly dependent on the particular
individuals in the study cohort. I observed that a small number of highly biased families
could significantly sway the heritability estimate. Repeated sub-sampling will be robust
to these types of biases. EHR-based heritability estimates are particularly well-suited for
complex traits that require large numbers of patients (e.g., Type 2 Diabetes Mellitus and
Obesity).
The unique nature of the relationships and phenotypes derived from the EHR may ne-
cessitate novel methods for estimating heritability. I used a mixed linear model imple-
mented in SOLAR (Almasy and Blangero 1998) to estimate heritability and used repeated
sampling, which I call SOLARStrap, for efficiency and to correct for ascertainment hetero-
geneities. I evaluated the impact of bias and missingness on SOLARStrapp by comparing
the heritability estimates with simulated data and demonstrated that SOLARStrap is robust
to bias. Overall, quantitative traits perform better than dichotomous traits, and traits com-
monly documented in EHRs perform better than rare and poorly documented conditions
(e.g. mental health disorders). There may be more accurate ways to estimate heritability
from this unique data source. Future work should focus on using only certain types or re-
lationships or use alternative modeling strategies. Fragmentation of care is an additional
limitation when using EHR data for genetic research. Patients often go to multiple health-
care systems, and therefore, the information available in a single institution is incomplete.
Future implementations may address this limitation by accounting for the number of vis-
its and documentation of primary care physician in the healthcare system or by integrating
160
records across a regional healthcare network.
There are significant bioethical considerations regarding the use of the RIFTEHR
method, including how best to balance the competing demands of protecting patients’ pri-
vacy with clinicians’ duty to warn relatives of potential genetic risks. The method could
readily be applied in EHR systems, such that clinicians could easily access the health infor-
mation of a patient’s family members. In the United States, accessing a family member’s
health information in this manner may be considered a violation of the 1996 Health Insur-
ance Portability and Accountability Act (HIPAA) Privacy Rule (United States, 1996). On
the other hand, case law in the United States has established that healthcare providers have
a responsibility to inform a patient’s relatives about heritable conditions that may reason-
ably put the relatives “at risk of harm” (Suarez 2011). These conflicts may need to be
resolved before automatic relationship inference can be used clinically. It is worth noting
there is a risk of reidentification of family structures, even when de-identified according
to the HIPAA Safe Harbor. For example, unique family structures could be identified by
cross-referencing obituaries and other online tools. Extra safeguards are necessary to miti-
gate these risks when releasing these data.
Conclusion
I have described and validated a novel method for identifying familial relationships
in patient medical records in Aim 2.2, and used 7.4 million relationships inferred from the
EHRs at three academic medical centers to estimate heritability of 500 traits without genetic
testing. I found that heritability estimates were concordant across the three centers, and are
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broadly consistent with published studies, suggesting that the method may have broad ap-
plicability. Genetic information is valuable but expensive and not always available. In this
case, familial relationships extracted from emergency contact information can personalize
disease risk prediction and facilitate heritability determination for phenotypes that were not
previously investigated in family-based or twin studies. The correspondence the heritabil-
ity estimates presented in this study with family-based estimates provides a direct and novel
validation of the value of electronic health records for generating inferences about disease,
making RIFTEHR a valuable tool for the advancement of precision medicine.
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5.2 Aim 3.2 - Estimating disease screening rates using
electronic health records data
Background
that are at a high risk for disease development, and therefore promote disease preven-
tion, screening, and early diagnosis and treatment. Current clinical guidelines, such as those
from the U.S. Preventative Services Task Force (USPSTF) recommend additional or early
disease screening for patients at higher risk for developing certain diseases, such as cancer,
cardiovascular, and gastrointestinal conditions. Despite these lofty goals, there remains a
gap in effectively screening patients. For instance, previous research has shown that breast
cancer screening takes up valuable time during patient care visits to conduct accurately
(Owens et al. 2011). Furthermore, there has been little research on clinician adherence to
the recommendation of early screening among high-risk patients (Jemal and Fedewa 2017;
Solbak et al. 2018).
The lack of clarity in understanding adherence to guidelines has a large potential impact
on how care is delivered. Adherence to clinical guidelines is important, particularly for
chronic diseases such as diabetes mellitus. Previous studies have shown that adherence
to treatment guidelines that include assessing various physiological and social determinant
information is generally low (Oude Wesselink et al. 2015). Prior work to evaluate clinical
guideline adherence in diabetes mellitus has focused on disease management, either by
determining the frequency of testing for disease outcomes, such as retinopathy, or process
measures, such as measuring for hemoglobin A1c (An et al. 2018; Khunti et al. 2018).
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There has been less focus in the literature on early or preventative screening for diabetes
mellitus, particularly in relation to family history. Fortuitously, the widespread use of EHRs
in combination with the method previously described in Aim 2.2, which identifies family
medical history from existing clinical databases, allowed us to study whether patients have
been properly screened for conditions in a comprehensive way.
Objectives
The purpose of this study was to use EHR data to determine the rates of screening among
patients known to be at high risk for a prevelant condition, diabetes mellitus, and for a rare
condiation, celiac disease.
Research Questions
• Can EHR data be used to measure disease screening and adherence to clinical guide-
lines?
Methods
As a proof-of-concept to determine the usefulness of EHR data in assessing disease
screening rates, I applied similar methodology focusing on two distinct conditions: dia-
betes and celiac disease. These conditions were determined because both conditions have
additional screening recommendations for patients with a known family history of disease
and both conditions have additional screening recommendations for patients with a known
family history of disease, with diabetes being highly prevalent affecting nearly 1 in 10
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Americans while celiac disease is considered a rare condition.
With approval of the Institutional Review Board of Columbia University Medical Cen-
ter, I conducted a retrospective analysis of family members of patients diagnosed with dia-
betes mellitus visiting NewYork-Presbyterian Hospital/Columbia University Medical Cen-
ter from 2007 to 2017. Patients with a diagnosis of diabetes mellitus were identified using
a validated and previously implemented EHR phenotype, available at PheKB (Phenotype
KnowledgeBase). This EHR phenotype used a combination of diagnosis codes, medica-
tions and laboratory test results to identify patients with diabetes mellitus in our institution.
Because an EHR phenotype for celiac disease had not been developed and validated, I ex-
amined relatives of patients (N=2,081) with biopsy-diagnosed celiac disease in a prospec-
tively maintained database at NewYork-Presbyterian Hospital/Columbia University Medi-
cal Center.
To identify family history in electronic health records (EHRs), patients’ relatives were
identified using RIFTEHR (Relationship Inference from the Electronic Health Record), as
described in Aim 2.2, a novel validated method that used the first name, last name, phone
number and ZIP code of patients’ emergency contacts to identify familial relationships.
Once the relationships were identified, RIFTEHR inferred additional relationships accord-
ing to family structure. The identified relationships were previously validated using both
clinical and genetic data, as previously described in Aim 2.2 (Polubriaginof et al. 2017).
Once the cohort of family members was identified, I extracted demographic informa-
tion, such as sex, age, race, and ethnicity from the EHR. While race and ethnicity were
stored as distinct fields in our database, I found that transforming the two fields into a sin-
gle field addressed many cases of missing data. Therefore, regardless of race, patients with
165
a reported ethnicity of “Hispanic” are reported in this study as “Hispanic.” Patients with
ethnicity recorded as “non-Hispanic” or “Unknown” were reported using the race informa-
tion available (e.g., “White,” “Black or African American,” “Asian”). Patients without race
and ethnicity information were reported as “Uninformative.”
Diabetes mellitus
I measured diabetes screening by identifying individuals that had at least one of the
following laboratory tests after the index case diagnosis date: fasting glucose (LOINC code
1558-6), random glucose (LOINC codes 2339-0, 2345-7), or hemoglobin A1C (LOINC
codes 4548-4, 17856-6, 4549-2, 17855-8). I included all family members over 18 years
of age. I calculated descriptive statistics of the identified cohort, along with the rate of
screening among family members. Additionally, I performed a multivariate analysis to
determine factors that increase the likelihood of receiving a screening test. To determine the
influence of each parameter in the logistic regression model, I computed the standardized
coefficients (β) by multiplying the beta coefficient (B) to the standard deviation of the
corresponding parameter in the data. Python 2.7 was used to perform these analyses.
Celiac disease
The EHR was queried and each patients’ records were manually reviewed to extract
celiac disease testing information. The manual review included extraction of the following
elements: 1) serology results, 2) duodenal biopsy results, 3) occurrence of a visit with a gas-
troenterologist, 4) presence of signs or symptoms of celiac disease in clinical notes and/or
ICD codes, and 5) documentation of family history of celiac disease. Demographic infor-
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mation such as gender, age, and race and ethnicity were queried from the EHR’s database.
Celiac disease screening was defined as either antibody testing or endoscopic evaluation
with duodenal biopsy. SAS (Cary, NC) version 9.4 was used to perform both univariate
and multivariate analyses to identify predictors of celiac disease screening. I tested the
following variables a priori and included all variables in the multivariable analysis. All
reported p values are 2-sided.
Results
Diabetes mellitus
Overall, I identified 13,086 patients with diabetes mellitus that also had familial re-
lationships extracted by RIFTEHR. These patients had 56,794 family members in our
database, distributed across 12,613 families. Familial relationships spanned up to four gen-
erations, including relationships such as great-great-grandparents. Of those, 45,778 family
members (12,181 families) were over 18 years of age, and 27,757 (8,188 families) had a
clinical visit after the index case had been diagnosed with diabetes mellitus; this was the
population deemed eligible for diabetes screening (Figure 5.4).
The cohort of patients eligible for diabetes screening was represented by 18,406 (66.3%)
females, with an average age of 46 years old, with the majority being self-reported as His-
panic (72.7%). Table 5.6 summarizes the demographic information of the study cohort.
Among the eligible-for-screening cohort, 19,264 (69.4%) received diabetes screening, and
8,493 (30.6%) patients did not. Among first-degree relatives of the index cases, 71.6% re-
ceived at least one diabetes screening test. The cohort of individuals that received screening
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Figure 5.4: Cohort of individuals eligible for early diabetes screening. Eligibility criteria included
being 18 years of age and having a clinical visit after the family member was diagnosed with diabetes
mellitus.
was significantly older than the group that did not receive screening (average age 50 vs. 38,
p < 0.0001).
The multivariate analysis found that age (β = 0.67, p < 0.0001), having more than one
family member affected (β = 0.11, p < 0.0001), and being a female (β = 0.08, p < 0.0001)
were the most important contributors to being screened for diabetes mellitus. Results for all
features are shown in Table 5.7, and screening rates for these features are shown in Table
5.8.
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Table 5.6: The traditional process of collecting patient-provided information.
Table 5.7: Results of a multivariate analysis. To determine the influence of each parameter in
the logistic regression model, I computed the standardized coefficients (β) by multiplying the beta
coefficient (B) to the standard deviation of the corresponding parameter in the data.
Table 5.8: Screening rates stratified by features.
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Celiac disease
I applied the RIFTEHR algorithm to identify family members of the 2,081 index cases
of celiac disease, yielding 379 distinct families and 852 relatives. The inclusion criteria
included only relatives seen at our institution after the index case was diagnosed, which
resulted in a total of 272 distinct families and 539 relatives (Table 5.9).
There was a relatively even distribution of men (47.1%) and women (52.9%), and of
those 18 years and older (52.5%) as compared to those under 18 years (47.5%). The ma-
jority of individuals identified were first-degree relatives (71.1%) of patients with celiac
disease and had been seen more than once (88.3%) at our institution after their relative was
diagnosed. Non-Hispanic White (58.6%) and Hispanic (28.9%) were the two most com-
monly documented ethnicities in our study population. From manual review of the EHR,
316 of the 529 total relatives (58.6%) did not have any associated symptoms or conditions
related to celiac disease.
I found that 193 of the 383 (50.4%) first-degree relatives had been screened for celiac
disease (Table 5.10). When restricting this analysis to first-degree relatives with associated
symptoms or conditions related to celiac disease, I found that 71.5% (118/165) were tested.
Since screening practices are largely influenced by the available data at the time of the visit,
each patient’s record was reviewed to determine if a family history of celiac disease had
been documented anywhere within the record. Of all 539 relatives, only 120 (22.3%) had
a family history of celiac disease documented. When subcategorized by degree of relative,
I found that 30.3% of first-degree relatives had documentation of family history of celiac







































































Table 5.10: Screening and charting practices based upon degree of relative. Percent of symptomatic
first degree relatives tested for CD 118/165 = 71.52%.
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On univariate analysis, there were several factors that were associated with a higher
likelihood of being screened (Table 5.11). Only 5.6% of relatives over the age of 69 were
screened, a far lower rate compared to all other age categories, which ranged from 35.3% -
44.1%. Screening practices also varied by race, with 58.6% of Non-Hispanic Whites, 25%
of Hispanics, and 0% of African Americans tested. Additionally, the presence of symp-
toms (59.2% vs. 25.3%, p < 0.0001), whether the relative was seen by a gastroenterologist
(87.1% vs. 20.1%, p < 0.0001), whether there was documentation of a family history of
celiac disease in the EHR (89.2% vs. 25.1%, p < 0.0001), and the degree of relative (first-
degree 50.4% vs. all other degrees 12.2%, p < 0.0001), were associated with testing for
celiac disease. Notably, neither sex (Male 39% vs. Female 39.7%, p=0.87) nor the number
of times a relative had been seen at our institution after the initial family member had been
diagnosed (once 36.5% vs. 2-5 times 45.2% vs. > 5 times 35.6%, p=0.09) affected the
likelihood of celiac disease testing.
On multivariate analysis (Table 5.12), I found that age, number of visits to our institu-
tion, being seen by a gastroenterologist, the presence of symptoms or conditions associated
with celiac disease, a documented family history of celiac disease, and the degree of rel-
ative, to be significant predictors of screening. Specifically, I found that relatives aged
18-39 were more than two times more likely to be screened than relatives under the age of
18 years old (OR 2.27, 95% CI: 1.12-4.58, p=0.02). When the number of visits was consid-
ered as a binary variable, those seen more than five times were less likely to be screened as
compared to those seen one to five times, though this was of borderline significance (OR
0.57, 95% CI: 0.32-1.00, p=0.05). Other significant predictors included the presence of any






























































Table 5.11: Factors associated with screening: univariate analysis.
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and being a first-degree relative (OR 4.90, 95% CI: 2.34-10.25, p < 0.0001). The two fac-
tors most strongly associated with screening were whether the relative had been seen by a
gastroenterologist (OR 15.16, 95% CI: 7.72-29.80, p < 0.0001) and whether there was doc-
umentation in the EHR of a family history of celiac disease (OR: 11.9, 95% CI: 5.56-25.48,
p < 0.0001). Race and sex were not associated with celiac disease testing on multivariate
analysis.
A total of 79 of the 539 relatives (14.7%) had biopsies consistent with celiac disease.
Fourteen individuals had biopsy-proven celiac disease but no record of antibody testing
recorded within the EHR. Of the 82 patients who tested positive for celiac antibodies (en-
domysial, transglutaminase, and/or gliadin peptide), 80 (97.6%) were first-degree relatives,
































































































Table 5.12: Multivariable analysis examining patient factors associated with screening in all rel-
atives. *Adjusted for all variables listed in the table. Symptoms/signs of celiac disease include
diarrhea, bloating, abdominal pain, fatigue, osteoporosis, osteoarthritis, GERD, Type 1 diabetes,

















Table 5.13: Pathology results of screened relatives.
Discussion
In this study, I measured clinician adherence to diabetes mellitus and celiac disease
screening among high-risk patients. Because current screening guidelines include family
history of diabetes or celiac disease as a risk factor, respectively, I used a novel method
for identifying families and gathering corresponding medical histories through patient-
provided emergency contact information stored in the EHR. This method, along with an
EHR phenotyping algorithm, was used to identify patients at risk for disease development
that were eligible for additional testing. I found that 30.6% of patients at high risk for dia-
betes and 49.6% of patients at high risk for celiac disease were not appropriately screened
for their respective diseases, even though early diagnosis is known to decrease morbidity.
Previous research suggests similar findings for a myriad of different diseases, most notably
in relation to cancer screening (Jemal and Fedewa 2017; Solbak et al. 2018).
Given that fewer resources are required to carry out proper screening for diabetes mel-
litus as compared to cancer screening, further studies should be conducted to understand
the challenges preventing recommended diabetes mellitus screening. While cancer screen-
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ing is often costly and requires more complex tests (e.g., MRI, genetic testing), diabetes
screening is relatively simple and inexpensive. In celiac disease, screening can be initiated
with serology, which is less invasive and less complex than a biopsy. Interestingly, I ob-
served that 28.5% of patients presenting symptoms who had a first-degree relative affected
by celiac disease were not screened.
This study found that there were several factors associated with increased screening for
diabetes mellitus. These factors included being female, age, and having more than one fam-
ily member diagnosed with diabetes. One of the major differences between the subpopula-
tions who received screening vs. no screening was age, where the screened subpopulation
was far more elderly on average (50 years old vs. 38 years old, p < 0.0001). One possible
interpretation of this finding is that individual clinicians are not adhering to clinician guide-
lines in favor of considering patient’s individual factors—in this case age—in determining
the necessity of screening.
For celiac disease, there were multiple contributing factors to the overall low adherence
to screening rates. As previously described in other conditions, being seen by a specialist
in that discipline is associated with a higher likelihood of being screened (Patwardhan et
al. 2011). In our study, only 39% of relatives were seen by a gastroenterologist, but those
who did were significantly more likely to be screened. Additionally, the American College
of Gastroenterology (ACG) guidelines recommend screening for first-degree symptomatic
relatives (Rubio-Tapia et al. 2013), but I found that both being a first-degree relative and
being symptomatic were independently associated with an increased likelihood of being
screened. Those patients seen more than five times without being screened were overall
less likely to be screened. This may be due to a significant number of acute conditions
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that dictated numerous visits and took precedence over celiac disease screening, or reflect
that after several visits, provider and patient may no longer be as cognizant of the family
member who was previously diagnosed with celiac disease, and as a result, were less likely
to be tested.
While clinicians may consciously consider but choose to not screen certain patients, I
believe this to be an improbable explanation of the low rate of screening adherence. Be-
cause our institution is a tertiary facility, patients are often seeking for specialized care,
where disease screening may not be a primary focus. Further, prior research provides a few
additional potential explanations for the low adherence to screening guidelines, including
lack of family history documentation and lack of patient and physician awareness (Sequist
et al. 2009; Wee, McCarthy, and Phillips 2005). Even though family history has always
been considered “a core element of clinical care” (Berg et al. 2009), it has been found to
be poorly captured in the EHR. Lack of time to obtain, organize, and analyze family his-
tory data is perhaps one of the most important challenges in the quality of family history
documentation (Green 2007; Guttmacher, Collins, and Carmona 2004; Rich et al. 2004;
Scheuner et al. 2009; Sussner, Jandorf, and Valdimarsdottir 2011; Wilson et al. 2012a).
Additionally, uncertainty about the medical history of family members, as well as inaccu-
racies in patient recall, compound the challenge of obtaining accurate family history data
(Green 2007; Peace, Valdez, and Lutz 2012; Sussner, Jandorf, and Valdimarsdottir 2011).
When it is captured in the EHR, family medical history information is frequently stored in
clinical notes, which cannot be easily abstracted during a patient visit (Chen et al. 2014;
Polubriaginof, Tatonetti, and Vawdrey 2015), and may ultimately result in poor screening
rates. The results of the logistic regression demonstrated that patients who had multiple
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family members diagnosed with diabetes was one of the most likely factors leading to a
patient being screened for diabetes. This result points to the importance of family history
data availability during the clinical encounter.
While the use of RIFTEHR for identifying family history in research has tremendous
benefits, there are privacy issues regarding the use of this method for clinical practice, and
tradeoffs must be made between providing optimal care and safeguarding the privacy and
confidentiality of family members’ health information (United States 1996). Notwithstand-
ing the ethical considerations, the use of RIFTEHR for identifying familial relationships
using EHR data unlocks new opportunities for secondary use of data to facilitate identifi-
cation patients at high risk for disease development and support appropriate monitoring of
prevention strategies such as disease screening.
Conclusion
In summary, 30.6% and 49.6% of patients that were eligible for early diabetes and celiac
disease screening, respectively, did not receive the appropriate testing that could lead to
early diagnosis, and therefore, decrease patient morbidity. In this study, I demonstrated
that electronic health record data along with novel and innovative informatics methods can
increase availability of data, and therefore utility of large electronic clinical databases, ul-
timately resulting in improvements in clinical care.
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Chapter 6
Conclusions and Future Work
6.1 Summary of Work
The body of research represented in this dissertation investigated the quality of patient-
provided databases, the impact of interventions targeting these data, and the usefulness of
these data in assessing disease risk.
In the first Aim, I focused on determining the quality of patient-provided data stored
in clinical databases. To accomplish this goal, I assessed the data quality of three patient-
provided data types: race and ethnicity, family history, and smoking status. When assessing
the quality of race and ethnicity, I identified that data completeness, correctness, and con-
cordance were all issues for this type of information. When assessing the quality of family
history, my results showed that patients’ family history records were rarely complete in the
EHR. Smoking status data suffered similar problems with concordance and completeness.
Furthermore, I found that changes to a patient’s smoking status had plausibility issues, in
that not all changes to smoking status could have been logically possible (e.g., a “current
smoker” becoming a “never smoker”). Overall, the results of these studies demonstrated
that such patient-provided information is currently poorly captured in the EHR.
The results from the three studies conducted in Aim 1 demonstrated that while the im-
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portance of patient-provided data is well-known, these data are not being optimally captured
during clinical encounters. The unavailability of patient-provided data at the point of care
can negatively impact clinical decisions, such as limiting the assessment of disease risk.
Disease risk assessment is a key factor in determining whether patients may benefit from
additional disease screening and modified treatment. The fact that these data are not readily
available to clinicians can result in disease comorbidity that might have been prevented or
mitigated.
Based on the results of Aim 1, I investigated the impact of various intervention types
on the quality of patient-provided data in Aim 2. Several types of interventions exist, in-
cluding 1) high-level policy changes, such as the Meaningful Use program, 2) local health
information technology initiatives, such as deploying patient-facing tools that collect and
share information with patients, and 3) the use of informatics methods that leverage existing
datasets to facilitate the identification of high-risk patients.
I found that each of the three types of interventions had a different effect on the qual-
ity of patient-provided data. While policy changes seemed to encourage the collection of
patient-provided data using pre-determined categories, they did not necessarily translate
into better data quality. I found that with patient-facing tools, patients were willing to pro-
vide even sensitive information, such as race and ethnicity, and that by doing so, they were
able to enhance the data quality of the information contained in their medical records. In
my studies, two forms of patient-facing tools, HCAHPS surveys and patient portals, en-
abled these changes. Using informatics methods, I demonstrated how issues of incomplete
family history information can be overcome, in some cases, by accurately and automati-
cally deducing certain family history information based on inferred relationships between
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patients using other patient-provided information.
In Aim 3, I applied the informatics method developed in Aim 2 to assess patients’ dis-
ease risk. This work analyzed disease risk at two levels: first at a population level, by
measuring disease heritability, and second, at the individual level, by assessing disease
screening rates among high-risk patients. In the first study on heritability, I successfully
estimated disease heritability for 500 distinct traits, some of which had not previously been
reported in the literature. Further, I showed how this method could be readily applied to
diverse racial and ethnic groups, which overcomes a significant limitation of most genetic
studies, which are based on a population of European descent.
In the second study from Aim 3, which focused on patient screening, I leveraged inferred
familial relationships to determine screening rates for two conditions: diabetes mellitus, a
prevalent condition that affects 1 in 10 Americans, and celiac disease, an autoimmune con-
dition that affects approximately 1% of the population. For both conditions, screening rates
among family members that are considered to be at high-risk for disease development were
very low. In sum, the studies I carried out in Aim 3 highlight the difficulty associated with
identification of high-risk individuals in the clinical setting. The results of these two stud-
ies demonstrate the impact of informatics methods utilizing patient-provided information
in both genetics and clinical practice.
183
6.2 Contributions
My research is a novel contribution to understanding how to use EHR data to assess
disease risk. The contributions of this thesis include: 1) an overview of the quality of
patient-provided information in clinical databases, 2) an assessment of the impact of dif-
ferent intervention types on the quality of patient-provided data, 3) the development and
evaluation of a novel method that uses patient-provided information to generate a unique
data set that can support biomedical research, and 4) the use of clinical data to understand
disease risk and assess disease screening rates among high-risk individuals. Each study
I conducted provided insight into new areas of exploration that had not been previously
reported in the biomedical literature. A summary of the publications and presentations
generated during the course of my research are shown in the following Table 6.1.
Aim 1 explored the data quality of patient-provided data, including race and ethnicity,
family history, and smoking status. The studies included in this chapter demonstrated that
patient-provided data suffers from the same data quality issues as clinical data when stored
in the EHR system.
Aim 2 assessed the impact of different intervention types on the quality of patient-
provided information. The results showed that patient-facing tools were a superior method
for capturing high-quality patient-provided data, compared with policy changes, which
were most effective for driving the collection of the data in a structured format. Further,
Aim 2 also introduced a novel and validated method to extract familial relationships from
clinical databases, enabling the inference of family history.
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185
support both genetic and clinical research. These studies demonstrated that the availability
of familial data along with clinical data can have a significant impact in multiple research
areas.
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6.3 Implications for Biomedical Informatics
The work in this dissertation contributed to the field of biomedical informatics in mul-
tiple areas, summarized in three main implications for the field.
First, I have shown that while patient-provided data is critical to accomplish multiple
clinical tasks, there are data quality concerns that should be addressed when utilizing these
data. Data available in the EHR are often incomplete or inaccurate, posing challenges for
reuse.
Second, I have shown that the implementation of different intervention types had differ-
ent impact in the collection and quality of patient-provided data. In general, policy changes
resulted in increased data collection of these data types, and patient-facing tools resulted
in higher data quality. These results suggest that there should be greater focus on using
patient-facing tools when the objective is to increase the quality of this information.
Third, the availability of family history through the use of familial relationships in ad-
dition to clinical data can open up new avenues of research, support knowledge discovery,
and facilitate the identification of clinical phenotypes.
187
6.4 Implications for Genetics Research
In this dissertation, I demonstrated the usefulness of utilizing EHR data to conduct large
genetic studies in a diverse patient population. The use of EHR data can be used to empower
genetic studies by significantly increasing the sample sizes available, with minor costs.
Genetic data is a valuable but expensive and not always available resource. The use of
EHR data in genetics can expedite research while decreasing cost. The RIFTEHR method
can be used to personalize disease risk prediction and facilitate heritability estimation for
phenotypes not previously studied in family-based or twin studies.
Further, the use of these data allowed for genetic research in multiple racial and ethnic
groups, demonstrating the utility of using EHR data in conjunction with traditional genetic
research data. Traditional genetic studies often focus on a single racial group, limiting the
generalizability of its findings to other populations. The use of EHR data allows for studies
to include other racial and ethnic groups, without impacting the research cost. The ability to
conduct genetic research on multiple racial and ethnic groups at once will help us achieve
the goals of precision medicine.
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6.5 Implications for Clinical Care
In addition to the contributions and implications described above, my dissertation also
impacts clinical care. First, my results indicate that patients are willing to participate in
their care by reviewing or providing information, suggesting that providers need to encour-
age and engage their patients in sharing relevant information. Second, using RIFTEHR, I
identified that disease screening rates among high-risk individuals were low. Future efforts
should focus on ways to improve the identification of high-risk individuals by incorporating
family history and other patient-provided information at the point of care.
189
6.6 Limitations
The work presented has many limitations. Many of the studies were conducted in a
single institution, a large urban academic medical center. As such, the research findings
may not be generalizable to other institutions. Additionally, one of the studies involved
patient recruitment, and only included English-speaking participants, in addition to small
sample size due to recruitment constraints. Overall, my studies focused on just three types
of patient-provided data. However, there are many other types of patient-provided informa-
tion. Other types of information may pose different data quality challenges compared with
the data types included in this dissertation. Some of the studies focusing on data quality
were not able to assess correctness of the data due to unavailability of data from the refer-
ence standard. Further, all reported studies heavily relied on EHR data, and therefore faced
challenges related to fragmentation of care. Patients often seek care in multiple healthcare
systems, resulting in data missingness which may impact the results of the studies reported.
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6.7 Future Work
This dissertation can be expanded into several areas of future work. First, this disserta-
tion built the foundational work to better inform how to capture patient-provided data. Ad-
ditional work should be conducted to improve the quality of these data in clinical databases.
These data currently face considerable data quality issues, as shown in Aim 1. Future in-
terventions could use the work presented here to identify approaches that can potentially
improve the quality of these data. Based on this work, patient-facing tools could greatly
improve the quality of patient-provided data in EHRs, while decreasing clinician burden
during clinical encounters. Future work could build on this finding by developing and de-
ploying patient-facing tools to capture a collection of patient-provided information relevant
to clinical care. Additionally, the work presented in Aim 2 exhibited multiple methods to
assess the impact of different types of interventions. Future work could use similar meth-
ods to measure outcomes after the implementation of an intervention, allowing for rigorous
evaluation of the intervention at hand, and directly assessing the impact of the data quality.
Second, future work should leverage the RIFTEHR method to power numerous research
studies. Availability of family data in conjunction with rich clinical data is a powerful com-
bination to support not only clinical studies but also clinical care. As demonstrated in Aim
3, the use of this data can generate new knowledge, such as estimation of disease heritability
for diseases that have not previously explored and in populations that had not been stud-
ied. This work could be used to generate new hypotheses that could subsequently be tested
using a traditional study design. While this dissertation has demonstrated one use case of
these data in genetic research, there are many more opportunities in other fields as well. For
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example, in this dissertation screening rates among high-risk individuals was explored for
two conditions, and it demonstrated that there are challenges to identifying these patients
during a clinical visit. Future work should investigate methods to use informatics solutions
to facilitate the identification of high-risk individuals at the point of care to mitigate bar-
riers to identifying high-risk patients. Such efforts could potentially increase adherence to
clinical guidelines, provide a more individualized disease management plan, and ultimately
decrease patient morbidity.
Third, in this dissertation, the identification of familial relationships was performed in
three institutions, independent from each other. Patients often receive medical care at more
than one institution. Future work should take advantage of health information exchange
efforts, to identify familial relationships broadly. This approach will potentially reduce the
challenges we currently face with the fragmentation of care, enabling robust and complete
population studies. One of the major biases that was accounted for in Aim 3 was ascertain-
ment bias, which affected the estimated heritability of disease. Linking the medical histo-
ries of patients from several different institutions (for example, through health information




Patient-provided information is needed to advance precision medicine, by enabling clin-
icians to provide more individualized disease screening and diagnosis as well as care man-
agement. The goal of this dissertation was to develop a better understanding of how patient-
provided information in the EHR could facilitate the identification of patients at increased
risk for developing disease. The studies included in this dissertation found data quality
concerns for patient-provided information, and that different interventions could lead to
increased collection and/or increased quality of patient-provided information. In general,
allowing patients to review or directly supply patient-provided information resulted in the
most complete and highest quality information. In the absence of patients providing infor-
mation themselves, informatics methods, such as RIFTEHR, can be utilized to infer certain
patient-provided information, such as family medical history. The use of inference meth-
ods unlocks new knowledge, such as disease heritability for multiple races and ethnicities,
and enables assessment of adherence to guidelines for high-risk patients, such as those for
diabetes mellitus or celiac disease. In conclusion, this dissertation outlines the data qual-
ity issues that exists for patient-provided information, how to overcome these data quality
issues, and how to apply patient-provided information to generate new knowledge.
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